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Orthopedic injuries are a major cause of lameness and morbidity in horses. Bone 
marrow (BM)- and adipose tissue (AT) derived mesenchymal stem cells (MSCs) have 
shown potential to facilitate the repair of orthopedic injuries and are being used 
increasingly in veterinary clinics. Presently, the use of MSCs as a therapy for equine 
patients is most commonly applied as autologous transplants, using BM- and AT-MSCs 
harvested from the patient shortly after the time of injury. Cell-based therapies are 
therefore delayed to enable primary cell numbers to be expanded in culture. Of concern, 
however, are human and rodent studies that have shown a sharp decline in MSC quantity 
and quality with increasing donor age. This may be problematic for the important equine 
demographic of older orthopedic patients due to current recommendations that often call 
for 10-100 million MSCs in treatment protocols.  
This thesis, therefore, examines the critical gap of knowledge on the relationship 
between donor age and MSC parameters in horses and tests the hypothesis that increasing 
donor age is a major variable in equine BM- and AT-MSC proliferation and 
chondrogenic/osteogenic differentiation with decreasing capacities following non-linear 
kinetics.  
To this end, BM- and AT-MSCs and dermal fibroblasts (biological negative 
control) were harvested immediately post mortem from horses in 5 different age groups, 
with 4 horses in each age group. The age groups were newborn (0 days), yearling (1-2 
years), adult (5-8 years), middle-aged (12-18 years), and geriatric (≥ 22 years) horses.  
In the first part of the study, the cellular proliferation of the cells was tested using 
an EdU incorporation assay and by targeted gene expression analysis of proliferation, 
aging and senescent biomarkers. The results showed that the cellular proliferation of 
equine MSCs declined with increasing donor age, but interestingly there were no 
significant difference in pairwise comparisons between age groups other than the 
geriatric horses. The cellular proliferation of the two MSC types was equally affected by 
donor age. Tumor suppressor gene expression was up-regulated with increasing donor 
age.  
In the second part of the study, the same cells were grown in culture and 
stimulated separately to differentiate into both chondrocytes and osteocytes. The 
chondrogenic differentiation potential of the cells was compared quantitatively by 
measuring pellet size, matrix proteoglycan, and gene expression of articular cartilage 
biomarkers. The osteogenic differentiation potential of the cells was assessed 
quantitatively by measuring alkaline phosphatase activity, calcium deposition, and gene 
     
 
expression of subchondral bone biomarkers. Overall, the data showed that the 
chondrogenic and osteogenic differentiation potential of equine MSCs decline with 
increasing donor age. The data further indicated that BM-MSCs have a larger 
chondrogenic pellet size and proteoglycan content, and a higher alkaline phosphatase 
activity compared to AT-MSCs, and that BM-MSCs calcium deposition was affected 
earlier by donor age. The chondrogenic and osteogenic differentiation performance of 
BM-MSCs declined already between newborn and yearlings. AT-MSCs showed minimal 
chondrogenic differentiation performance in all age groups. Gene expression of growth 
factors, chondrogenic and osteogenic biomarkers were down-regulated with increasing 
donor age.  
Together, these results support the hypothesis that equine BM- and AT-MSCs 
proliferation and chondrogenic/osteogenic differentiation decline with increasing donor 
age following non-linear kinetics. Hence, the study highlights the importance of donor 
age considerations and MSC selection for autologous treatment of orthopedic injuries. 
This new knowledge has the potential to optimize autologous stem cell therapies of 
cartilage and bone injuries in horses, and will help advice owners on when to harvest and 
potentially cryopreserve the cells. 
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CHAPTER 1.  INTRODUCTION  
1.1 Orthopedic injuries in horses 
Orthopedic injuries are a major cause of lameness and morbidity in horses worldwide, 
leading to substantial personal and financial losses for horse owners and the horse 
industry [1–3]. Articular cartilage injuries are particularly problematic since cartilage has 
a very limited intrinsic repair capacity, believed to be due in part to a lack of vasculature 
and low mitotic activity of the chondrocytes. Articular cartilage is present on opposing 
bone surfaces in diarthrodial synovial joints, where its main functions are to distribute 
load and provide a smooth and lubricated surface for articulation to minimize the load-
friction of movement [4]. Lesions involving articular cartilage often progress and 
potentially involve subchondral bone, which leads to significant pain and loss of function, 
resulting in long periods of rest with a poor prognosis to return to full athletic function 
(Figure 1.1) [4,5].  
One of the major orthopedic diseases responsible for retirement of horses is 
osteoarthritis [3]. Osteoarthritis is a degenerative joint disease that historically has been 
identified as a cartilage disease, but is now recognized as a disease of the whole 
osteochondral unit with alterations to the articular cartilage and subchondral bone, 
together with low-grade systemic and local inflammation as measured by an up-
regulation in e.g. peripheral CD8+ T-cells, and synovial tumor necrosis factor-α, 
interleukin-1, and interleukin-6 [6–8]. Abnormalities in the subchondral bone include 
sclerosis, bone marrow lesions, and osteophyte formations [6,7]. In the horse, evidence 
furthermore suggests that subchondral bone injuries can be an important etiological 
variable leading to initial cartilage damage during osteoarthritis [3,9,10]. Unlike articular 
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cartilage, bone is vascularized and has access to progenitor cells which in general 
provides for healing capabilities. Nevertheless, a bone persistent reparative response with 
unmatched bone formation and resorption is reported in horses where architectural 
disruption leads to weak areas and is associated with some subchondral bone lesions, and 
dense bone may never remodel completely. Bone persistent resorption areas are therefore 
believed to be one of the contributing factors to osteoarthritis in horses [3].   
Another major risk factor for developing osteoarthritis is an increase in age. It is 
recognized, however, that age is only one of many contributing factors and that aging and 
osteoarthritis are independent processes although osteoarthritis is a progressive disease 
[6,7]. An ―adipogenic switch‖ has been reported in some studies where bone marrow 
(BM) derived mesenchymal stem cells (MSCs) from aged donors are more prone to 
adipogenic differentiation compared to osteogenic differentiation. As BM-MSCs are 
progenitors for the bone forming cell, osteoblasts, an age-related switch may potentially 
affect osteoblast formation and bone remodeling in vivo, and thus be a risk factor for 
bone diseases [11]. Intense athletic training, trauma, infection, and conformation 
deformities are amongst other risk factors of osteoarthritis, and the disease can hence be 
seen at all ages [12].  
Current therapies for osteoarthritis in the horse include administration of anti-
inflammatory and pain relieving drugs including intra-articular injections of 
corticosteroids and/or hyaluronic acid, and surgical debridement [13,14]. Unfortunately, 
none of the existing techniques have been able to fully restore articular cartilage structure 
and function with complete integration into the normal surrounding tissue, and 
fibrocartilage formation is often seen together with osteophyte formation after bone 
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involvement (Figure 1.1) [5,6,15–19]. Moreover, these therapies have the potential for 
unwanted systemic adverse effects like gastric ulcers and diarrhea, together with local 
side effects as corticosteroids have shown toxicity towards chondrocytes [13,14,20]. 
Consequently, there is a great need for new cartilage and bone restoration methods.   
 
Figure 1.1: Left: Joint surfaces of an equine fetlock with osteoarthritis where the 
cartilage is severely worn with score lines (arrows). Right: Safranin-O stained 
histological section of normal hyaline articular cartilage and fibrocartilage repair tissue 
illustrating the poor integration between the two. Images courtesy of Drs. MacLeod, 
Todhunter, and Fortier.         
 
1.2 Mesenchymal stem cells as a treatment of orthopedic injuries 
Cell-based therapies with MSCs are an area of high scientific and clinical interest within 
the broad field of regenerative medicine, as MSCs have shown capacity to facilitate the 
repair of orthopedic injuries in addition to managing the symptoms [17,18,21–23].  
MSCs are multipotent spindle-shaped stromal cells capable of plastic adherence, 
self-renewal, and differentiation into multiple mesodermal lineages including cartilage, 
bone, and adipose tissue. MSCs were first described in the 1960‘s and 1970‘s in a series 
of studies by Friedstein and coworkers as a plastic-adherent fibroblast-like population 
isolated from the bone marrow capable of osteogenic differentiation [24,25]. The term 
‗mesenchymal stem cell‘ was later popularized by Caplan in 1991 [26]. MSCs can be 
4 
 
isolated from multiple tissues such as adipose tissue, bone marrow, synovial fluid, 
peripheral blood, and umbilical cord blood [27–31]. The international Society of Cellular 
Therapy (ISCT) have suggested the following criteria for identification of human MSCs: 
1) plastic-adherence when cultured under standard conditions, 2) in vitro tri-lineage 
differentiation into chondrocytes, osteoblasts, and adipocytes, and 3) expression of 
surface markers CD105, CD73, and CD90, and an absence of CD45, CD34, CD14, 
CD11b, CD79α, CD19, and HLA-DR [32].  
Cell surface markers of equine MSCs are not exactly the same as those found in 
humans, and a limited availability of equine specific antibodies have made surface 
marker assessment and clarification challenging [33]. However, a recent study by 
Bundgaard et al. reported expression of CD29, CD44, CD90, CD105, and CD166 in 
equine BM- and AT-MSCs, and a lack of CD34, CD45, and CD79α when using mass 
spectrometry [34]. Nevertheless, there is still a lack of a uniform agreement on how to 
characterize equine MSCs. Furthermore, recently published studies no longer perform tri-
lineage differentiation to verify stemness [34–37].   
For the purpose of this dissertation, MSCs will be defined as spindle-shaped post-
embryonic, bone-marrow- or adipose tissue derived cells, capable of plastic adherence 
and expansion when cultured under standard culture conditions, with an ability to 
undergo chondrogenic and osteogenic differentiation in vitro.  
Clinically relevant equine tissue sources of MSCs include bone marrow (BM) and 
adipose tissue (AT), where published literature has reported a promising capacity to 
differentiate into chondrogenic and osteogenic lineages with the potential to restore 
orthopedic lesions [35,38–42]. Several studies have compared chondrogenic and 
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osteogenic in vitro differentiation in a range of MSCs [35,38,39,41,43], and most studies 
report a higher potential of BM-MSCs to treat cartilage and bone injuries compared to 
AT-MSCs [35,41,44–46]. This was supported by an in vivo equine osteoarthritis model, 
where Frisbie et al. noted a greater improvement when using BM-MSCs compared to 
AT-MSCs or placebo [46].  
For successful therapies, a substantial number of cells are needed, which requires 
extensive ex vivo cell expansion. Generally, cell-based therapy protocols call for 10-100 x 
10
6
 MSCs per treatment depending on injury type [40,47–49]. MSC yield after primary 
isolation depends on cell type, donor age and gender, and inter-animal variation [42,50]. 
Vidal et al. reported a low frequency of BM-MSCs with a mean of 1.5 x 10
4
 BM-MSCs 
per 10 mL bone marrow aspirate in young horses, whereas 1.3 x 10
6
 AT-MSCs were 
found per 10 mL adipose tissue in young horses below the age of 5 [31,42]. Equine 
MSCs consequently need to be expanded in vitro for about 2-3 weeks prior to 
implantation [31,40]. However, this depends on injury type, aspirate/tissue volume, MSC 
frequency, proliferation rate, and expansion medium. Repeated MSC applications have 
shown beneficial effects in vivo, which also clearly necessitates additional cell numbers 
[51,52].    
The first report on culture-expanded MSC treatment in horses dates back to 2003, 
where Smith et al. implanted autologous BM-MSCs into a spontaneous lesion in a 
superficial digital flexor tendon [53]. The cells were injected together with blood plasma 
and were assessed to result in an improvement in tendon healing and lameness. This 
finding could also be due to the growth factors in the plasma, but importantly, this study 
showed the ability to expand MSCs in vitro to obtain higher cell numbers without 
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producing adverse patient effects 10 days and 6 weeks post implantation. In 2007, Wilke 
et al. treated 6 horses with femoropatellar cartilage defects with autologous BM-MSCs 
combined with fibrin or with fibrin alone. They reported an improved cartilage healing in 
horses treated with the combined product 30 days after treatment compared to horses 
treated with fibrin alone, but observed no difference between the 2 groups 8 months after 
treatment [54]. This raises the possibility that multiple MSC treatments may be 
beneficial, which was later supported in osteoarthritis and meniscus regeneration studies 
[51,52]. In another study by McIlwraith et al., 10 young adult horses with induced micro-
fractured chondral defects were treated with 20 x 10
6 
BM-MSCs and hyaluronan, and 
found no clinical improvement compared to horses treated with hyaluronan alone. They 
did, however, report an enhanced cartilage repair with improved tissue firmness and 
increased aggrecan content in the MSC treated horses [18]. A recent dose-response study 
highlighted the importance of MSC numbers for long-term success of knee osteoarthritis 
in humans. They noted an improved range of motion and lower pain score in patients 
treated with a single low dose (10 x 10
6
) or high dose (100 x 10
6
) of BM-MSCs at 6 
months, but only saw improved cartilage healing and improved clinical symptoms in the 
high-dose group at 12 months [55]. A canine bone defect model showed that 15 x 10
6
 
BM-MSCs/mL of implant volume (total of 30 x 10
6
 MSCs) was required to improve bone 
regeneration of a 21 mm long segment of the femoral diaphysis [56]. This study was 
supported by a mathematical model, which found that 70 x 10
6
 osteoblasts were needed 
to produce 1 cm
3
 of bone [57]. Timing of MSC treatment may also be a key factor as ter 
Huurne et al. showed reduced cartilage destruction in mice when implanting AT-MSCs 7 
days after inducing experimental collagenase osteoarthritis, whereas no difference was 
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seen between MSC treated and control joints when applying AT-MSCs 14 days after 
osteoarthritis induction [58]. Together this exemplifies the importance of cell choice, 
dosage, timing, and the potential need for multiple treatments in order to optimize cell-
based treatments of orthopedic lesions.            
Previous studies using labeled MSCs have shown that MSCs have an affinity for 
injured joint tissue and that they localize and participate to a certain degree in repair of 
joint structures including articular cartilage [22,23]. In contrast, a recent study 
demonstrated that the primary localization of MSCs after intra-articular injection was in 
the synovial membrane and to a lesser extent in the articular cartilage [59]. The current 
understanding is thus that the major regenerative effect of MSCs primarily lies in their 
paracrine effects and that the persistence of intra-articular injected MSCs is limited in the 
joint [60,61]. To enhance retention of MSCs within the injury site and to promote tissue 
like morphology, MSCs are with recent techniques being incorporated into scaffolds like 
poly-ε-caprolactone (PCL), which is a synthetic porous biomaterial that is relative 
resistant to hydrolysis and support proliferation, viability, and differentiation of 
implanted MSCs. Differentiation capability is thereby becoming increasingly important 
[59,61–64].  
 
1.3 Culture and cryopreservation of mesenchymal stem cells  
In the body, MSCs remain predominantly in G0 of the cell cycle (quiescence) while 
maintaining their differentiation capacity. When plated in vitro they exit their quiescent 
state and begin to proliferate and to form individual colonies [65,66].   Ideal culture 
conditions preserve MSC phenotype and functional characteristics similar to in vivo 
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properties, with self-renewal and differentiation capacity. High cell density and long-term 
culture are known to cause a loss of differentiation potential in equine MSCs. Equine 
MSCs grow well in Dulbecco modified essential medium (DMEM) with glucose and 
glutamine, supplemented with 1% penicillin/streptomycin to minimize the risk of 
bacterial contamination. Such medium limits the growth of hematopoietic cells and 
macrophages. Serum (typically 10% fetal bovine serum) or other serum-mimicking 
supplements also has to be added to the expansion medium to provide e.g. mitogens 
essential for growth [67–69].  
 Equine MSCs have been cryopreserved in cryogenic medium containing 10% 
dimethyl sulfoxide (DMSO) for multiple years with no alteration in proliferation, multi-
potency, or morphology. However, some cells are lost during the freezing and thawing 
process [68,70]. Cryopreservation allows for cells to be standardized for research 
purposes and for MSCs to be stored for autologous (same donor and recipient) or 
allogenic (donor and recipient are different) use in patients.  
 Medium can be modified to initiate differentiation, but despite much research 
there is still a lack of standardization and induction medium ingredients and 
concentrations varies between studies [34,35,38,41].  
 
1.4 Chondrogenic differentiation and validation in culture 
Induction of chondrogenesis of MSCs in culture has been more successful as 3D pellets 
than in monolayer cultures, as it appears that cell-cell interaction enhances 
chondrogenesis and chondrocyte survival [71,72]. Induction mediums of chondrogenesis 
typically consists of high glucose DMEM, penicillin/streptomycin, low levels of serum or 
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serum-supplement, growth factors from the transforming growth factor-β (TGF-β) 
superfamily, ascorbic acid, dexamethasone, non-essential amino acids, and insulin-
transferrin-selenium-sodium pyruvate [34,35,39,71,73,74]. Addition of TGF-β has been 
demonstrated to induce chondrogenesis in 3D MSC pellets, with a significant increase in 
proteoglycans and collagen type II, which are essential components of the extracellular 
matrix of articular cartilage. Expression of collagen type I, which is a marker of 
biomechanically inferior fibrocartilage, was down-regulated [73–75]. TGF-β stabilizes 
SRY-box transcription factor 9 (SOX9) protein, which is a key transcriptional regulator 
of chondrogenesis [76]. An equine study reported that TGF-β3 was more potent to induce 
chondrogenesis of MSCs compared to TGF-β1 [77]. In contrast, a high throughput 
mRNA-profiling study concluded that TGF-β1 induced superior chondrogenesis of 
human MSCs compared to TGF-β3 [74]. Addition of dexamethasone to the medium has 
been shown to increase TGF-β signaling, which resulted in higher proteoglycan and 
collagen type II content [74,75,78]. High level glucose (4.5 g/L) DMEM has also been 
reported to increase TGF-β signaling and chondrogenic induction by enhancing recycling 
of TGF-β receptors [79]. Ascorbic acid is an essential co-factor for hydroxylation and 
stabilization of selected prolines and lysines, which are components of pro-collagen. 
Supplementing the chondrogenic induction medium with ascorbic acid is hence 
demonstrated to increase expression of collagen type II [80].  
Chondrogenic induction can be evaluated in a variety of ways. Articular 
chondrocytes are elongated to cuboidal in shape depending on distance from the articular 
surface. Each chondrocyte is centered in a lacunae, which is a cavity within the 
extracellular matrix. The extracellular matrix of articular cartilage consists primarily of 
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water, proteoglycans, and collagen type II and to a minor extent of glycoproteins and 
non-collagenous proteins [4]. Morphological evaluation of chondrogenic induced pellets 
using Hematoxylin & Eosin staining is important to assess cell viability and structure, 
together with pellet composition [33,35]. Measurement of pellet size is another 
assessment, as production of extracellular matrix has been shown to be positively 
correlated with an increase in pellet size instead of cell proliferation [35,38,81]. 
Chondrogenic differentiation can be further validated by assessing proteoglycan content 
in the extracellular matrix using Safranin-O or Toludine Blue staining. Safranin-O is an 
orange to red stoichiometric orthochromatic dye that adheres to the sulfate groups of 
proteoglycan molecules in a 1:1 manner [82].  Safranin-O staining has hence been shown 
to be proportional to the proteoglycan content present in articular cartilage, whereas 
Toludine Blue is a more intense staining due to higher affinity for sulfur in cartilage [83]. 
Sulfated glycosaminoglycans (GAGs) (attached to the protein core in proteoglycans like 
aggrecan) and glycoproteins can furthermore be identified with an Alcian Blue staining. 
GAGs are however also found in skin [84]. Masson‘s Trichrome staining and 
immunohistochemistry can be used to identify collagen content, where 
immunohistochemistry can locate collagen type II and collagen type I specifically 
[33,71,85]. Gene expression of cartilage markers like SOX9, aggrecan, and collagen type 
II are also commonly applied to validate chondrogenesis [33,35,71].     
 
1.5 Osteogenic differentiation and validation in culture 
Osteogenic differentiation of MSCs is typically done in monolayer cultures in osteogenic 
induction medium containing low glucose DMEM, serum, penicillin/streptomycin, 
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dexamethasone, ascorbic acid, and β-glycerophosphate [42,86,87]. Addition of 
dexamethasone has been shown to induce osteogenesis by up-regulating runt-related 
transcription factor 2 (RUNX2) expression, which is an essential early transcription 
factor for osteogenesis [88]. RUNX2 is amongst others a transcription factor for 
osteogenic alkaline phosphatase (ALP), and dexamethasone has thereby shown to 
enhance ALP activity in osteogenic induced MSCs [87]. Ascorbic acid is an essential co-
factor for hydroxylation and stabilization of selected prolines and lysines, which are 
components of pro-collagen. Supplementing the osteogenic induction medium with 
ascorbic acid has hence demonstrated to increase expression of collagen type I, which is 
an essential component in bone extracellular matrix [86,88]. β-glycerophosphate provides 
phosphate, which is essential for hydroxyapatite (Ca10(PO4)6(OH2)2). Hydroxyapatite is 
the main inorganic component of bone and is hence a crucial bone crystalline mineral 
[89]. Addition of β-glycerophosphate has thereby shown to enhance osteogenic 
mineralization and to facilitate phosphorylation of intracellular signaling molecules 
required to activate RUNX2 [88].  
 Osteogenic differentiated cells show a change in morphology from spindle-shaped 
fibroblast-like cells to mainly polygonal cells with an overlaying mineral deposition 
making the cells hard to see [39]. Osteogenesis is typically validated by Alizarin Red S 
staining and Van Kossa staining, which stain calcium deposits and phosphate deposits 
respectively [33]. Alizarin Red S staining is highly specific for bone, as approximately 
99% of calcium in the body is localized in bone [84]. Measuring of ALP activity is 
another important validation method, as ALP activity is an early marker of osteogenesis 
and highly expressed in bone [89,90]. Gene expression of osteogenic markers like 
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RUNX2, ALP, osterix, collagen type I and osteocalcin are also commonly used to 
evaluate osteogenic differentiation of MSCs [33,87].     
 
1.6 Autologous versus allogenic mesenchymal stem cell treatment 
Historically, MSCs are said to be free of or to have very low levels of major 
histocompatibility complex (MHC) class II on their cell surface, which would make them 
capable of avoiding/minimizing T-cell recognition and allow for allogenic treatments 
where cells from one donor are applied to another recipient [60,91]. Recent studies have 
shown that that is not entirely true. In 2014, Schnabel et al. [92] demonstrated that equine 
BM-MSCs are heterogeneous in expression of MCH class II, and that an MCH class II 
mismatch could cause in vitro immune reactions. They also showed that MHC class II-
negative BM-MSCs were able to up-regulate MHC class II expression in vitro if exposed 
to inflammatory stimuli, which problematize the idea of purely using established MHC 
class II-negative stem cells for allogenic treatment. The same research group showed that 
intradermal injection of allogenic MHC class II mismatched BM-MSCs cause strong 
antibody responses in vivo [93]. A repeated intra-articular study by Joswig et al. later 
showed that immunological adverse effects occurred already after the second intra-
articular injection in horses with allogenic MSCs [94]. As repeated MSC treatments have 
shown beneficial effects in vivo [51,52], this emphasizes the potential issues with 
allogenic treatments. Advantages of allogenic treatments are a more standardized unit 
that could be applied fast in cases where it is impossible to obtain quality MSCs from the 
patient. Advantages of autologous cell transplants are decreased risk of host-versus-graft 
reactions, no need to screen potential donors for compatibility, and less risk of infection 
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[95]. Furthermore, reduced osteoarthritis progression has been reported in horses when 
autologous chondro-progenitor cells were applied but not when using allogenic cells [96]. 
Clinical application of allogenic MSCs is regulated by national authorities [40]. Due to 
the risk of immunological reactions mentioned above, the current application of MSCs in 
equine practice is usually autologous, using cells harvested from the patient shortly after 
the time of injury [43].    
 
1.7 Mesenchymal stem cells in regeneration 
The normal function of MSCs in the body is to perform organ specific self-renewal and 
to be responsible for tissue regeneration through direct differentiation, 
immunomodulatory- and growth factor excreting properties [21,22,97–99]. An overview 
of these properties is shown in Figure 1.2. However, a reduced tissue regenerative 
capacity is seen in vivo with increasing age. This is believed to be strongly correlated 
with an age-related decline in adult MSCs quantity with increasing donor age [7,97]. In 
vitro studies suggest that an age-related decrease in MSC functionality might also be a 
contributing factor, although this factor is still debated [7,97,100]. A recent study by 
Khong et al. used single-cell sequencing to determine a loss in MSC quiescence with 
increasing donor age, which could explain the reported stem cell depletion with aging and 
an imbalance of progenitor cells [66]. In support of this, induction of quiescence in BM-
MSCs has shown to enhance stemness both in vitro and in vivo [101]. The important 
issue about age-related changes in MSC functionality in horses is the focus of my 
dissertation as described below.   




Figure 1.2: Overview of mesenchymal stem cell properties – cell replacement versus cell 
empowerment. When tissue is damaged, inflammation occurs and MSCs are attracted to 
the injury site. Due to their multipotent differentiation capacity, the recruited MSCs can 
differentiate themselves into functional cells to replace the damaged cells, which is called 
cell replacement or direct differentiation. In response to inflammatory cytokines, MSCs 
also have the capacity to produce immunoregulatory factors that modulate the 
progression of inflammation, which is beneficial for the inflammatory process occurring 
during osteoarthritis. Lastly, MSCs excrete large amounts of growth factors, which 
stimulate fibroblasts, endothelial cells, and importantly progenitor cells in situ, which 
facilitate tissue repair through extracellular matrix remodeling, angiogenesis, and 
differentiation of progenitor cells. The two later properties are collected called cell 
empowerment. Reprinted by permission from Springer Nature: Nature Immunology, [99], 
copyright 2014.          
 
1.8 Definition of age and aging 
Age and aging can be defined in multiple ways depending on the scientific area 
investigated and the research questions asked. Chronological age describes the age of an 
individual from the calendar time that has passed since date of birth and hence follows a 
stable curve. Biological age describes the functional capability age and depends on the 
biological state of the individual/organism, which can be impacted by endogenous and 
exogenous stress factors. The biological age does not have to correlate perfectly with the 
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chronological age [102]. Recent studies have shown that DNA methylation is the most 
promising molecular estimator of biological age, also known as the epigenetic clock 
[102,103].  
For the purpose of this study, chronological age will be used as age and donor-age, 
and aging will be defined as ―a gradual process marked by the deterioration of 
functionality in living multicellular organisms with the passage of time‖ as described by 
Ganguly et al. [7]. Using this definition emphasizes the importance of MSCs in cell 
renewal and thus in impacting lifespan. Furthermore, aging relates to a multicellular 
organism, and can be distinguished from mitotic age and cellular senescence/aging, 
which refers to the number of cell divisions and to the related irreversible arrest of cell 
division on a cellular level [104,105].  
 
1.9 Cellular senescence  
Normal somatic cells have a limited proliferative capability due to a process called 
cellular senescence. One of the mechanisms responsible for cellular senescence is 
shortening and eventual dysfunction of the telomeres. Telomeres in mammals are the 
TTAGGG repetitive DNA sequences and associated cap proteins at the ends of 
chromosomes that stabilize the ends of linear chromosomes and thus prevent their fusion 
and degradation [106–109]. Due to the nature of lagging-strand DNA synthesis, DNA 
polymerase cannot completely replicate the 3‘ end of the telomeres. Native DNA 
polymerase only replicate DNA in a 5‘ to 3‘ direction, and synthetize the leading strand 
in a continuous manner. The lagging strand is however made in a discontinuous manner 
with a short set of Okazaki fragments each requiring a new primer. During discontinuous 
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lagging strand DNA synthesis the most distal primer in the 3‘ end cannot be replaced. 
Telomeric DNA is therefore lost with each cell cycle, which leads to a progressive 
telomere shortening unless the cell expresses telomerase [104,107,110].  
Telomerase is an enzyme that adds the telomeric sequence to the chromosome end 
and prevents shortening of the telomeres. Most normal cells do not express this enzyme 
and develops short telomeres that signal for the cell to cease proliferation by inducing 
cellular growth arrest. When the telomeres are critically shortened and have lost their 
protective cap protein, the exposed chromosome ends are recognized as DNA damage, 
which trigger a p53/p21 induced cell cycle arrest [104,107,110]. p53 is a tumor 
suppressor and transcription factor for p21. p21 inhibit cyclin dependent kinases, which is 
necessary for the cell to progress from G1- to S-phase during cell cycle, leading to 
growth arrest [107]. Senescent cells can also activate the p16/Retinoblastoma (Rb) 
pathway independent of p53. p16 is a tumor suppressor that inhibits DNA replication by 
inhibiting cyclin dependent kinases 4/6 necessary for phosphorylating and inactivating 
Rb family members. Non-phosphorylated Rb thereby binds E2F transcription factor 1 
resulting in G1-arrest (Figure 1.3) [107,111]. Cellular senescence hence occurs via one or 
both of these pathways, with p53/21 mediated senescence being primarily due to 
telomere dysfunction and DNA damage, and the p16/Rb pathway being primarily due to 




Figure 1.3: Flow diagram showing the role of major components of the p53/p21 and the 
p16/RB pathway in cell cycle regulation. Modified figure from Jayasurya et al. [112]. 
Reprinted by permission from Springer Nature: Modern Pathology, [112], copyright 
2005. 
 
The two independent processes are believed to be an evolutionary protective mechanism 
to prevent excessive cell growth. When a senescent cell is arrested in G1 it is irreversible 
if the p53 and p16 pathways are intact and the cell cannot be stimulated to proliferate by 
mitogens [107].  Fibroblasts from normal human tissue have the capability to go through 
20-50 population doublings when cultured in growth medium containing mitogens before 
undergoing cellular senescence [110]. The process by which cultured normal mammalian 
cells have limited capacity to divide and become senescent are known as the Hayflick 
limit [104].  
Most if not all cancer cells have recovered the capability to produce telomerase, 
and have mutations in p53 and/or p16/RB making them immortal with unlimited 
proliferative capacity [105,110,111]. Besides cancer cells, telomerase activity is 
documented in germ-line cells [113], embryonic stem cells [114], and to a lower degree 
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in some adult stem cells [115,116]. In MSCs, the expression of telomerase is still debated 
as some studies report low levels of telomerase while others find no expression or activity 
[105,117–119]. Differences may be caused by measurement techniques with various 
sensitivity levels and different cut-offs for telomerase presence. It has furthermore been 
speculated that telomerase-active MSCs might be a minor subpopulation [105]. In horses, 
a telomere shortening of 70-116 base pairs per population doubling has been reported in 
MSCs [120], which correlate with a 30-120 base pair shortening seen in human MSCs 
[105,109]. Senescent cells remain alive in a metabolically altered state and are 
morphologically enlarged and flattened [105,121]. It is important to remember that 
different cell lines proliferate at various rates and hence reach cellular senescence at 
different time points if measured on a chronological scale.  Proliferation is furthermore 
faster during growth and development, and multiple studies have shown that the cellular 
proliferation rate decreases with increasing donor age [27,42,50,97,102,120,122–124]. 
Accumulation of senescent cells is thereby said to drive aging and age-related diseases 
[121].   
 
1.10 Donor age effects on mesenchymal stem cells 
Multiple studies have shown a sharp decline in MSC quantity and quality with increasing 
donor age, which may be problematic for the important demographic of older equine 
orthopedic patients with regards to autologous treatments [65,85,97,122,123,125–127]. 




1.10.1 Donor age effects on MSC frequency 
The frequency of MSCs when harvested can be determined by utilizing a colony forming 
unit-fibroblast (CFU-F) assay. MSCs are rare and can be found in 0.001% to 0.01% of 
bone marrow aspirates [128] and in near 2% of adipose tissue stromal vascular fraction in 
humans [129]. However, most human and rodent studies agree on a decline in MSC 
frequency with increasing donor age [50,105,124,130].  This change has been suggested 
to be caused by an increased predisposition to cellular senescence and a decrease in 
quiescence [27,66,131]. Species and gender may also be important determinants of MSC 
frequency. A human study by Siegel et al. [130] reported a general decline in BM-MSC 
frequency with increasing age when mixing both genders, but only found a significant 
age-related decline within females, even though they produced more CFU-Fs than seen in 
males. Likewise, Katsara et al. [50] reported a 3.5 fold higher BM-MSC frequency in 
young mice compared to old mice, but found a higher frequency of BM-MSCs in males 
compared to females in all age groups. In contrast, Guercio et al. [125] found no 
difference in AT-MSC frequency in young and old canines. Likewise, Justesen et al. 
[100] reported no significant correlation between donor age and total number of colonies 
in human BM-MSCs. Some of these variances may be due to difference in isolation and 
culture methods.   
  
1.10.2 Donor age effects on MSC proliferation in culture 
Multiple assays exist to determine cellular proliferation. These include cell doubling 
methods, 5-bromo-2‘-deoxyuridine (BrdU) assays, 5-ethynyl-2‘-deoxyuridine (EdU) 
assays, and fluorescence activated cell sorting (FACS) [110,132]. The cell doubling 
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method is fast and cheap, but has a low specificity, is investigator-dependent, includes 
potential cells without plastic adherence, and is potentially affected by trypsinization. 
Advantages of the BrdU and the EdU assays are that they can detect cells that have gone 
through the S-phase by applying markers that are incorporated in the DNA during 
replication. EdU is a thymidine analog and is readily incorporated into cellular DNA 
during the S-phase. Advantages of the EdU assay over the BrdU assay are no requirement 
for cell denaturation, more time-efficient, more specific, and less investigator dependent 
[132]. Advantages of a FACS approach is a location of the cells within the cell cycle and 
determination of apoptotic cells, while disadvantages include a high cost and complex 
equipment [110]. Gene expression of markers of proliferation, growth factors, and 
senescence are also commonly included.  
As shown in Table 1.1., the vast majority of studies report a decline in MSC 
proliferation with increasing donor age. Some studies however found no difference in 
cellular proliferation between young and old MSCs. It should be noticed that those 
studies compared age groups closer in age than some of the others. An equine study by 
Schröck et al. [133] reported a heterogeneous population of equine BM-MSCs with a 
decreasing population of cells with maximum proliferation speed with increasing donor 
age. However, the study had a limited study population and was not designed to provide 
kinetics or clinically relevant thresholds with regards to donor age. On the other hand, 
Vidal et al. [42] found no effect of donor age on the proliferative capacity of equine BM-
MSCs, but Vidal‘s study only included horses below 5 years of age (mean 2.4 years old), 
which could explain the different conclusions. Chen et al. [134] furthermore reported that 
the proliferative capacity of AT-MSCs was less affected by donor age than BM-MSCs.  
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Donor age effects on telomere length is more ambiguous as some studies show no 
difference in telomere length [27,105,131], whereas others show a shortening of telomere 
length with increasing age [105,135]. At the same time Asumda et al. [97] reported a 
higher telomerase activity in BM-MSCs from young rats, whereas other studies found no 
telomerase activity in human BM-MSCs [130,131]. An equine study by Wilson et al. 
tested telomerase activity in BM-MSCs from young horses aged 3-5 years, and found 
only 1 sample positive for telomerase activity at day 2 after collection and all the samples 
negative on day 10 [119]. With regards to senescence markers, studies have shown an 
increase in β-galactosidase activity, and p16, p21, and p53 expression with increasing 
donor age [27,37,122–124]. It should however be noted, that β-galactosidase activity is 
not a specific marker of donor age, but considered a reliable marker of cellular 
senescence as shown by Stenderup et al. where β-galactosidase activity was up-regulated 
in late passages, but not between BM-MSCs from young and old donors [105,131]. It has 
however been suggested that accelerated senescence is seen in old MSCs [27,131]. 
Multiple studies have shown a down-regulation in growth factors in old MSCs [37,97]. 
An age-related increase in expression of tumor suppressors and a down-regulation of 
growth factors may very well cause the lower in vitro cellular proliferation described in 
old MSCs in most studies. These studies were supported by a recent proteomics study, 
where the majority of MSC age-related changes were seen in proteins related to cell 
survival and death, and cellular proliferation [85].    
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Table 1.1: Mesenchymal stem cell proliferation characteristics as a function of donor age 
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[37] 
*Y: young age group, M: middle-aged age group, O: old age group, d: days old, w: weeks old, mo: months old, yo: years old, ↑: up-
regulated gene expression, ↓: down-regulated gene expression.   
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1.10.3 Donor age effects on MSC differentiation in culture 
Donor age also appears to be a major factor altering the chondrogenic and osteogenic 
differentiation performance of BM- and AT-MSCs in culture. Currently, most work has 
been performed on assessing the osteogenic differentiation potential as a function of age. 
As shown in Table 1.2 and Table 1.3 most studies report a decline in chondrogenic and 
osteogenic differentiation potential of MSCs with increasing donor age. A study by 
Asumda et al. [97] found that BM-MSCs from 15 months old rats had lost their 
chondrogenic and osteogenic differentiation potential altogether, which was supported by 
a 76% decline in osteogenic alkaline phosphatase activity in adult human BM-MSCs 
[65], and a 82% decline in proteoglycan content of chondrogenic induced BM-MSC 
pellets from 1 year old rats compared to 1 week old rats [127]. Previous studies have 
reported, that AT-MSCs osteogenic differentiation capacity was less affected by donor 
age than BM-MSCs [134,137]. It should be noted that most of the studies reporting no 
effect of donor age compare age groups that are relatively closer to each other as seen in 
Table 1.2 and Table 1.3. On a gene level, most studies also report a down-regulation in 
expression of chondrogenic (e.g. SOX9, aggrecan, collagen type II) and osteogenic 
markers (e.g. RUNX2, alkaline phosphatase, osteocalcin) with increasing donor age after 
culture in induction medium [122,124,127].  
An ―adipogenic switch‖ has been reported in some studies where BM-MSCs from 
aged donors are more prone to adipogenic differentiation compared to osteogenic 
differentiation [11,105]. This observation may be explained by Kretlow et al.’s finding 
that chondrogenic and osteogenic differentiation performance decline earlier than 
adipogenic differentiation in BM-MSCs [136].  
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Table 1.2: Mesenchymal stem cell chondrogenic differentiation performance as a 
function of donor age 
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Table 1.3: Mesenchymal stem cell osteogenic differentiation performance as a function 
of donor age 
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*Y: young age group, M: middle-aged age group, O: old age group, d: days old, w: weeks old, mo: months old, yo: years old, ↓: 






1.11 Priority knowledge gaps and hypotheses 
As reported in other species, the age of the horse may be an important variable for 
orthopedic injuries treated with autologous cells. Very little is however known about 
donor age effects on MSCs in horses, and no donor age related equine MSC proliferative, 
and chondrogenic and osteogenic differentiation studies have been designed with 
multiple age groups or sufficient donors to provide thresholds relevant for clinical 
practice. It is furthermore unknown if the cellular proliferation and chondrogenic and 
osteogenic differentiation performance of equine BM- and AT-MSCs are equally affected 
by donor age. Ultimately, age-associated alterations may impact the efficacy of 
autologous transplanted MSCs in aged horses resulting in poorer regenerative results.  
The studies described in this dissertation were designed to address these priority 
questions using 2 clinically relevant stem cell types from 5 clinically relevant and well 
distinguished age groups. Experiments reported in chapter 2 test the hypothesis that 
increasing donor age is a major variable impacting equine BM- and AT-MSC 
proliferation with decreasing capacities following non-linear kinetics. These data are 
further expanded in chapter 3, where the reported experiments tests the hypothesis that 
increasing donor age is a major variable impacting equine BM- and AT-MSC 
chondrogenic and osteogenic differentiation performance with decreasing capacities 
following non-linear kinetics. Finally, chapter 4 reflects on the combined dissertation 
work and elaborates on the clinical importance of donor age, together with proposed 




CHAPTER 2.  DONOR AGE EFFECTS ON THE CELLULAR PROLIFERATION OF 
EQUINE MESENCHYMAL STEM CELLS IN CULTURE 
2.1 INTRODUCTION 
Musculoskeletal injuries are the leading cause of lost training days and early retirement 
of horses, and can affect horses at all ages [1,2,138]. Current treatment options aiming at 
restoring the inherent function of cartilage, tendon, ligament, and some bone injuries and 
enhancing the long term prognosis are however of limited availability [17]. Fortunately, 
mesenchymal stem cells (MSCs) have shown potential to facilitate the repair of 
musculoskeletal injuries including bone, cartilage, and tendon injuries through 
immunomodulatory-, differentiating-, and growth factor excreting properties 
[21,22,38,47,48,98,139], and are hence being used increasingly in equine practice. Bone 
marrow (BM)- and adipose tissue (AT) derived MSCs are currently the choice of therapy, 
where BM-MSCs have shown higher potential to treat cartilage and bone injuries 
[35,41,44,45]. Nevertheless, Vidal et al. reported a low frequency of BM-MSCs with a 
mean of 1.5 x 10
4
 BM-MSCs per 10 mL bone marrow aspirate in young horses, whereas 
a mean of 1.3 x 10
6
 AT-MSCs was found per 10 mL adipose tissue in young horses 
[31,42]. Notably, MSC frequency depends on cell type, donor age, donor sex, and inter-
animal variation [42,50]. For successful therapies, a substantial number of cells are 
needed, which requires extensive ex vivo cell expansion. Generally, cell-based therapy 
protocols require 10-100 x 10
6
 MSCs per treatment [40,47–49], and equine MSCs 
consequently need to be expanded in vitro for about 2-3 weeks prior to implantation 
[31,40]. However, this depends on injury type, aspirate/tissue volume, MSC frequency, 
proliferative rate, and expansion medium. A canine bone defect model showed that 15 x 
10
6
 MSCs/mL of implant volume (total of 30 x 10
6
 MSCs) was required to improve bone 
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regeneration of a 21 mm long segment of the femoral diaphysis [56]. This study was 
supported by a mathematical model, which found that 70 x 10
6
 osteoblasts were needed 
to produce 1 cm
3
 of bone [57]. Additionally, repeated MSC applications have shown 
beneficial effects in vivo, which increases the need for cells [51]. 
Unfortunately, human and rodent studies have shown a decline in frequency and in 
vitro proliferative capacity of BM- and AT-MSCs with increasing donor age 
[27,37,50,97,122–124,131]. A human study performed on donors from the age of 17 to 
90 years old, revealed a doubling rate that was almost twice as long in BM-MSCs from 
old donors (≥ 55 years old) [122]. It has furthermore been determined that MSCs from 
aged human, non-human primate, and rodent donors have increased levels of cell cycle 
arrest genes like p21 and p53 [27,122,123], and decreased expression of growth factors 
like vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF) [97].  
Very little is, however, known about these age-dependent relationships in horses, 
and no equine MSC proliferative age studies have been designed with multiple age 
groups or sufficient donors to provide thresholds relevant for clinical practice 
[36,42,133]. A lack of direct age correlating models between horses and other species 
highlights the importance of equine studies to investigate the potential donor age issue 
further. Expansion issues cause in best case a delay of treatment, which may be an issue 
for some applications where early treatment has been shown to be of essence [58], but 
can be devastating if the cells cannot be expanded. Together, this may limit the clinical 
potential of MSCs from aged horses, as the ability to expand the cells is vital to obtain 
sufficient numbers for autologous treatment, and cellular proliferation has been shown to 
be positively correlated with regenerative potential [140]. Presently, autologous treatment 
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is preferred over allogenic treatment due to the potential risk of immunological reactions 
associated with allogenic treatments in equine models [40,92–94,141]. This is 
problematic as many patients with osteoarthritis are aged [142]. The need for 
regenerative medicine in equine practice is thus believed to increase tremendously partly 
due to the progressively aging equine population [143]. Together, this emphasizes the 
significance of understanding the changes in the proliferative capacity of equine MSCs as 
a function of donor age.  
The studies reported in this chapter were therefore designed to test the hypothesis 
that increasing donor age is a major variable impacting equine BM- and AT-MSC 
proliferation with decreasing capacities following non-linear kinetics.  Specific aims were 
to 1) compare the cellular proliferation of BM- and AT- MSCs from horses in different 
age groups using an EdU proliferation assay, and to 2) assess the expression of targeted 
biomarkers of cellular proliferation, cellular senescence, and proliferation related markers 
that have shown age-dependent variation in other species.   
 
2.2 MATERIALS AND METHODS 
2.2.1 Experimental samples 
BM-MSCs, AT-MSCs, and dermal fibroblasts (DF) (biological control) were harvested 
immediately post-mortem from horses of mixed breeds in 5 different clinically relevant 
and well-distinguished age groups with 4 horses in each age group. The age groups were 
newborn (0 days old), yearling (1-2 year old), adult (5-8 year old), middle aged (12-18 
year old), and geriatric (≥ 22 year old) horses. All horses were euthanized due to reasons 
unrelated to this study. The study was conducted according to the ethical guidelines of 
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animal research at the University of Copenhagen and the University of Kentucky. A 
written consent was obtained from all privately-owned horses prior to collection.   
 
Sample size was determined by power analysis. Two-sample t-test power 
calculations were performed in R (version 3.6.0) using pilot study data (not shown) to 
assess BM- and AT-MSC cellular proliferation using cells from newborn foals and 
geriatric horses (n=2 horses per age group per cell type) and the following equation: 
    
    
 
       
 
   ⁄   
 
where   is the standard deviation for the outcome, α is the significance level, 1 – β is the 
power,     
 
 
 = 1.96 for α = 0.05,      = 0.84 for 1 – β = 0.80, and δ was set to 10% 
as the minimum relevant difference. The estimated sample size to achieve a power of 
0.80 was determined as 4 horses per age group per cell type. An overview of the 












Table 2.1:  Overview of biological replicates used as study population 




DF Reason for 
euthanasia 
Newborn 0 d. Pony M EQF1701 x x x Research 
Newborn 0 d. Pony M EQF1703 x x x Research 
Newborn 0 d.  Pony M EQF1704 x x x Research 
Newborn 0 d. Pony F EQF1705 x x x Research 
Yearling 16 mo. Thoroughbred F EQA1504 x x x Research 
Yearling 16 mo. Thoroughbred F EQA1505 x x x Research 
Yearling 15.5 
mo. 
Thoroughbred M EQA1506 x   Research 
Yearling 15 mo. Thoroughbred M EQA1507 x  x Research 
Yearling 15 mo. Thoroughbred M EQA1508  x x Research 
Yearling 16 mo. Thoroughbred M EQA1509  x  Research 
Adult 8 yo. Warmblod M O115 x x  Unknown 
Adult 5 yo. Standardbred F 1607 x x  Research 
Adult 7 yo.  Standardbred F 1608 x x  Research 
Adult 6 yo. Standardbred F V1804   x Research 
Adult 6 yo. Standardbred F V1805   x Research 
Adult 5 yo.  Standardbred F V1806   x Research 
Adult 7 yo. Standardbred M V1807 x x x Research 
Middle-aged 16 yo. Thoroughbred F S1702 x  x Research 
Middle-aged 18 yo.  Thoroughbred F S1703 x  x Weight loos  
Middle-aged 12 yo. Standardbred F S1704   x Research 
Middle-aged 12 yo.  Standardbred F S1705   x Research 
Middle-aged 16 yo. Fjord horse M O315  x  Unknown 
Middle-aged 14 yo. Pony M O415  x  Unknown 
Middle-aged 13 yo. Standardbred F 1606 x x  Research 
Middle-aged 15 yo. Standardbred F O916  x  Research 
Middle-aged 15 yo. Standardbred F 1116 x   Research 
Geriatric 25 yo.  Coldblood M O314 x x  Unknown 
Geriatric 22 yo. Thoroughbred F G1609 x x x Research 
Geriatric 32 yo. Thoroughbred F G1610   x Research 
Geriatric 25 yo. Thoroughbred F G1801 x x x Lymphoma 
Geriatric 31 yo. Thoroughbred F G1802 x x x Colic 
*d.=days old, mo.=months old, yo.=years old, M=Male, F=Female, BM= Bone marrow, 








2.2.1.1 Bone marrow derived MSC collection and isolation 
BM or BM aspirates were collected immediately post-mortem from the sternum of 12 
female and 8 male horses, with the following age distribution; newborn (mean=0 days, 
range=0-0 days), yearling (mean=15.7 months, range=15.3-16 months), adult (mean=6.8 
years, range=5-8 year), middle aged (mean=15.5 years, range=13-18 year), and geriatric 
(mean=25.8 years, range=22-31 year).  
For the newborns, BM was collected as described by Vidal et al. [42] with few 




 sternebrae by sterile curettage 
after splitting the sternum in midline. The marrow trabecular bone was transported on ice 
to the laboratory in ice cold sterile Dulbecco‘s phosphate buffered saline (dPBS, Gibco, 
Cat# 14190144) with 2% (v/v) amphotericin B (Gibco, Cat# 15290026), and 2% (v/v) 
penicillin/streptomycin (P/S, Gibco, Cat#15070063) (isolation juice) and processed 
within 2 hours of collection. In the cell laboratory, the marrow trabecular bone was rinsed 
twice in 37
o
C pre-warmed isolation juice and crushed before being grown as an explant 
culture in 2 T75 cm
2
 culture flasks (Cellstar BioGreiner, VWR, Cat# 82050-856) with 12 
mL/flask Dulbecco‘s modified Eagle‘s medium (DMEM, 1 g/L glucose, with phenol red, 
GlutaMAX, and pyruvate, Gibco, Cat# 10567-022), 10% (v/v) fetal bovine serum (FBS), 
1% (v/v) P/S, and 1% amophotericin B (isolation medium). After 48 hours, BM crusts 
and non-adherent cells were aspirated along with the isolation medium, and the medium 
was changed to expansion medium containing 1 g/L DMEM, 10% FBS, and 1% P/S. The 
cells were cultured at 37
o
C in a humidified atmosphere containing 5% CO2 and expansion 
medium was changed every 2-3 days.  
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 sternebrae as 
previously described [34,42]. In short, the area over the sternum was clipped and 
surgically prepared with 2% chlorohexidine medical scrub and 70% ethanol. A total of 20 
mL of BM was collected using a 10 cm, 11 G Jamshidi® bone biopsy needle (Henry 
Schein Vet, Cat# DJ4011X) and two 20 mL Luer-Lock syringes preloaded with 1000 IU 
sodium heparin (Henry Schein Vet, Cat# 4327680) per 10 mL BM aspirate. The BM 
aspirate was transferred to a 50 mL falcon tube and gently inverted, before being 
transported on ice to the laboratory and further processed within 2 hours of collection. In 
the cell laboratory, the BM aspirate was layered slowly onto Ficoll-Paque® PREMIUM 
(GE Healthcare, Cat# 17-5442-02) in a 1:1 (v/v) manner and centrifuged for 30 minutes 
at 600 g. The mononuclear cell layer containing BM-MSCs was collected and washed 
twice in sterile dPBS and centrifuged for 5 minutes at 200 g between the washes. The 
supernatant was removed and the pellet was re-suspended in 24 mL isolation medium and 
equally divided into two T75 cm
2
 culture flasks. After 48 hours, allowing the BM-MSCs 
to adhere to the bottom of the flasks, the first medium change occurred and isolation 
medium was replaced with expansion medium. The cells were incubated at 37
o
C and 5% 
CO2.  
2.2.1.2 Adipose tissue derived MSC collection and isolation 
AT was collected from the gluteal region above the biceps femoris muscle next to the tail 
base of 10 female and 10 male horses as previously described [34], with the following 
age distribution; newborn (mean=0 days, range=0-0 days), yearling (mean=15.8 months, 
range=15.3-16.1 months), adult (mean=6.8 years, range=5-8 year), middle aged 
(mean=14.5 years, range=13-16 year), and geriatric (mean=25.8 years, range=22-31 
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year). Briefly, the gluteal area next to the tail base was surgically clipped and prepared as 
described for BM-MSCs, and 10 grams of AT was collected through a ~8 x 8 cm surgical 
window. The AT was transferred to a 50 mL falcon tube with ice cold isolation juice and 
transported on ice to the laboratory where the tissue was further processed within 2 hours 
of collection. In the cell laboratory, the AT was washed two times in isolation juice and 
dissected into smaller pieces where visible blood vessels were removed. The AT was 
digested in sterile filtered (0.2 µm) AT enzyme medium consisting of DMEM (1 g/L), 
1% P/S, 50 µg/mL gentamycin (Sigma-Aldrich, Cat# G1264-1G), and 1 mg/mL 
collagenase type I (Worthington, Cat# X7H9763A) for 3 hours at 37
o
C and 30 rpm. The 
enzyme medium containing released cells was transferred through a 70 µm cell strainer 
and the pellet with AT-MSCs was washed twice in sterile dPBS and centrifuged at 500 g 
for 5 minutes between the washes. The pellet was re-suspended in 24 mL isolation 
medium supplemented with 50 µg/mL gentamycin and distributed into 2 T75 cm
2
 culture 
flasks.  The first medium change occurred 48 hours after isolation, where fresh expansion 
medium was added. The cells were grown at 37
o
C in air with 5% CO2 with medium 
change every 2-3 days. 
2.2.1.3 Dermal fibroblast collection and isolation 
DFs (biological control) were harvested from the gluteal region above the biceps femoris 
muscle next to the tail base of 14 female and 6 male horses as previously described [35], 
with the following age distribution; newborn (mean=0 days, range=0-0 days), yearling 
(mean=15.6 months, range=15.3-16 months), adult (mean=6 year, range=5-7 year), 
middle aged (mean=14.5 years, range=12-18 year), and geriatric (mean=27.5 years, 
range=22-32 year). Briefly, 6 grams of dermal tissue was collected from the surgical 
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window made to collect AT-MSCs. The dermis was transferred to a 50 mL falcon tube 
with ice cold isolation juice and transported on ice to the laboratory where the tissue was 
further processed within 2 hours of collection. In the cell laboratory, the dermal tissue 
was washed two times in isolation juice and dissected into smaller pieces. The dermis 
was digested in sterile filtered (0.2 µm) DF enzyme medium consisting of dPBS, 1% P/S, 
1% bovine serum albumin (BSA – Sigma, Cat# A9418-10G), 50 µg/mL gentamycin, and 
1 mg/mL collagenase type I for 2 hours at 37
o
C and 30 rpm. The enzyme medium 
containing released cells was transferred through a 70 µm cell strainer and the pellet with 
DFs was washed twice in sterile dPBS and centrifuged at 1000 g for 4 minutes between 
the washes. The pellet was re-suspended in 24 mL isolation medium supplemented with 
50 µg/mL gentamycin and distributed into 2 T75 cm
2
 culture flasks and grown at 37
o
C in 
air with 5% CO2. The first medium change occurred 48 hours after isolation, where fresh 
expansion medium was added. Expansion medium was changed every 2-3 days.   
 
Figure 2.1: Representative images showing collection sites for sternal bone marrow from 
newborn foals (A) and adult horses (C), adipose tissue (B) and dermal tissue (E). Some of 
the materials needed for tissue collection are shown in image D. *Modified anatomy 
horse from: www.rainbowresource.com.   
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2.2.2 Cell expansion and storage 
At approximately 80% confluence, the cells were passaged with 1 mL 0.25% Trypsin/1 
mM EDTA (Gibco, Cat# 11560626) per T75 cm
2
 culture flask. Cell counting was 
performed manually using tryphan blue (Fisher Scientific, Cat# 11538886) and a 
hemocytometer. The cells were grown with a seeding density of 500,000 cells per T75 
cm
2
 culture flask. At passage 2 (P2), the cells were cryopreserved with Recovery-Cell 
Culture Freezing Medium® (Gibco, Cat# 11560446, containing 10% DMSO) at a 
concentration of 2-3 x 10
6
 cells per 1 mL freezing medium in cryogenic vials (Nalgene, 
Thermo Scientific, Cat# 5000-0020). The cells were thawed in 37
o
C pre-warmed 
expansion medium and washed three times in dPBS to remove leftover freezing medium 
before being grown in expansion medium and incubated at 37
o
C and 5% CO2 with 
medium change every 2-3 days. Proliferation assays were performed at passage 4.    
2.2.3 Assessment of cellular proliferation 
Cellular proliferation was quantified by determining levels of incorporated 5-ethynyl-2‘-
deoxyuridine (EdU) after pulse labeling. EdU is a thymidine analog that is integrated into 
newly synthetized DNA when the cell goes through the synthesis (S) phase of the cell 
cycle. Using Click-iT chemistry, EdU incorporated proliferating cells can be 
fluorescently labeled and visualized through fluorescence microscopy. EdU pulsing, 
fluorophore labeling, and subsequent visualization was done as described previously 
[36,132], and by the manufacturer using a Click-iT Plus Alexa Fluor 594 EdU Imaging 
Kit
®
 (Life Technologies, Cat# C10639).  
In short, passage 4 cells were seeded at a density of 25,000 cells per well in a 24-
well plate (Nunc, Thermo Scientific, Cat# 10604903) and cultured in expansion medium 
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for 48 hours. Seeding density and expansion duration was determined based on a pilot 
study to avoid overlapping of cells (data not shown). The cells were then pulsed for 24 
hours with 8 µM EdU (Jena Bioscience, Cat# CLK N001-25). A total of 8 technical 
replicate wells were pulsed with EdU, and 1 control well was kept under normal 
expansion medium without pulsing. Next, the cells were fixed in 4% methanol-free 
paraformaldehyde (Fisher Scientific, Cat# 11586711, in dPBS) and washed with 3% BSA 
(Sigma, Cat# A7906, in dPBS) before being permeabilized with 0.1% Triton-X (Sigma, 
Cat# T9284). For EdU label detection, the cells were incubated for 30 minutes with 250 
µL kit cocktail containing Alexa 594 per well. The staining cocktail was removed and the 
cells were washed with 3% BSA and dPBS before being counterstained with 300 µL 4‘, 
6-diamidino-2-phenylindole dihydrochloride (DAPI - Invitrogen, Life Technologies, 
Cat# D1306) per well for 15 minutes at a concentration of 1µg/mL. The fluorophore 
staining cocktail was prepared fresh for each assay and the cells were incubated protected 
from light. 
Images of the cells were taken in the dark using a fluorescence microscope with 
DAPI and Texas Red (equivalent to Alexa 594) filters using exposure times between 100-
150 ms. A total of 3 random images were taken per well for each fluorophore. The total 
number of cell nuclei (DAPI stained) and the number of proliferating cells (EdU labeled 
and Alexa 594 stained) were counted using automated imaging software (NIH Image-J 
version 1.48). The cellular proliferation rate was calculated as the number of EdU labeled 
nuclei as a percentage of total cell nuclei in each image. The proliferation percentage was 
calculated for all 3 images per well and then averaged.  
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2.2.4 Differential gene expression 
2.2.4.1 RNA isolation and reverse transcription 
Passage 4 cells were grown as monolayer cultures in T75 cm
2
 flasks with expansion 
medium. At approximately 80% confluence, the cells were extracted with QIAzol
®
 
(Qiagen, Cat# 79306), a guanidinium thiocynate-phenol-chloroform lysis reagent, and 
snap frozen in liquid nitrogen before being stored at -80
o
C prior to RNA isolation. The 
cells were homogenized in 2 mL of QIAzol
®
 using a PowerGen 125 homogenizer (Fisher 
Scientific, Cat# 15120247). Total RNA was isolated using a spin column-based Qiagen 
RNeasy Mini Kit
®
 (Qiagen, Cat# 74104) with modifications as previously described 
[144]. RNA quantity was determined immediately after RNA isolation using a NanoDrop 
ND 1000 spectrophotometer. The samples then underwent ethanol precipitation to 
remove processing contaminants. Quantification of the purified RNA was performed 
using the Qubit BR Assay (Life Technologies, Cat# Q10210) and NanoDrop ND 1000 
spectrophotometer. The quality of the purified RNA was assessed with a Bioanalyzer 
2100 (Agilent Technologies, Eukaryotic Total RNA Nano & Pico Series II). All purified 
RNA samples met the following quality thresholds; 260/280 ratios of 1.9-2.1, 260/230 
ratios of 1.8-2.28, and an Agilent RNA integrity number (RIN) of ≥ 8.0, with the 
exception of one sample (Appendix 1) that behaved as expected in down-stream analyses 
and thus were not excluded from the study.  
 Removal of potential genomic DNA contamination and reverse transcription of 
total RNA to cDNA was achieved using a commercially available kit as per 
manufacturer‘s protocol (Maxima First Strand cDNA Synthesis Kit
®
 for RT-qPCR with 
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dsDNase, Life Technologies, Cat# K1672). All cDNA samples were diluted with 
nuclease-free water to 13.9 ng/uL and stored at -80
o
C.   
2.2.4.2 Real-time quantitative PCR 
Forty-seven biomarkers were selected for the gene expression panel based on functional 
annotation to have biological relevance important for cell proliferation, cellular 
senescence, or evidence in the literature of age-dependent variation related to 
proliferation. The biomarker panel e.g. included known mitogens, cell cycle regulators, 
tumor suppressors, anti- and pro-apoptotic genes, and markers of cellular senescence 
(Genes and annotations are shown in Appendix 2).  
Commercially available, validated equine-specific TaqMan
®
 primer-probe sets 
(FAM dye-labeled MGB probes - Thermo Fisher) for all biomarkers were used to 
quantitate the steady state mRNA levels. Details on the primer-probe sets are listed in 
Table 2.2. The functionality of all primer-probe sets was tested against a positive control 
equine sample containing mixed cDNA consisting of a 43-sample pool of various tissue 
[145], day 35 whole fetus, and neonatal epiphyseal cartilage. Negative controls of RNase-
free water and minus-template was incorporated, and each sample was run in duplicate. 
Real-time quantitative PCR (RT-qPCR) reactions were conducted in a 384-well 
plate with a total reaction volume of 10 µL using 62.55 ng cDNA per reaction. A robotic 
ViiA
TM
 RT-qPCR System (Thermo Fisher Scientific) was used to perform the reactions. 
LinRegPCR was used to measure reaction amplification efficiencies and cycle threshold 
(Ct) values were calculated [146]. All targets amplified with amplification efficiencies 
close to 2 except for the negative controls that showed no amplification (data not shown).    
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Three commercially available equine-specific endogenous control TaqMan
®
 
primer-probe sets were tested against all samples. The endogenous controls consisted of 
β-2-microglobulin (B2M), β-glucoronidase (GUSB), and ribosomal protein lateral stalk 
subunit P0 (RPLP0). Using NormFinder software [147], GUSB was determined as 
having the most uniform performance across all cell types and age groups (data not 
shown).  
The gene expression of the experimental samples were analyzed by RT-qPCR 
using the BIOMARK HD System (Fluidigm) as previously described [148]. Fluidigm is 
an automated nanofluidic RT-qPCR system that uses microfluidic technology in which 
dynamic arrays of integrated fluidic circuits are used, allowing for samples and reagents 
to be mixed in a variety of patterns. Hence, little sample quantity is needed to be tested 
against multiple (e.g. 96) targets, making it less time-consuming and more cost-effective 
compared to standard qPCR [148].   
Briefly, all experimental cDNA samples were shipped at a concentration of 13.9 
ng/µL (middle of positive standard curve), together with the positive control (7 three-fold 
dilutions to detect high and low expressed genes), negative controls, and primer-probe 
sets (including endogenous controls) to The Carver Biotechnology Center, University of 
Illinois, IL, USA, where the Fluidigm was performed. A total of 7 µL of cDNA and 25 
µL of primer-probe sets were shipped per sample or target, respectively. The Fluidigm 
was carried out using 96.96 dynamic arrays (Fluidigm Corporation, CA, USA) according 
to manufacturer‘s instructions.  
The data were analyzed with Fluidigm Real-Time PCR Analysis Software in the 
BIOMARK instrument (Fluidigm Corporation, CA, USA) where Ct values were 
41 
 
calculated. Delta Ct values were determined for each sample by subtracting the 
corresponding Ct value of the endogenous control (GUSB). The positive control was 
used as a calibrator to calculate ΔΔCt values. Relative expression (RQ) of the gene 
targets were calculated using the 2
-ΔΔCt
 method [149]. RQ levels were used for graphical 
bar/boxplot presentations made in GraphPad Prism 8.0.1, and Ln(RQ) values were used 
for heatmap and statistical analysis to linearize the data again and to avoid right-shifting 
of data. Gene expression heatmap visualization was done on averaged Ln(RQ) levels for 
each study group, grouping the samples according to cell type and donor age, and genes 
according to biological function. Heatmap was generated in RStudio 3.6.0 using the 
heatmap ggplot function.  
  
2.2.5 Inter-laboratory control 
The study was performed in two different laboratories (University of Copenhagen 
(UCPH) and University of Kentucky (UK)). To control for potential inter-laboratory 
differences, an inter-assay control was included. BM-MSCs from the same cell line was 
shipped on dry-ice from UK to UCPH and tested using the same procedures in both 
laboratories. Plastic ware, mediums, reagents, commercially available kits, and protocols 
were kept constant throughout the entire study for all samples. The inter-laboratory 
control was tested using the EdU proliferation assay and by Fluidigm RT-qPCR. Isolated 
RNA was shipped on dry-ice from UCPH to UK to allow for all RNA and cDNA samples 
to be analyzed on the same machines. Laboratory was furthermore added as a variable in 
the statistical model used for data analysis. All inter-laboratory controls showed no 
indication of significant differences between laboratories (data not shown). 




Table 2.2: Overview of TaqMan primer-probe sets used in RT-qPCR reactions.  
Gene ID Gene name(s) ThermoFisher Assay ID  
ABI3BP ABI family member 3 binding protein Ec06625599_m1 
AQP1 Aquaporin Ec06625425_m1 
AREG Amphiregulin Ec06992855_m1 
BARD1 BRCA1-associated RING domain 1 Ec07061151_m1 
BAX BCL2 associated X apoptosis regulator Ec07016716_s1 
BCL2 B-cell lymphoma 2 Ec07005800_g1 
BMP3 Bone morphogenic factor 3 Ec07037656_m1 
BRCA1 Breast cancer type 1 Ec07017862_s1 
CASP3 Caspase 3 Ec03470391_m1 
CASP8 Caspase 8 Ec06959413_m1 
CAVIN1 Caveolae associated protein 1 Ec07036873_m1 
CCND1 Cyclin D1 Ec07036996_m1 
CDKN1A p21, Cyclin-dependent kinase inhibitor 1A Ec06955195_m1 
CLU  Clusterin Ec03468575_m1 
COMP Cartilage oligomeric matrix protein Ec03468062_m1 
CSF2 Colony stimulating factor 2 Ec03468208_m1 
CTGF Connective tissue growth factor Ec06625777_gH 
CTNNB1 Beta-catenin Ec00991819_m1 
EPGN Epithelial mitogen Ec06992859_m1 
FGF1 Fibroblast growth factor 1 Ec01092738_m1 
FGF5 Fibroblast growth factor 5 Ec04656774_m1 
FGF18 Fibroblast growth factor 18 Ec03248217_g1 
GDF6 Growth differentiation factor 6 Ec07097112_m1 
GLB1 Beta-galactosidase Ec06954363_m1 
GLI3 GLI family zinc finger 3 Ec06625512_m1 
HDGF Hepatoma-derived growth factor Ec07037751_m1 
HGF Hepatocyte growth factor Ec07000054_m1 
IGF1 Insulin-like growth factor 1 Ec03468689_m1 
IGFBP5 Insulin-like growth factor binding protein 5 Ec03470296_m1 
LOC100146270 p16, Cyclin-dependent kinase 4 inhibitor B Ec07037471_mH 
MET MET proto-oncogene, receptor tyrosine kinase Ec02622441_m1 
MYC c-myc Ec07007511_m1 
PCNA Proliferating cell nuclear antigen Ec06974312_m1 
PDGFD Platelet-derived growth factor subunit D Ec06997714_m1 
PHB Prohibitin Ec07055990_m1 
PTCH2 Patched 2 Ec06625424_g1 
S100A1 S100 calcium binding protein A1 Ec03470173_g1 
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Table 2.2: (Continued) 
Gene ID Gene name(s) ThermoFisher Assay ID  
SNAI2 Snail family transcriptional repressor 2 Ec06625397_m1 
SOST Scherostin Ec07036868_m1 
TERT Telomerase reverse transcriptase Ec06972692_m1 
TGFA Transforming growth factor alpha Ec06949183_m1 
TGFB1 Transforming growth factor beta 1 Ec06625477_m1 
TGFB2 Transforming growth factor beta 2 Ec07074189_g1 
TGFB3 Transforming growth factor beta 3 Ec00682163_m1 
TIMP2 Metallopeptidase inhibitor 2 Ec03470558_m1 
TP53 Tumor protein 53 Ec03470648_m1 
VEGFA Vascular endothelial growth factor A Ec03467879_m1 
B2M Beta-2-microblobulin Ec03468699_m1 
GUSB Beta-glucoronidase Ec03470630_m1 
RPLP0 Ribosomal protein lateral stalk subunit P0 Ec04947733_g1 















2.2.6 Statistical analysis 
The cellular proliferation data, comparing age-groups within cell types and across cell 
types, were analyzed with a generalized linear mixed model using The GLIMMIX 
Procedure in SAS 9.4 with Tukey-Kramer‘s post hoc modifications for multiple 
comparisons. Gene expression data were analyzed in 2 steps. Initially, one-way analysis 
of variance (ANOVA) using SAS 9.4 was applied individually to all 47 gene targets 
within each cell type to look for donor age effects. Next, targets showing significant 
difference on the ANOVA and more than 5-fold difference between study groups on the 
heatmap (Figure 2.6) were analyzed using The GLIMMIX Procedure with Tukey-
Kramer‘s post hoc modifications for multiple comparisons to compare across tissue 
types. Statistical analysis of Fluidigm RT-qPCR results was performed on individual 
extracted Ln(RQ) values. Genes with missing data points (as visualized on Figure 2.6) 
were removed from the statistical analysis for the given cell type. To control for non-
paired samples and potential inter-laboratory variables, horse number and laboratory 
were added to the statistical models as additional factors. Due to age-clustering within 
age groups, statistical linear regression analyses were not feasible and kinetics were 
determined based on graphical presentations. Data were considered statistically 







2.3.1 EdU proliferation assay  
All cell lines were able to be expanded to ~80% confluence at passage 4. When assessing 
the effect of donor age within one cell type, there was a significant decrease in cellular 
proliferation with increasing donor age for BM-MSCs (p=0.0154), AT-MSCs 
(p=0.0003), and DFs (p<0.0001) (Table 2.3 and Figure 2.3). For BM-MSCs, there was a 
significant difference in pair-wise comparisons between newborn and geriatric 
(p=0.0234), yearling and geriatric (p=0.0352), and adult and geriatric (p=0.0247) horses. 
Representative images of proliferating BM-MSCs from horses in different age groups are 
shown in Figure 2.2. Similarly for AT-MSCs, there was a significant difference between 
newborn and geriatric (p=0.0007), yearling and geriatric (p=0.0015), adult and geriatric 
(p=0.001), and middle-aged and geriatric (p=0.0016) horses (Figure 2.3). Hence, there is 
interestingly no difference in pairwise comparisons between age groups other than 
geriatric horses for BM- and AT-MSCs. For DFs, there was a significant difference in 
pair-wise comparisons between newborn and middle-aged (p=0.0453), newborn and 
geriatric (p<0.0001), yearling and middle-aged (p=0.0275), yearling and geriatric 
(p<0.0001), adult and geriatric (p<0.0001), and middle-aged and geriatric (p=0.0006) 
horses (Figure 2.3).  
When comparing across cell types, all cell types were equally affected by donor 
age (p=0.3359), and there was no significant difference in the cellular proliferation 
between BM- and AT-MSCs in any of the age groups (p>0.4) (Figure 2.4). When 
comparing cell types independent of age groups, DFs had a higher cellular proliferation 
than BM-MSCs (p=0.0055) and AT-MSCs (p=0.0177).  
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As an evaluation of the study set up, no Alexa 594 background staining was 
detected in any of the negative control wells grown without EdU pulsing, and no study 
group reached a cellular proliferation of 100% (Table 2.3). Furthermore, Alexa594 
staining was detected in all wells pulsed with EdU, together with DAPI staining. 
  
Table 2.3: Cellular proliferation data of equine adipose tissue (AT)- and bone marrow 
(BM) derived mesenchymal stem cells (MSC) and dermal fibroblasts (DF) from horses in 
5 different age groups after 24 hours of labeling with 8 µM EdU.   








0 d.  AT-MSC 4 91.87 8.07 80.00 98.02 
 BM-MSC 4 89.25 3.20 85.26 92.80 
 DF 4 95.16 1.63 93.13 97.00 
1-2 yo.  AT-MSC 4 89.96 7.90 79.64 96.82 
 BM-MSC 4 88.12 2.05 85.12 89.67 
 DF 4 95.66 1.77 94.02 97.71 
5-8 yo.  AT-MSC 4 90.87 5.49 82.78 94.34 
 BM-MSC 4 89.10 3.12 84.48 91.26 
 DF 4 93.93 1.48 92.78 95.98 
12-18 yo. AT-MSC 4 89.72 3.15 85.08 92.06 
 BM-MSC 4 84.10 4.79 80.50 91.13 
 DF 4 89.29 1.46 87.14 90.43 
≥ 22 yo.  AT-MSC 4 67.66 6.13 61.02 75.56 
 BM-MSC 4 70.91 15.14 48.58 82.16 
 DF 4 79.23 4.98 73.71 84.75 




Figure 2.2: Representative images (20X magnification) of EdU-labeled proliferating cell 
nuclei (Alexa594 – Red/Pink) and all cell nuclei (DAPI – Blue) from equine bone marrow 






Figure 2.3: Bar plots showing the cellular proliferation in percentage of bone marrow 
(BM)- and adipose tissue (AT) derived mesenchymal stem cells (MSC) and dermal 
fibroblasts (DF)  from horses in 5 different age groups (n=4, N=60) after 24 hours of 
labeling with 8 µM EdU. Age groups within the same cell type not labeled with the same 
letter are significantly different from each other (p<0.05).    
 
 
Figure 2.4: Box plots showing the cellular proliferation (%) of equine adipose tissue 
(AT)- and bone marrow (BM) derived mesenchymal stem cells and dermal fibroblasts 
(DF)  from horses in 5 different age groups (n=4 horses per age group per cell type) 
after 24 hours of labeling with 8 µM EdU. Cell types within the same age group not 
labeled with the same letter are significantly different from each other (p<0.05).    
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2.3.2 Gene expression  
Out of the 47 biomarkers related to proliferation and aging, gene expression was affected 
by donor age in 4 biomarkers (9%) in AT-MSCs, 17 biomarkers (36%) in BM-MSCs, 
and 15 biomarkers (32%) in DFs. Differentially expressed genes as a function of donor 
age within each cell type are shown in Table 2.4 and in a Venn-diagram in Figure 2.7 
where intersections are visualized.  
Multiple growth factors (FGF1, FGF18, GDF6, PDGFD, TGFA, and VEGFA) 
were up-regulated in BM-MSCs from old horses compared to young horses. On the other 
hand, fibroblast growth factor 5 (FGF5) were found at lower levels in BM-MSCs from 
geriatric horses compared to newborns (p=0.0212), and in higher levels in AT-MSCs 
compared to BM-MSCs (p=0.0078). Cell cycle regulators, cyclin D (CCND1) and 
proliferating cell nuclear antigen (PCNA), were not affected by donor age in either of the 
two stem cell types, but were down-regulated in DFs from geriatric horses (p=0.0118 and 
p<0.0001, respectively). In general, cyclin D were found at higher levels in BM-MSCs 
compared to AT-MSCs and DFs (p<0.0032), whereas PCNA was found at higher levels 
in DFs compared to AT-MSCs (p<0.0001) and BM-MSCs (p=0.0004). The positive 
regulators of cell proliferation, colony stimulating factor 2 (CSF2), were up-regulated in 
BM-MSCs from geriatric horses compared to all other age groups (p<0.0005), whereas 
GLI family zinc finger 3 (GLI3) were down-regulated in geriatric BM-MSCs (p≤0.0157) 
(Figure 2.6).   
For BM-MSCs, expression of the senescent marker β-galactosidase (GLB1) was 
significantly higher in geriatric horses compared to newborn (p=0.0018), yearlings 
(p=0.0163), and adult horses (p=0.0293), and in middle-aged compared to newborn 
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horses (p=0.0116). GLB1 was not affected by donor age in AT-MSCs or DFs. Higher 
GLB1 expression was seen in BM-MSCs compared to AT-MSCs and DFs in geriatric 
horses (p=0.0011 and p=0.0003, respectively) (Figure 2.6).  
As shown in Figure 2.5, the tumor suppressors p16 (LOC100146270) and p21 
(CDKN1A) were both up-regulated in geriatric BM-MSCs compared to newborn horses 
(p=0.0103 and p=0.0228, respectively). Moreover, p16 and p21 showed higher levels in 
BM-MSCs than in AT-MSCs (p≤0.0155) or DFs (p≤0.0002). For AT-MSCs, the tumor 
suppressor p53 (TP53) had higher expression in geriatric horses compared to newborn 
(p=0.0024) or yearlings (p=0.0075). The pro-apoptotic genes caspase 3 (CASP3) and 
caspase 8 (CASP8) were up-regulated in BM-MSCs from older horses (p≤0.0028).     
 
 
Figure 2.5: Bar plots showing mean relative gene expression (RQ) of p16 and p21 steady 
state mRNA in monolayer cultures of bone marrow (BM)- and adipose tissue (AT) 
derived mesenchymal stem cells (MSC) and dermal fibroblasts (DF) from horses in 5 
different age groups (n=4, N=60) relative to the positive control. *: indicate significant 
difference between geriatric and newborn age group for BM-MSCs (p<0.05). N: 
Newborn (black), Y: Yearling (gray), A: Adult (green), M: Middle-aged (blue), G: 




Figure 2.6: Heatmap showing the Ln(RQ) levels of gene expression by color change 
between average levels in bone marrow (BM) and adipose tissue (AT) derived 
mesenchymal stem cells (MSCs) and dermal fibroblasts (DF) from horses in 5 different 
age groups (n= 4 horses per age group per cell type). Gray boxes indicate no detection 
of gene expression. *N: Newborn, Y: Yearling, A: Adult, M: Middle-aged, G: Geriatric, 
CHM: grown in T75 cm
2
 culture flasks with normal expansion medium containing 





Table 2.4: Differentially expressed genes related to cellular proliferation as a function of 
donor age within adipose tissue (AT)- and bone marrow (BM) derived mesenchymal 
stem cells (MSC) and dermal fibroblasts (DF) from horses in 5 different age groups (n=4, 






















































































































*All listed genes were significantly affected by donor age within the given cell type.  
Red marked genes indicate an up-regulation in gene expression with increasing donor 
age. Blue marked genes indicate a down-regulation in gene expression with increasing 




Figure 2.7: Venn-diagram showing the distribution of differentially expressed genes as a 
function of donor age between adipose tissue (AT)- and bone marrow (BM) derived 
mesenchymal stem cells (MSC) and dermal fibroblasts (DF) from horses in 5 different 
age groups.   
 
2.4 DISCUSSION 
In this study, we examined the effect of donor age on the cellular proliferation of equine 
BM- and AT-MSCs and DFs from horses in 5 different age groups, together with 
potential underlying gene expression changes in biomarkers related to proliferation and 
aging. Cellular proliferation in vitro is an essential component for MSC evaluation and 
expansion to therapeutically required numbers, and is furthermore positively correlated 
with regenerative capacity [140].    
The results from the present study support the hypothesis that increasing donor 
age is a major variable impacting equine BM- and AT-MSCs proliferation with 
decreasing capacities following non-linear kinetics, which is similar to previous reports in 
other species [27,50,97,122,123]. Our results were furthermore supported by Schröck et 
al. who reported a heterogeneous population of equine BM-MSCs with a decreasing 
population of cells with maximum proliferation speed with increasing donor age [133]. 
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Schröck‘s study, however, had a limited study population and was not designed to 
provide kinetics or clinically relevant thresholds with regards to donor age. Our study 
design with multiple clinically relevant age groups fills this knowledge gap, and 
interestingly shows that difference in equine BM- and AT-MSC cellular proliferation was 
only seen in pair-wise comparisons involving geriatric horses. High cellular proliferation 
was hence feasible in MSCs from horses below 18 years of age. This finding was 
supported by the gene expression data, where the majority of age related changes in 
expression only were seen in comparisons involving geriatric horses. However, the pair-
wise comparison stands in contrast with other species where differences in proliferation 
were reported already in 8 year old monkeys [27] and in humans above 40 years of age 
[123].  
On the other hand, Vidal et al. found no effect of donor age on the proliferative 
capacity of equine BM-MSCs [42]. However, Vidal‘s study only included horses below 5 
years of age (mean 2.4 years old), and applied a less optimized manually cell doubling 
counting method which could explain the different conclusions. The EdU proliferation 
assay utilized in our study is a widely used cellular proliferation assay that provides 
several advantages over BrdU (5-bromo-2‘-deoxyuridine) and cell doubling techniques 
used in previous studies [27,42,122]. Advantages includes no requirement for cell 
denaturation, high sensitivity, less investigator-dependent output and more time-efficient 
[36,132]. By using the EdU assay and automated cell counting, this study was able to 
determine proliferating cells that have gone through the S-phase of the cell cycle and thus 
were not in G0 or G1 phase arrest. The EdU assay was thereby more objective than 
previous approaches, and only included cells that had plastic adherence and were actively 
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proliferating, which is important as Yu et al. showed more cells in cell arrest and 
prolonged time in S-phase with increasing donor age [27].    
The cellular proliferation of human AT-MSCs have previously been reported to 
be less prominently affected by donor age compared to BM-MSCs [134]. This was 
however not the case in the present study, where equine BM- and AT-MSCs showed 
similar cellular proliferation in all age groups and were equally affected by donor age.  
Together, this may heighten the relevance of BM-MSCs for autologous treatments as 
they have shown higher potential to treat cartilage and bone injuries [35,41,44]. On the 
other hand, less age related gene expression changes were seen in AT-MSCs with the 
selected biomarker panel compared to BM-MSCs and DFs. The age related changes were 
however all in intersection with alterations seen in BM-MSCs or DFs, and there was a 
consistency in up-regulation of genes suppressing proliferation and a down-regulation in 
genes promoting proliferation with increasing donor age. It is furthermore likely that AT-
MSCs have other age related expression changes outside the selected biomarker panel as 
the phenotypic cellular proliferation was equal for AT- and BM-MSCs across age groups.    
Our finding that DFs have a general higher cellular proliferation compared to 
BM-and AT-MSCs is supported by previous studies where DFs have been shown to be 
highly sensitive to mitogenic stimuli and readily expand in adherent monolayer cultures 
[36,150]. Proliferating cell nuclear antigen (PCNA), which is a cofactor for DNA 
polymerase δ and essential for DNA replication [151] was furthermore found at higher 
levels in DFs, together with less expression of the tumor suppressors p16 and p21. 
Compared with the two stem cell types, gene expression data from DFs showed a greater 
mixture of up- and down-regulated genes as a function of donor age within each 
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functional group. The decrease in cellular proliferation with increasing donor age for all 3 
different cell types suggest that there is a general decline in the proliferative capacity of 
healthy equine cells with increasing donor age, which would be in accordance with 
Hayflick‘s limit [104].   
The observed decrease in equine cellular proliferation with increasing donor age 
could e.g. be due to a decrease in growth factors and their receptors, a decrease in pro-
cycling molecules, and/or an increase in cell cycle arrest genes and apoptotic factors. 
Similar to previous studies in other species, the tumor suppressor genes p16, p53, and 
p21 were up-regulated in MSCs from old donors [27,37,122–124]. p16 is a tumor 
suppressor that inhibits DNA replication by binding to cyclin dependent kinase 4/6 
necessary for phosphorylating and inactivating Rb family members. Non-phosphorylated 
Rb thereby binds E2F transcription factor 1 resulting in G1-arrest [111]. An up-regulation 
in p16 may be due to an epigenetic de-repression of p16 reported to trigger cellular 
senescence [102].  p53 is a transcription factor for p21, and the growth inhibitory effect 
of p21 lies primarily in its ability to inhibit cyclin dependent kinases, which is necessary 
for the cell to progress from G1- to S-phase during the cell cycle [107]. Hence, p16 and 
p21 are considered markers of senescence [111,124,152]. Another function of p53 is its 
ability to induce transcription of apoptosis-associated genes like BAX, which leads to 
activation of caspase 3 [153]. Interestingly, increased p53 expression in old AT-MSCs 
did not result in detectable up-regulation of p21 or BAX in geriatric AT-MSCs, which 
e.g. can occur due to lacking phosphorylation of p53 and a resulting rapid degradation.  
An increase in the apoptotic pro-factor caspase 8 can also cause up-regulation of 
caspase 3 [153], which is likely the reason why both CASP8 and CASP3 were up-
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regulated in BM-MSCs from geriatric horses. Age related up-regulation of tumor 
suppressors and apoptotic factors could explain the lower cellular proliferation seen in 
aged horses as fewer cells would have been allowed to progress through the S-phase and 
get EdU incorporated. β-galactosidase (GLB1) activity is an additional marker of 
senescence [152], but higher gene expression in senescent cells is also reported [154]. In 
BM-MSCs, an age related increase in GLB1 expression was seen in geriatric horses 
corresponding well with a previous study showing accelerated cellular senescence with 
increasing donor age in human BM-MSCs [131].  
In a recent study, knockdown of GLI family zinc finger 3 (GLI3) decreased 
stemness and cellular proliferation of cancer stem cells [155]. The observed decrease in 
GLI3 in BM-MSCs from geriatric horses may thus not only affect its proliferative 
capability but also its stemness, which has been shown to be negatively correlated with 
immunogenicity in allogenic transplants in an in vivo equine model [156]. On the other 
hand, multiple growth factors had higher expression in BM-MSCs from geriatric horses, 
which stands in contrast to the cellular proliferation finings and to previous rodent studies 
[97,126]. In support of the results is, however, a study by Zheng et al. where multiple 
growth factors including FGF1, PDGFA, and TGFA were up-regulated in BM-MSCs 
from older rats although not at significant levels [127]. Together, the gene expression 
data suggests that the decreased proliferation observed in BM-MSCs from geriatric 
horses may be more due to an up-regulation in tumor-suppressors and apoptotic factors 
than a decrease in growth factors or pro-cycling factors. It is moreover possible that aged 
BM-MSCs are less responsive to secreted growth factors, which highlights the need for 
more studies to investigate this further.   
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All of our cell lines independent of donor age were able to reach ~80% 
confluence at passage 4, which has also been documented in other species [50], and in an 
equine study reporting a decreased population doubling rate by passage 10 for BM-MSCs 
and by passage 20 for AT-MSCs in young horses [120]. Nevertheless, Yu et al. found 
that BM-MSCs from 12 year old rhesus macaque monkeys underwent senescence already 
at passage 2 and therefore could not be expanded [27]. Hillmann et al. also reported that 
the proliferation of equine adult AT-MSCs were higher at later passages compared to 
human adult cells [157]. Taken together with the pair-wise EdU comparison only 
involving geriatric horses and the majority of age related gene expression changes only 
involving geriatric horses, this raises the question if the cellular proliferation of equine 
BM- and AT-MSCs may follow a different biological aging pattern compared to other 
species or if the differences are due to technical variations?  
All cells were collected immediately after euthanasia. This is, however, not 
believed to affect the translational value of the results into autologous transplantations, as 
no difference have been reported in MSCs from newly euthanized and anesthetized 
horses [133]. Collection of BM-MSCs varied for newborn and the other age groups as the 
newborn sternum was too cartilaginous and Jamshidi
®
 bone marrow aspiration 
unfeasible. By splitting the sternum and growing the trabecular bone marrow as tissue 
explants, the same principles as described for foals previously were utilized [42], and the 
cells seeded down and followed the same expansion pattern as seen in yearlings. The 
newborn age group furthermore consisted only of cells from ponies, but this is believed 
to have minor importance as the cellular proliferation pattern and gene expression in this 
age group were similar to the other young age groups. The cells were collected from a 
59 
 
mixture of female and male horses, with both genders represented in each age group. 
However, there was a higher presentation of cells from female horses, but in vitro 
proliferation has been shown not to be affected by gender [50].      
In conclusion, all cells independent of age group were able to be expanded to 
passage 4, but the cellular proliferation of equine BM- and AT-MSCs declined 
significantly in the geriatric age group. Furthermore, the cellular proliferation of BM- and 
AT-MSCs was similar in all age groups and they were equally affected by donor age. 
Underlying gene expression changes related to proliferation and aging showed a primary 
up-regulation in tumor suppressors, apoptotic genes and multiple growth factors in stem 
cells from old horses, and a down-regulation in some pro-cycling genes depending on cell 
type. AT-MSCs showed less age related expression changes in the selected biomarkers 
compared to BM-MSCs and DFs. Together, this highlights the importance of donor age 
considerations for autologous treatments in horses.     
This study is the first equine study comparing the cellular proliferation potential 
of MSCs from horses in multiple age groups. Incorporation of 5 well-distinguished 
clinically relevant age groups furthermore sets it apart from most previous studies in 
other species where few wider age groups have been compared. The results are thus 
believed to be highly interpretable for clinical practice and when advising horse owners. 
By assessing changes in gene expression, we have identified targets to potentially 
improve the cellular proliferation capacity of MSCs from geriatric horses through 
molecular manipulations. Further transcriptome and mechanistic studies will be valuable 
in elucidating the exact effect of the identified biomarkers, their pathways, and how they 
are involved in regulating the cellular proliferation of equine MSCs as a function of 
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donor age. Our results showed that MSCs can be expanded in vitro at high rates in horses 
below 18 years of age, which is promising to obtain sufficient numbers for autologous 
treatments, but lacks to investigate how the cells proliferate in vivo. Furthermore, the 
proliferative capacity of MSCs needs to be held together with their potential to heal 
musculoskeletal injuries, which remains to be investigated as a function of donor age in 
horses. The next chapter in this dissertation will therefore focus on the effect of donor age 
on the chondrogenic and osteogenic differentiation potential of equine BM- and AT-
MSCs in culture.    
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CHAPTER 3. DONOR AGE EFFECTS ON THE CHONDROGENIC AND 
OSTEOGENIC DIFFERENTIATION PERFORMANCE OF EQUINE 
MESENCHYMAL STEM CELLS IN CULTURE 
3.1 INTRODUCTION 
Orthopedic injuries are a major cause of lameness and morbidity in horses worldwide, 
leading to substantial personal and financial losses for horse owners and the horse 
industry [1–3]. Articular cartilage injuries are particularly problematic since cartilage has 
a very limited intrinsic repair capacity, believed to be due in part to a lack of vasculature 
and low mitotic activity of the chondrocytes. Articular cartilage is present on opposing 
bone surfaces in diarthrodial synovial joints, where its main functions are to distribute 
load and provide a smooth and lubricated surface for articulation to minimize the 
coefficient of friction for movement [4]. Lesions involving articular cartilage often 
progress and potentially involve subchondral bone, which leads to significant pain and 
loss of function, resulting in long periods of rest with a poor prognosis to return to full 
athletic function [4,5]. In the horse, evidence suggest that subchondral bone injuries can 
be an important etiological variable leading to the initial cartilage damage during 
osteoarthritis development [3,9,10]. Unlike articular cartilage, bone is vascularized and 
has access to progenitor cells which in general provides for healing capabilities. 
Nevertheless, a bone persistent reparative response with unmatched bone formation and 
resorption is reported in horses where architectural disruption leads to weak areas and is 
associated with some subchondral bone lesions and dense bone may never remodel 
completely. Bone persistent resorption areas are therefore believed to be one of the 
contributing factors to osteoarthritis in horses [3]. Consequently, there is a great need for 
articular cartilage and bone restoration methods as it applies to the functional unit of 
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diarthrodial joints. Unfortunately, none of the existing techniques have been able to fully 
restore articular cartilage structure and function with complete integration into the normal 
surrounding tissue [5,15–19].  
Cell-based therapies with multipotent mesenchymal stem cells (MSCs) are an area 
of high scientific and clinical interest within the broad field of regenerative medicine, 
since MSCs have shown capacity to facilitate the repair of orthopedic injuries through 
differentiating, immunomodulatory, and growth factor excreting properties, in addition to 
managing the symptoms [17,18,21,22]. The normal function of MSCs in the body is to 
maintain and repair tissue from the germ layer they are derived from [158]. Clinically 
relevant equine tissue sources of MSCs include bone marrow (BM) and adipose tissue 
(AT), where published literature has reported a promising capacity to differentiate into 
chondrogenic and osteogenic lineages capable of restoring orthopedic lesions [38–42]. 
Differentiation capacity of these cells is becoming increasingly important with recent 
incorporation techniques of scaffolds containing MSCs to enhance retention of the cells 
within the injury site [61–64]. A positive correlation between in vitro differentiation 
capacity and growth factor excretion has also been reported [97].  
Currently, the cell choice is mainly influenced by existing precedence, 
convenience of sampling, cost, and commercial interests, with BM and AT being the 
most commonly used sources in equine practice. The choice of MSC type, however, must 
also prioritize the cell type with the greatest potential for generating the injured tissue. 
Several studies have compared chondrogenic and osteogenic differentiation in a range of 
MSCs [35,38,39,41,43], and most studies report a higher potential of BM-MSCs to treat 
cartilage and bone injuries compared to AT-MSCs [35,41,44,45]. Presently, the 
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application of MSCs in equine practice is usually autologous, using cells harvested from 
the patient shortly after the time of injury, to avoid potential risks of immunological 
reactions associated with allogenic MSC treatments in equine models [92–94].  
Of some concern, human, canine, and rodent studies have shown an unfortunately 
sharp decline in MSC quantity and quality with increasing donor age [85,97,123,125]. 
However, no donor age studies have been published on equine MSCs with regards to 
chondrogenic and osteogenic differentiation performance. A study by Asumda et al. 
found that BM-MSCs from 15 month old rats had lost their chondrogenic and osteogenic 
differentiation potential altogether [97], which was supported by a 76% decline in 
osteogenic alkaline phosphatase activity in adult human BM-MSCs [65], and a 82% 
decline in proteoglycan content of chondrogenic induced BM-MSC pellets from 1 year 
old rats compared to 1 week old rats [127].  
 Donor age may thus be an important variable in equine patients for orthopedic 
injuries treated with autologous cells, as many horses with osteoarthritis are aged. 
Ultimately, age-associated alterations may impact the efficacy of autologous transplanted 
MSCs in aged horses resulting in poorer regenerative results. The majority of MSC donor 
age studies in other species are made on BM-MSCs, and it is currently unclear if stem 
cells from different sources are equally affected by donor age, but AT-MSCs are reported 
to be less affected by donor age than BM-MSCs [134].  
The need for regenerative medicine in equine practice is believed to increase 
tremendously partly due to the progressively aging equine population [143]. It is thus 
essential to scientifically examine how donor age affects different types of clinically 
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relevant equine MSCs to determine an age threshold for when a horse is no longer a 
suitable donor.  
The studies reported in this chapter were designed to test the hypothesis that 
increasing donor age is a major variable impacting equine BM- and AT-MSC 
chondrogenic and osteogenic differentiation performance with decreasing capacities 
following non-linear kinetics.  Specific aims were to 1) compare pellet size, histological 
cell morphology and proteoglycan staining in chondrogenic induced cell pellets, and to 
compare calcium deposits and alkaline phosphatase activity in osteogenic induced 
monolayer cultures, and to 2) compare the expression of targeted genes specific to 

















3.2 MATERIALS AND METHODS 
Cells used for this study are identical as the ones described in Chapter 2 for the cellular 
proliferation studies. 
 
3.2.1 Experimental samples 
BM-MSCs, AT-MSCs, and dermal fibroblasts (DF) (biological negative control) were 
harvested immediately post-mortem from horses of mixed breeds in 5 different clinically 
relevant and well-distinguished age groups with 4 horses in each age group. The age 
groups were newborn (0 days old), yearling (1-2 year old), adult (5-8 year old), middle 
aged (12-18 year old), and geriatric (≥ 22 year old) horses. All horses were euthanized 
due to reasons unrelated to this study. The study was conducted according to the ethical 
guidelines of animal research at the University of Copenhagen and the University of 
Kentucky. A written consent was obtained from all privately-owned horses prior to 
collection. 
Sample size was determined by power analysis. Two-sample t-test power 
calculations were performed in R (version 3.6.0) using pilot study data (not shown) to 
assess the calcium deposition of osteogenic induced BM- and AT-MSC harvested from 
newborn foals and geriatric horses (n=2 horses per age group per cell type) and the 
following equation: 
    
    
 
       
 
   ⁄   
 
where   is the standard deviation for the outcome, α is the significance level, 1 – β is the 
power,     
 
 
 = 1.96 for α = 0.05,      = 0.84 for 1 – β = 0.80, and δ was set to an 
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Alizarin Red S concentration of 1 mM as the minimum relevant difference. The estimated 
sample size to achieve a power of 0.80 was determined as 4 horses per age group per cell 
type.  
 
3.2.1.1 Bone marrow derived MSC collection and isolation 
Bone marrow/bone marrow aspirates were collected immediately post-mortem from the 
sternum of 12 female and 8 male horses, with the following age distribution; newborn 
(mean=0 days, range=0-0 days), yearling (mean=15.7 months, range=15.3-16 months), 
adult (mean=6.8 years, range=5-8 year), middle aged (mean=15.5 years, range=13-18 
year), and geriatric (mean=25.8 years, range=22-31 year). For the newborns, BM was 
collected as described by Vidal et al. [42] with few modifications. Briefly, BM was 




 sternebrae by sterile curettage after splitting the sternum in 
midline. The marrow trabecular bone was transported on ice to the laboratory in ice cold 
sterile Dulbecco‘s phosphate buffered saline (dPBS, Gibco, Cat# 14190144) with 2% 
(v/v) amphotericin B (Gibco, Cat# 15290026), and 2% (v/v) penicillin/streptomycin (P/S, 
Gibco, Cat#15070063) (isolation juice) and processed within 2 hours of collection. In the 
cell laboratory, the marrow trabecular bone was rinsed twice in 37
o
C pre-warmed 
isolation juice and crushed before being grown as an explant culture in 2 T75 cm
2
 culture 
flasks (Cellstar BioGreiner, VWR, Cat# 82050-856) with 12 mL/flask Dulbecco‘s 
modified Eagle‘s medium (DMEM, 1 g/L glucose, with phenol red, GlutaMAX, and 
pyruvate, Gibco, Cat# 10567-022), 10% (v/v) fetal bovine serum (FBS), 1% (v/v) P/S, 
and 1% amophotericin B (isolation medium). After 48 hours, BM crusts and non-
adherent cells were aspirated along with the isolation medium, and the medium was 
changed to expansion medium containing 1 g/L DMEM, 10% FBS, and 1% P/S. The 
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cells were cultured at 37
o
C in a humidified atmosphere containing 5% CO2 and expansion 
medium was changed every 2-3 days.  




 sternebrae as 
previously described [34,42]. In short, the area over the sternum was clipped and 
surgically prepared with 2% chlorohexidine medical scrub and 70% ethanol. A total of 20 
mL of BM was collected using a 10 cm, 11 G Jamshidi® bone biopsy needle (Henry 
Schein Vet, Cat# DJ4011X) and two 20 mL Luer-Lock syringes preloaded with 1000 IU 
sodium heparin (Henry Schein Vet, Cat# 4327680) per 10 mL BM aspirate. The BM 
aspirate was transferred to a 50 mL falcon tube and gently inverted, before being 
transported on ice to the laboratory and further processed within 2 hours of collection. In 
the cell laboratory, the BM aspirate was layered slowly onto Ficoll-Paque® PREMIUM 
(GE Healthcare, Cat# 17-5442-02) in a 1:1 (v/v) manner and centrifuged for 30 minutes 
at 600 g. The mononuclear cell layer containing BM-MSCs was collected and washed 
twice in sterile dPBS and centrifuged for 5 minutes at 200 g between the washes. The 
supernatant was removed and the pellet was re-suspended in 24 mL isolation medium and 
equally divided into 2 T75 cm
2
 culture flasks. After 48 hours, allowing the BM-MSCs to 
adhere to the bottom of the flasks, the first medium change occurred and isolation 
medium was replaced with expansion medium. The cells were incubated at 37
o
C and 5% 
CO2. 
3.2.1.2 Adipose tissue derived MSC collection and isolation 
AT was collected from the gluteal region above the biceps femoris muscle next to the tail 
base of 10 female and 10 male horses as previously described [34], with the following 
age distribution; newborn (mean=0 days, range=0-0 days), yearling (mean=15.8 months, 
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range=15.3-16.1 months), adult (mean=6.8 years, range=5-8 year), middle aged 
(mean=14.5 years, range=13-16 year), geriatric (mean=25.8 years, range=22-31 year). 
Briefly, the gluteal area next to the tail base was surgically clipped and prepared as 
described for BM-MSCs, and 10 grams of AT was collected through a ~8 x 8 cm surgical 
window. The AT was transferred to a 50 mL falcon tube with ice cold isolation juice and 
transported on ice to the laboratory where the tissue was further processed within 2 hours 
of collection. In the cell laboratory, the AT was washed two times in isolation juice and 
dissected into smaller pieces where visible blood vessels were removed. The AT was 
digested in sterile filtered (0.2 µm) AT enzyme medium consisting of DMEM (1 g/L), 
1% P/S, 50 µg/mL gentamycin (Sigma-Aldrich, Cat# G1264-1G), and 1 mg/mL 
collagenase type I (Worthington, Cat# X7H9763A) for 3 hours at 37
o
C and 30 rpm. The 
enzyme medium containing released cells was transferred through a 70 µm cell strainer 
and the pellet with AT-MSCs was washed twice in sterile dPBS and centrifuged at 500 g 
for 5 minutes between the washes. The pellet was re-suspended in 24 mL isolation 
medium supplemented with 50 µg/mL gentamycin and distributed into 2 T75 cm
2
 culture 
flasks.  The first medium change occurred 48 hours after isolation, where fresh expansion 
medium was added. The cells were grown at 37
o
C in air with 5% CO2 with medium 
change every 2-3 days. 
 
3.2.1.3 Dermal fibroblast collection and isolation 
DFs were harvested from the gluteal region above the biceps femoris muscle next to the 
tail base of 14 female and 6 male horses as previously described [35], with the following 
age distribution; newborn (mean=0 days, range=0-0 days), yearling (mean=15.6 months, 
range=15.3-16 months), adult (mean=6 year, range=5-7 year), middle aged (mean=14.5 
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years, range=12-18 year), geriatric (mean=27.5 years, range=22-32 year). Briefly, 6 
grams of dermal tissue was collected from the surgical window made to collect AT-
MSCs. The dermis was transferred to a 50 mL falcon tube with ice cold isolation juice 
and transported on ice to the laboratory where the tissue was further processed within 2 
hours of collection. In the cell laboratory, the dermal tissue was washed two times in 
isolation juice and dissected into smaller pieces. The dermis was digested in sterile 
filtered (0.2 µm) DF enzyme medium consisting of dPBS, 1% P/S, 1% bovine serum 
albumin (BSA – Sigma, Cat# A9418-10G), 50 µg/mL gentamycin, and 1 mg/mL 
collagenase type I for 2 hours at 37
o
C and 30 rpm. The enzyme medium containing 
released cells was transferred through a 70 µm cell strainer and the pellet with DFs was 
washed twice in sterile dPBS and centrifuged at 1000 g for 4 minutes between the 
washes. The pellet was re-suspended in 24 mL isolation medium supplemented with 50 
µg/mL gentamycin and distributed into 2 T75 cm
2
 culture flasks and grown at 37
o
C in air 
with 5% CO2. The first medium change occurred 48 hours after isolation, where fresh 
expansion medium was added. Expansion medium was changed every 2-3 days. 
 
3.2.2 Cell expansion and storage 
At approximately 80% confluence, the cells were passaged with 1 mL 0.25% Trypsin/1 
mM EDTA (Gibco, Cat# 11560626) per T75 cm
2
 culture flask. Cell counting was 
performed manually using tryphan blue (Fisher Scientific, Cat# 11538886) and a 
hemocytometer. The cells were grown with a seeding density of 500,000 cells per T75 
cm
2
 culture flask. At passage 2 (P2), the cells were cryopreserved with Recovery-Cell 
Culture Freezing Medium® (Gibco, Cat# 11560446, containing 10% DMSO) at a 
concentration of 2-3 x 10
6
 cells per 1 mL freezing medium in cryogenic vials (Nalgene, 
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Thermo Scientific, Cat# 5000-0020). The cells were thawed in 37
o
C pre-warmed 
expansion medium and washed 3 times in dPBS to remove leftover freezing medium 
before being grown in expansion medium and incubated at 37
o
C and 5% CO2 with 
medium change every 2-3 days. Chondrogenic and osteogenic differentiation assays were 
performed at passage 4. 
 
CHONDROGENIC ASSAYS 
3.2.3 Pelleting and chondrogenic differentiation   
To generate 3D cell pellets at passage 4, cells were trypsinized at passage 3, counted 
manually, and washed twice in dPBS before being resuspended at 500,000 cells per mL 
in chondrogenic induction medium as described previously [35,39,71,73,74]. The pellet 
was generated by centrifuging 1 mL of cell suspension at 500 g for 3 minutes in a vented 
1.5 mL polypropylene microcentrifuge tube. The chondrogenic induction medium 
consisted of DMEM (4.5 g/L glucose – Gibco, Cat# 10569044), 1% P/S, 12.5 mg/mL 
BSA (Sigma, Cat# A9418-10G), 1x insulin-transferrin-selenium-sodium pyruvate (ITS-
A) growth supplement (Gibco, Fisher Scientific, Cat# 51300044), 1x MEM non-essential 
amino acids (Gibco, Fisher Scientific, Cat# 11140050), 100 nM dexamethasone (Sigma, 
Cat# D4902-100MG), 50 µg/mL L-ascorbic acid-2-phosphate sesquimagnesium salt 
hydrate (A2P - Sigma, Cat# A8960-5G), and 10 ng/mL human recombinant transforming 
growth factor β1 (rhTGFβ1 – Sigma, Cat# T7039-50UG). A total of 15 pellets were made 
per cell line per biological replicate. After 24 hours, the pellets were transferred to a 1% 
poly 2-hydroxyethyl methacrylate (polyHEMA, Sigma, Cat# P3932) coated 24-well plate 
with 1 pellet per well. Coating of the wells with polyHEMA enabled suspension-culture 
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of the pellets by preventing adhesion of the cells to the plastic surface. After transfer, 1 
mL of new chondrogenic induction medium was added to each pellet. The pellets were 
grown in freshly made chondrogenic induction medium for 21 days with 1 mL of 
complete medium change every 3 days at 37
o
C and 5% CO2. As a control for gene 
expression, P4 cells from each cell line per biological replicate were seeded at 500,000 
cells in one T75 flask and grown as monolayer in expansion medium until being 
harvested at ~80% for RNA isolation. Six pellets from yearling BM-MSCs were grown in 
chondrogenic medium without TGF-β1 and dexamethasone as a non-induced control for 
pellet size and proteoglycan staining.   
  
3.2.4 Chondrogenic pellet size 
Out of the 15 pellets per biological replicate, 6 were randomly chosen to be measured in 
size and to be histologically assessed. The remaining 9 pellets were used for RNA 
isolation and were not measured to prevent potential contamination. Pellets size has been 
shown to be positively correlated with extracellular matrix production and 
chondrogenesis [35,38] given that the pellets are made from the same amount of cells, 
which was the case for the present study where all pellets were made from 500,000 cells.  
In preparation for pellet measurement, the pellets were gently washed with dPBS and 
transferred to a 24-well plate with 0.5 mL dPBS per well and one pellet per well. 2D 
brightfield images of the pellets were captured at 4x using a microscope. The shortest and 
longest side of the pellet was measured in µm using Nikon NIS Analysis Software 4.13. 
The measurements were averaged per pellet and per biological replicate.    
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3.2.5 Histological assessments of pellets 
Following pellet measurement, the pellets were fixed in 4% paraformaldehyde at 4
o
C for 
24 hours. The pellets were then pre-embedded in 2% bacto
TM
 agar (BD, Cat# 214050) 
/2.5% gelatin blocks as previously described to prevent folding of the pellets at sectioning 
[159] with 2 pellets per block. Next, the blocks were fixed in 4% paraformaldehyde for 
24 hours at 4
o
C, before being placed in 70% ethanol at 4
o
C for batched histological 
processing and paraffinization. The pellets were sectioned at 5 µm at approximate 
midline and stained with either Hematoxylin and Eosin (H&E) for cell morphology and 
pellet architecture or Safranin-O to evaluate proteoglycan content and distribution. 
Analyses of cell morphology and staining patterns within the pellets were performed in 
consultation with board certified veterinary pathologist (Dr. Jennifer Janes, University of 












3.2.6 Proteoglycan staining of pellets and quantification 
Safranin-O staining was used to measure the extracellular matrix proteoglycan content of 
the pellets, as an essential protein marker of chondrogenesis. Safranin-O is an orange to 
red stoichiometric orthochromatic dye that adheres to the sulfate groups of proteoglycan 
molecules in a 1:1 manner, which makes the stain semi-quantitative [82]. The redness 
intensity of the section staining thus represents the proteoglycan content assuming a 
uniform distribution of negatively charged proteoglycans across the sample. All sections 
were stained with Weigert‘s Iron Hematoxylin for 7 minutes to stain cell nuclei, and 1% 
Fast Green (Sigma, Cat#F7252) for 5 minutes as a background stain. Proteoglycan 
sulfation was identified with a 0.05% Safranin-O (Sigma, Cat# S8884) staining for 2 
minutes as described previously [35]. The sections were stained in 30-slide racks in the 
same batch of Safranin-O and Fast Green stain to avoid inter-batch technical variation, 
with refreshing of the stain between every two racks. Equine articular cartilage from a 7 
year old horse was included as a positive control calibrator sample with 3 randomly 
placed slides in each rack. Non-induced BM-MSC pellets from a yearling and epithelial 
tissue from a foal was incorporated as negative controls with 1 slide of each per rack. 
Mounted sections were imaged in brightfield with a Zeizz AX10 Imager A2 microscope 
at 5x using the same microscope brightness and exposure settings for all images. Images 
of the 0.05% Safranin-O staining used in the experiment were captured using a chamber 
slide as a pure red calibrator.  
The redness values of the Safranin-O stained sections were measured using Fiji 
software in ImageJ (https://imagej.net/Fiji/Downloads) as previously described [35]. 
Color contributions from the background light and microscope were corrected for by 
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using the pure red stain as a calibrator and by subtracting the fixed background intensity 
measures from each individual color histogram. After red balancing and background 
assessment, mean red, green, and blue values were determined for all controls and pellets 
using the whole pellet as the focus area. The redness value of each section was calculated 
as follows:  
                                           
                                           
                      (
                           
 
)  
where mean represents the pellet value, and background represents the pure red value. 
The redness value characterizes the red color of the Safranin-O stained proteoglycan 
molecules, making semi-quantitative comparisons between pellets possible. The redness 
value of each pellet was recorded and normalized to articular cartilage control sections, 
and then averaged per biological replicate.  
 
OSTEOGENIC ASSAYS 
3.2.7 Monolayer cell culture and osteogenic differentiation  
Passage 3 cells were trypsinized, counted, and seeded as passage 4 monolayer cells with a 
density of 25,000 cells per well in 6-well plates (NUNC, Fisher Scientific, Cat# 
10469282). The cells were initially grown in expansion medium at 37
o
C and 5% CO2 and 
re-feed every 2-3 days. Upon ~90% confluence, expansion medium was discarded and 
osteogenic induction medium was added to 3 of the wells while the other 3 wells were 
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kept under expansion medium as a non-induced control. The osteogenic induction 
medium consisted of DMEM (1g/L glucose), 10% FBS, 1% P/S, 100 nM dexamethasone, 
0.05 mM ascorbic acid (A2P), and 10 mM β-glycerophosphate disodium salt hydrate 
(Sigma, Cat# G9422) as previously described [42,86,87]. The medium in both groups 
were changed every 3 days with 2 mL medium per well. Four 6-well plates were made 
from each cell line per biological replicate, with 1 plate for day 0 RNA harvest, 1 plate 
for day 21 RNA harvest, 1 plate for day 7 alkaline phosphatase activity assay, and 1 plate 
for day 21 Alizarin Red S staining.  
 
3.2.8 Alkaline phosphatase activity assay 
After 7 days of osteogenic induction, alkaline phosphatase (ALP) activity was measured 
using a commercially available colorimetric kit (Abcam, Cat# ab83369) according to the 
manufacturer‘s instructions and as described previously [160]. ALP is a membrane-
bound glycoprotein that catalyzes the hydrolysis of phosphates at high pH, and is an early 
marker of osteogenesis that enhances mineralization [90] with the highest detection for 
equine BM-MSCs after 6-7 days of osteogenic culture [87].  
Briefly, the cell layers were washed with dPBS and harvested by 0.05% 
Trypsin/EDTA and cell scraping. The cell suspension from each well was transferred 
individually to a microcentrifuge tube, spun down, and washed to remove left over 
trypsin. The pellet was then resuspended in fridge cold dPBS and centrifuged. The 
supernatant was discarded and 200 µL assay buffer was added to each pellet before being 
homogenized in a QIAshredder (Qiagen, Cat# 79654) at 20,000 g for 2 minutes, followed 
by top speed (14000 RPM) for 15 minutes at 4
o
C. The samples were transferred to 
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cryogenic vials and stored at -80
o
C until batch ALP assays were performed. ALP activity 
of the cells was measured in flat-bottomed 96-well plates by adding 5 mM p-nitrophenyl 
phosphate substrate, which turns yellow when dephosphorylated to p-nitrophenol by ALP 
[160]. The cell suspension was incubated with the phosphate substrate for 60 minutes at 
25
o
C protected from light. Stop solution was added and optical density was measured at 
405 nm using a microplate reader. ALP activity was calculated based on standard curve 
solutions incorporated in the assay and by subtracting mean blank values from the 
samples. All technical replicates were tested in duplicate with 3 osteogenic-induced and 3 
non-induced wells per cell line. The ALP activity levels of the technical replicates were 
averaged per biological replicate per cell type per medium.    
 
3.2.9 Alizarin Red S assay 
After 21 days of osteogenic induction, calcium deposition was measured with a 
commercially available colorimetric Alizarin Red S (ARS) quantification kit (ARed-Q, 
ScienCell, Cat#8678) following manufacturer‘s protocol based on a study by Gregory et 
al. [161]. Calcium is a key component in hydroxyapatite (Ca10(PO4)6(OH2)2), which is 
the main inorganic component of bone. Calcium deposition thus functions as a marker of 
bone mineralization for osteogenic induced cells [161,162].  
In short, the osteogenic medium was removed and the cells were gently washed 3 
times in dPBS without calcium and magnesium (Gibco, Fisher Scientific, Cat# 
14190144) before being fixed in 4% paraformaldehyde. The calcium deposits were then 
visualized by adding 40 mM ARS staining and incubating for 20 minutes with gentle 
shaking. The dye was removed and the wells were washed 5 times with milli-Q water 
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with 5 minute incubation between the washes to remove excess dye. The calcified 
minerals were extracted at low pH by means of 10% acetic acid and a cell scraper, 
followed by a heating process in parafilm-coated microcentrifuge tubes at 85
o
C for 10 
minutes and a cooling process on ice for 5 minutes. The solution was then neutralized 
with 10% ammonium hydroxide (pH between 4.1-4.5). ARS concentration was 
quantified by colorimetric detection at 405 nm in flat-bottomed 96-well plates using a 
microplate reader. The ARS concentration of the samples was calculated based on a 
standard curve incorporated in the assay and by subtracting the mean blank value from all 
samples. All technical replicates were analyzed in triplicates with 3 osteogenic-induced 
and 3 non-induced wells per cell line. ARS concentration was averaged per cell line per 
biological replicate per medium. 
  
GENE EXPRESSION ASSAYS         
3.2.10 Gene expression  
3.2.10.1 RNA isolation and reverse transcription 
Passage 4 cells were grown as monolayer cultures in T75 cm
2
 flasks with expansion 
medium as a non-induced control for chondrogenesis. At approximately 80% confluence, 
the cells were extracted with QIAzol
®
 (Qiagen, Cat# 79306), a guanidinium thiocynate-
phenol-chloroform lysis reagent, and snap frozen in liquid nitrogen. After 21 days of 
culture in chondrogenic medium, 9 pellets from each cell line were washed with dPBS, 
and snap frozen in aliquots with 3 pellets per aliquot.   
At approximately 90% confluence, cells grown in expansion medium in 6-well 
plates were harvested with QIAzol
®
 as a day 0 non-induced control for osteogenesis and 
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snap frozen. After 21 days of culture, cells were harvested with QIAzol
®
 from a 6-well 
plate with 3 wells cultured in osteogenic induction medium and 3 wells kept under 
expansion medium as a day 21 non-induced osteogenic control and snap frozen. All 
samples were stored at -80
o
C prior to RNA isolation. 
The monolayers and pellets were homogenized in 2 mL of QIAzol
®
 using a 
PowerGen 125 homogenizer (Fisher Scientific, Cat# 15120247). Total RNA was isolated 
using a spin column-based Qiagen RNeasy Mini Kit
®
 (Qiagen, Cat# 74104) with 
modifications as previously described [144], with pooling of the technical replicates. 
RNA quantity was determined immediately after RNA isolation using a NanoDrop ND 
1000 spectrophotometer. The samples then underwent ethanol precipitation to remove 
processing contaminants. Quantification of the purified RNA was performed using the 
Qubit BR Assay (Life Technologies, Cat# Q10210) and NanoDrop ND 1000 
spectrophotometer. The quality of the purified RNA was assessed with a Bioanalyzer 
2100 (Agilent Technologies, Eukaryotic Total RNA Nano & Pico Series II). All purified 
RNA samples met the following quality thresholds; 260/280 ratios of 1.7-2.1, 260/230 
ratios of 1.8-2.28, and an Agilent RNA integrity number (RIN) of ≥ 7.4, with the 
exception of 3 samples (Appendix 1) that behaved as expected in down-stream analyses 
and thus were not excluded from the study.  
Removal of potential genomic DNA contamination and reverse transcription of 
total RNA to cDNA was achieved using a commercially available kit as per 
manufacturer‘s protocol (Maxima First Strand cDNA Synthesis Kit
®
 for RT-qPCR with 
dsDNase, Life Technologies, Cat# K1672). cDNA samples were diluted with nuclease-





3.2.10.2 Real-time quantitative PCR 
Ninety-three biomarkers were selected for the gene expression panel based on functional 
annotation to have biological relevance important for cell proliferation, chondrogenesis, 
osteogenesis, or evidence in the literature of age-dependent variation. The gene 
expression panel e.g. included known growth factors, cell cycle regulators, articular 
cartilage markers, subchondral bone markers, and markers of cellular senescence (Genes 
and annotations are shown in Appendix 2).  
Commercially available, validated equine-specific TaqMan
®
 primer-probe sets 
(FAM dye-labeled MGB probes - Thermo Fisher) for all biomarkers were used to 
quantitate the steady state mRNA levels. Details on the primer-probe sets are listed in 
Table 3.1. The functionality of all primer-probe sets was tested against a positive control 
equine sample containing mixed cDNA consisting of a 43-sample pool of various tissue 
[145], day 35 whole fetus, and neonatal epiphyseal cartilage. Negative controls of RNase-
free water and minus-template was incorporated, and each sample was run in duplicate. 
Real-time quantitative PCR (RT-qPCR) reactions were conducted in a 384-well 
plate with a total reaction volume of 10 µL using 62.55 ng cDNA per reaction. A robotic 
ViiA
TM
 RT-qPCR System (Thermo Fisher Scientific) was used to perform the reactions. 
LinRegPCR was used to measure reaction amplification efficiencies and cycle threshold 
(Ct) values were calculated [146]. All targets amplified with amplification efficiencies 
close to 2 except for the negative controls that showed no amplification (data not shown).    
Three commercially available equine-specific endogenous control TaqMan
®
 
primer-probe sets were tested against all samples. The endogenous controls consisted of 
β-2-microglobulin (B2M), β-glucoronidase (GUSB), and ribosomal protein lateral stalk 
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subunit P0 (RPLP0). Using NormFinder software [147], GUSB was determined as 
having the most uniform performance across all cell types and age groups (data not 
shown).  
The gene expression of the experimental samples were analyzed by RT-qPCR 
using the BIOMARK HD System (Fluidigm) as previously described [148]. Fluidigm is 
an automated nanofluidic RT-qPCR system that uses microfluidic technology in which 
dynamic arrays of integrated fluidic circuits are used, allowing for samples and reagents 
to be mixed in a variety of patterns. Hence, little sample quantity is needed to be tested 
against 96 targets, making it less time-consuming and more cost-effective compared to 
standard qPCR [148].   
Briefly, experimental cDNA samples were shipped at a concentration of 13.9 
ng/µL (middle of positive standard curve), together with the positive control (7 three-fold 
dilutions), negative controls, and primer-probe sets (including endogenous controls) to 
The Carver Biotechnology Center, University of Illinois, IL, USA, where the Fluidigm 
assay was performed. A total of 7 µL of cDNA and 25 µL of primer-probe sets were 
shipped per sample or target, respectively. The Fluidigm was carried out using 96.96 
dynamic arrays (Fluidigm Corporation, CA, USA) according to manufacturer‘s 
instructions.  
The data were analyzed with Fluidigm Real-Time PCR Analysis Software in the 
BIOMARK instrument (Fluidigm Corporation, CA, USA) where Ct values were 
calculated. Results from 5 primer-probe sets (TNF, NODAL, MATN1, HAPLN1, and 
MEPE) were removed from the final panel, as gene expression was below assay detection 
level in almost all samples, making comparisons unfeasible. Delta Ct values were 
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determined for each sample by subtracting the corresponding Ct value of the endogenous 
control (GUSB). The positive control was used as a calibrator to calculate ΔΔCt values. 
Relative expression (RQ) of the gene targets were calculated using the 2
-ΔΔCt
 method 
[149]. RQ levels were used for graphical bar/box plot presentations made in GraphPad 
Prism 8.0.1 or SAS 9.4, and Ln(RQ) values were used for heatmap and statistical analysis 
to linearize the data again and to avoid right-shifting of data. Gene expression heatmap 
visualization was done on averaged Ln(RQ) levels for each study group, grouping the 
samples according to cell type, donor age, and medium, and genes according to biological 

















Table 3.1: Overview of TaqMan primer-probe sets used in RT-qPCR reactions. 
Gene ID Gene name(s) ThermoFisher 
Assay ID  
ABI3BP ABI family member 3 binding protein Ec06625599_m1 
ACAN Aggrecan core protein Ec03469667_m1 
ALPL Alkaline phosphatase Ec06625502_g1 
AQP1 Aquaporin Ec06625425_m1 
AREG Amphiregulin Ec06992855_m1 
BARD1 BRCA1-associated RING domain 1 Ec07061151_m1 
BAX BCL2 associated X apoptosis regulator Ec07016716_s1 
BCL2 B-cell lymphoma 2 Ec07005800_g1 
BGN Biglycan Ec03467971_m1 
BMP2 Bone morphogenic factor 2 Ec06974239_m1 
BMP3 Bone morphogenic factor 3 Ec07037656_m1 
BMP4 Bone morphogenic factor 4 Ec03470252_s1 
BMP6 Bone morphogenic factor 6 Ec03469925_m1 
BMP7 Bone morphogenic factor 7 Ec04320876_m1 
BRCA1 Breast cancer type 1 Ec07017862_s1 
CASP3 Caspase 3 Ec03470391_m1 
CASP8 Caspase 8 Ec06959413_m1 
CAVIN1 Caveolae associated protein 1 Ec07036873_m1 
CCND1 Cyclin D1 Ec07036996_m1 
CDKN1A p21, Cyclin-dependent kinase inhibitor 1A Ec06955195_m1 
CHADL Chondroadherin Ec03470206_m1 
CLU  Clusterin Ec03468575_m1 
COL1A1 Collagen type 1 alpha 1 Ec03469676_m1 
COL2A1 Collagen type 2 alpha 1 Ec03467411_m1 
COL4A1 Collagen type 4 alpha 1 Ec06943950_m1 
COL5A3 Collagen type 5 alpha 3 Ec06999559_g1 
COL9A2 Collagen type 9 alpha 2 Ec03470083_m1 
COL11A1 Collagen type 11 alpha 1 Ec07051918_m1 
COL12A1 Collagen type 12 alpha 1 Ec03469523_m1 
COMP Cartilage oligomeric matrix protein Ec03468062_m1 
CRTAC1 Cartilage acidic protein –CEP-68 Ec07040335_g1 
CRYAB Crystalline-alpha B Ec06997901_m1 
CSF2 Colony stimulating factor 2 Ec03468208_m1 
CTGF Connective tissue growth factor Ec06625777_gH 
CTNNB1 Beta-catenin Ec00991819_m1 
DCN Decorin Ec03468474_m1 
DMP1 Dentin matrix acidic phosphoprotein 1 Ec06992382_m1 
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Table 3.1: (Continued) 
EBF2 Early B-cell factor 2 Ec06966528_m1 
EPGN Epithelial mitogen Ec06992859_m1 
FGF1 Fibroblast growth factor 1 Ec01092738_m1 
FGF5 Fibroblast growth factor 5 Ec04656774_m1 
FGF18 Fibroblast growth factor 18 Ec03248217_g1 
FGFR3 Fibroblast growth factor receptor 3 Ec03470545_m1 
FN1 Fibronectin 1 Ec03470760_m1 
GDF6 Growth differentiation factor 6 Ec07097112_m1 
GLB1 Beta-galactosidase Ec06954363_m1 
GLI3 GLI family zinc finger 3 Ec06625512_m1 
HAPLN1 Hyaluronan and proteoglycan link protein 1 Ec03468716_m1 
HDGF Hepatoma-derived growth factor Ec07037751_m1 
HGF Hepatocyte growth factor Ec07000054_m1 
IBSP Integrin Binding Sialoprotein Ec06625402_m1 
IGF1 Insulin-like growth factor 1 Ec03468689_m1 
IGFBP5 Insulin-like growth factor binding protein 5 Ec03470296_m1 
LOC100146270 p16, Cyclin-dependent kinase 4 inhibitor B Ec07037471_mH 
LOC100146589 Osteocalcin, bone gamma-carboxyglutamic acid containing 
protein 
Ec07103628_m1 
MATN1 Matrilin-1 Ec06963427_m1 
MEPE Matrix extracellular phosphoglycoprotein Ec06992377_m1 
MET MET proto-oncogene, receptor tyrosine kinase Ec02622441_m1 
MIA CD-RAP, Cartilage-derived retinoic acid-sensitive protein Ec03469434_m1 
MMP3 Matrix metalloproteinase 3 Ec03468676_m1 
MMP13 Matrix metalloproteinase 13 Ec03467796_m1 
MYC c-myc Ec07007511_m1 
NODAL Nodal growth differentiation factor Ec07036659_m1 
OMD Osteomodulin Ec06625496_m1 
PCNA Proliferating cell nuclear antigen Ec06974312_m1 
PDGFD Platelet-derived growth factor subunit D Ec06997714_m1 
PHB Prohibitin Ec07055990_m1 
PHEX Phosphate regulating endopeptidase homolog, X-linked Ec07034292_s1 
PTCH2 Patched 2 Ec06625424_g1 
RUNX2 Runt-related transcription factor 2 Ec03469741_m1 
RUNX3 Runt-related transcription factor 3 Ec06625430_g1 
S100A1 S100 calcium binding protein A1 Ec03470173_g1 
SMOC1 SPARC related modular calcium binding Ec06978758_m1 
SMPD3 Sphingomyelin phosphodiesterase 3 Ec06625668_m1 
SNAI2 Snail family transcriptional repressor 2 Ec06625397_m1 
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Table 3.1: (Continued) 
SOST Scherostin Ec07036868_m1 
SOX5 SRY-box transcription factor 5 Ec01552798_m1 
SOX9 SRY-box transcription factor 9 Ec03469763_s1 
SP7 Osterix Ec06625770_g1 
SPARC Osteonectin Ec03818202_m1 
SPP1 Osteopontin, Secreted phosphoprotein 1 Ec06992376_g1 
TBX3 T-box 3 Ec07003300_m1 
TERT Telomerase reverse transcriptase Ec06972692_m1 
TGFA Transforming growth factor alpha Ec06949183_m1 
TGFB1 Transforming growth factor beta 1 Ec06625477_m1 
TGFB2 Transforming growth factor beta 2 Ec07074189_g1 
TGFB3 Transforming growth factor beta 3 Ec00682163_m1 
TIMP2 Metallopeptidase inhibitor 2 Ec03470558_m1 
TNF Tumor necrosis factor Ec03467871_m1 
TNFRSF11B Osteoprotegerin Ec07007303_m1 
TNFSF11 RANKL, TNF superfamily member 11 Ec06625532_m1 
TP53 Tumor protein 53 Ec03470648_m1 
VEGFA Vascular endothelial growth factor A Ec03467879_m1 
B2M Beta-2-microblobulin Ec03468699_m1 
GUSB Beta-glucoronidase Ec03470630_m1 
RPLP0 Ribosomal protein lateral stalk subunit P0 Ec04947733_g1 
 
3.2.11 Inter-laboratory control  
The study was performed in 2 different laboratories (University of Copenhagen (UCPH) 
and University of Kentucky (UK)). To control for potential inter-laboratory differences, 
inter-assay controls were included. BM-MSCs were included as an inter-assay control for 
the osteogenic assays, and articular chondrocytes were incorporated as an inter-assay 
control for the chondrogenic assays. Both samples were from yearlings, and had shown 
high differentiation potential in pilot and previous studies [35] to ensure a positive 
foreground to compare to. The two cell lines were shipped on dry-ice from UK to UCPH 
and tested using the same procedures in both laboratories. Plastic ware, mediums, 
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reagents, commercially available kits, and protocols were kept constant throughout the 
entire study for all samples. The osteogenic inter-laboratory control was tested using the 
ALP and ARS assay and by Fluidigm RT-qPCR. The chondrogenic inter-laboratory 
control was tested by pellet size measurement, Safranin-O staining and with Fluidigm 
RT-qPCR. Isolated RNA was shipped on dry-ice from UCPH to UK to allow for all RNA 
and cDNA samples to be analyzed on the same machines. Laboratory was furthermore 
added as a variable in the statistical model used for data analysis. All inter-laboratory 
controls showed no indication of significant differences between laboratories (data not 
shown). 
 
3.2.12 Statistical analysis   
The differentiation data, comparing age-groups within cell types and across cell types, 
were analyzed with a generalized linear mixed model using The GLIMMIX Procedure in 
SAS 9.4 with Tukey-Kramer‘s post hoc modifications for multiple comparisons. Gene 
expression data were analyzed in two steps. Initially, one-way analysis of variance 
(ANOVA) using SAS 9.4 was applied individually to all 88 gene targets within each cell 
type to look for donor age effects. Next, targets showing significant difference on the 
ANOVA and more than 5-fold difference between study groups on the heatmap (Figure 
3.12) were analyzed using The GLIMMIX Procedure with Tukey-Kramer‘s post hoc 
modifications for multiple comparisons to compare across tissue types. Statistical 
analysis of Fluidigm RT-qPCR results was performed on individual extracted Ln(RQ) 
values. Genes with missing data points (as visualized on Figure 3.12) were removed from 
the statistical analysis for the given cell type. For the statistical analysis, pellets were 
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compared to T75 non-induced monolayer cultures, and osteogenic-induced cells were 
compared to non-induced 6-well cultures at day 21 to minimize time and well bias. To 
control for non-paired samples and potential inter-laboratory variables, horse number and 
laboratory were added to the statistical models as additional factors. Due to age-
clustering within age groups, statistical linear regression analyses were not feasible and 
kinetics were determined based on graphical presentations. Data were considered 


















3.3.1 Cell expansion 
All cell lines proliferated actively after isolation when the primary cell cultures had been 
established. No differences were seen in the proliferative capacity of pilot cells before 
and after cryopreservation (data not shown).  
 
CHONDROGENIC DATA  
3.3.2 Pellet size 
No pellets disassociated during culture and it was feasible to measure all pellets. 
Chondrogenic induced pellet size varied from ~0.5 mm to over 1 mm in mean diameter 
as shown in Figure 3.2, with the following general relationship: BM-MSC > AT-MSC > 
DF (p<0.006). Representative images of pellets are shown in Figure 3.1. Non-induced 
control pellets made from yearling BM-MSCs had a diameter between 0.38 and 0.45 mm. 
No effect of donor age was seen in BM-MSC pellets. For AT-MSCs, pellets from adult 
horses were significantly smaller compared to newborn (p=0.0063) and yearlings 
(p=0.0141). Pellets from BM-MSCs were only significantly larger than AT-MSCs in 
yearlings (p=0.0037), whereas BM-MSC pellets were significantly larger compared to 




Figure 3.1: Representative images of pellets made from the same newborn foal after 21 
days of culture in chondrogenic induction medium. All pellets were generated from 5x10
5
 
cells. On image A, the pellets are shown in dPBS prior to pellet size measurement, as 
seen on the brightfield 4x magnification shown as image C. Image B, shows aliquoted 
BM-MSC pellets prior to snap-freezing and RNA isolation. *AT-MSC: Adipose tissue 
derived mesenchymal stem cell, BM-MSC: Bone marrow derived mesenchymal stem cell, 
DF: Dermal fibroblast.    
 
Figure 3.2: Box plot showing pellet size (µm) of chondrogenic induced bone marrow 
(BM)- and adipose tissue (AT) derived mesenchymal stem cells and dermal fibroblasts 
(DF) in 5 different age groups (n= 4 horses per cell type per age group). All pellets were 
generated from 5x10
5
 cells and cultured in chondrogenic induction medium for 21 days. 
Cell types within the same age group not labeled with the same letter are significantly 
different from each other (p<0.05).    
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3.3.3 Morphological description of chondrogenic induced pellets 
Figure 3.3, 3.4, and 3.4 show representative images of pellets made from AT-MSCs, BM-
MSCs, and DFs from horses in 5 different age groups described in this section over a 
range of magnifications after H&E staining.  
 
Figure 3.3: Panel showing representative hematoxylin and eosin (H&E) stained sections 
of adipose tissue derived mesenchymal stem cell pellets from horses in 5 different age 
groups under different magnifications after 21 days of culture in chondrogenic induction 
medium. Size-bar on 4x magnification images is equivalent to 500 µm.    
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Figure 3.4: Panel showing representative hematoxylin and eosin (H&E) stained sections 
of bone marrow derived mesenchymal stem cell pellets from horses in 5 different age 
groups under different magnifications after 21 days of culture in chondrogenic induction 




Figure 3.5: Panel showing representative hematoxylin and eosin (H&E) stained sections 
of dermal fibroblast pellets from horses in 5 different age groups under different 
magnifications after 21 days of culture in chondrogenic induction medium. Size-bar on 
4x magnification images is equivalent to 500 µm. 
 
Newborn bone marrow derived mesenchymal stem cell pellets (BM-N-P): The pellets 
were composed of polygonal cells with minimal acidophilic cytoplasm and round to oval 
nuclei often within lacunae separated by moderate to marked amounts of lightly 
basophilic matrix. There was mild variation in cell size.  Along the outer rim were 
streams of spindle cells (4-8 cell layers thick). The spindle cells had acidophilic 
cytoplasm and oval nuclei, and partially to completely formed the outer rim of the pellets. 
Few pellets had 1-2 cores of necrotic cells and debris is the center of the pellet.  
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Yearling bone marrow derived mesenchymal stem cell pellets (BM-Y-P): The pellets 
were composed of a central accumulation of polygonal cells with minimal acidophilic 
cytoplasm and round to oval nuclei often within lacunae separated by moderate amounts 
of lightly basophilic matrix. Few necrotic cells were interspersed with this population. 
Mild variation was seen in cell size.  The cellular population was circumferentially 
bordered by organized rim spindle cells (3-5 cell layers thick). The spindle cells had 
acidophilic cytoplasm and oval nuclei.  The outermost portion of the pellets was 
composed of less organized polygonal cells with necrotic cells interspersed. 
Adult bone marrow derived mesenchymal stem cell pellets (BM-A-P): The pellets were 
composed of a central accumulation of polygonal cells with minimal acidophilic 
cytoplasm and round to oval nuclei often within lacunae separated by moderate amounts 
of lightly basophilic matrix. A small core of necrotic cells were observed centrally or 
interspersed throughout the pellets. Mild variation was seen in cell size.  The cellular 
population was circumferentially bordered by organized rim spindle cells several layers 
thick. The spindle cells had acidophilic cytoplasm and oval nuclei. The outermost portion 
of the pellets was composed of less organized polygonal cells with necrotic cells 
interspersed. 
Middle-aged bone marrow derived mesenchymal stem cell pellets (BM-M-P): The pellets 
were composed of a central core of necrotic cells or necrotic cells interspersed throughout 
the pellet. Bordering the center were low numbers of polygonal cells with minimal 
acidophilic cytoplasm and round to oval nuclei often within lacunae separated by small to 
moderate amounts of lightly basophilic matrix. A rim of spindle cells formed the 
outermost portion of the pellets.  
93 
 
Geriatric bone marrow derived mesenchymal stem cell pellets (BM-G-P): The pellets 
were largely composed of small, polygonal cells with pyknotic nuclei (necrosis). Some 
pellets had margins with a small focus of polygonal cells with minimal acidophilic 
cytoplasm and round to oval nuclei separated by small amounts of lightly basophilic 
matrix. 
Newborn adipose tissue derived mesenchymal stem cell pellets (AT-Y-P): The pellets 
were composed of a large central core of necrotic cells (approximately two-thirds the size 
of the pellet) bordered by fairly organized steams of spindle cells with small amounts of 
acidophilic cytoplasm and oval nuclei. The spindle cell layer was 3-12 cell layers thick.   
Yearling adipose tissue derived mesenchymal stem cell pellets (AT-Y-P): The pellets 
were composed of a large central core of necrotic cells (between one and two-thirds the 
size of the pellet) bordered by fairly organized streams of spindle cells with small 
amounts of acidophilic cytoplasm and oval nuclei. The remaining of the pellets was 
composed of spindle cell layers.  
Adult adipose tissue derived mesenchymal stem cell pellets (AT-A-P): The pellets were 
composed of a large central core of necrotic cells (between one to two-thirds the size of 
the pellet) bordered by fairly organized streams of spindle cells with small amounts of 
acidophilic cytoplasm and oval nuclei. Spindle cell layers comprised the remaining of the 
pellets.  
Middle-aged adipose tissue derived mesenchymal stem cell pellets (AT-M-P): The pellets 
were composed of a central core of necrotic cells (approximately one-third to one-half the 
size of the pellet) bordered by fairly organized streams of spindle cells with small 
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amounts of acidophilic cytoplasm and oval nuclei. Spindle cell layers comprised the 
remaining of the pellets.  
Geriatric adipose tissue derived mesenchymal stem cell pellets (AT-N-P): The pellets 
were composed of a central core of necrotic cells (approximately one-third to one-half the 
size of the pellet) bordered by fairly organized streams of spindle cells with small 
amounts of acidophilic cytoplasm and oval nuclei. Spindle cell layers comprised the 
remaining of the pellets. 
Newborn dermal fibroblast pellets (DF-N-P): The pellets were composed of a large 
central core of necrotic cells (approximately one-third to four-fifth the size of the pellet) 
bordered by fairly organized streams of spindle cells with small amounts of acidophilic 
cytoplasm and oval nuclei. Spindle cell layers comprised the remaining of the pellets. 
Yearling dermal fibroblast pellets (DF-Y-P): The pellets were composed of a central core 
of necrotic cells (approximately one-quarter to one-half the size of the pellet) bordered by 
fairly organized streams of spindle cells with small amounts of acidophilic cytoplasm and 
oval nuclei. Spindle cell layers comprised the remaining of the pellets. 
Adult dermal fibroblast pellets (DF-A-P): The pellets were composed of a large central 
core of necrotic cells (approximately one-quarter to two-thirds the size of the pellet) 
bordered by fairly organized streams of spindle cells with small amounts of acidophilic 
cytoplasm and oval nuclei. Spindle cell layers comprised the remaining of the pellets. 
Middle-aged dermal fibroblast pellets (DF-M-P): The pellets were composed of a large 
central core of necrotic cells (varies from one-quarter to three-quarters the size of the 
pellet) bordered by fairly organized streams of spindle cells with small amounts of 
95 
 
acidophilic cytoplasm and oval nuclei. Spindle cell layers comprised the remaining of the 
pellets. 
Geriatric dermal fibroblast pellets (DF-G-P): The pellets were composed of a large 
central core of necrotic cells (varies from one-fifth to two-thirds the size of the pellet) 
bordered by fairly organized streams of spindle cells with small amounts of acidophilic 
cytoplasm and oval nuclei. Spindle cell layers comprised the remaining of the pellets. 
 
3.3.4 Proteoglycan staining 
All slides were stained on the same day using aliquots of the same staining solutions. 
Control articular cartilage sections from the same horse, incorporated in each staining 
batch, showed no significant difference between slide-position within the 30-slide 
staining rack or difference between batches. Representative images of BM-MSC pellets 
after Safranin-O staining are shown under different magnifications in Figure 3.6. Figure 
3.7 shows representative images of BM-MSC pellets, AT-MSC pellets, and DF pellets 
from horses in 5 different age groups after Safranin-O staining. Safranin-O stains 
proteoglycans an orange to deep red color and showed some variation between biological 
replicates, but also consistent experimental group features as shown in the Redness data 
in Figure 3.8. Sections absent of proteoglycans presents in a turquoise blue color due to 
Fast Green background staining.  
When comparing the Safranin-O staining with the H&E staining for the same 
pellets under microscopy, portions of the BM-MSC pellets with polygonal cells 
(especially in lacunae) and organized stream of bordering spindle cells in general stained 
red for proteoglycans (Figure 3.4 and 3.6). Using microscopy, no red staining was 
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detectable for the eye of two individual observers (Drs. Jasmin Bagge and Jennifer Janes, 
University of Kentucky, USA) in any of the pellets made from AT-MSCs or DFs 
(biological negative control) (Figure 3.7). Likewise, no redness was detected in the non-
induced pellets or skin samples.   
 
  
Figure 3.6: Panel showing representative Safranin-O stained pellets of bone marrow 
derived mesenchymal stem cells (BM-MSCs) from horses in 5 different age groups under 
different magnifications after 21 days of culture in chondrogenic induction medium. Size-





Figure 3.7: Panel showing representative Safranin-O stained pellets of bone marrow 
(BM)- and adipose tissue (AT) derived mesenchymal stem cells (MSCs), and dermal 
fibroblasts (DF) from horses in 5 different age groups after 21 days of culture in 
chondrogenic induction medium. All images are taken under 5x magnifications. The size-
bar on the images is equivalent to 250 µm. 
 
In general, BM-MSC pellets had a significantly higher proteoglycan content than pellets 
from AT-MSC or DF (p<0.0001) (Figure 3.7 and 3.8). The proteoglycan content was 
significantly higher in chondrogenic BM-MSC pellets compared to AT-MSC pellets in 




When looking within BM-MSCs, pellets from newborn had a significantly higher 
proteoglycan content compared to all other age groups (p<0.0001), and yearlings had a 
significantly higher proteoglycan content compared to middle-aged horses (p=0.0190). 
For AT-MSC pellets, no statistical difference was seen in the Redness values between 
any of the age groups.         
 
 
Figure 3.8: Box plot showing proteoglycan Redness value of Safranin-O stained pellets 
of bone marrow (BM)- and adipose tissue (AT) derived mesenchymal stem cells and 
dermal fibroblasts (DF) (biological negative control) in 5 different age groups after 
normalization to articular cartilage (n=4 horses per cell type per age group). All pellets 
were cultured in chondrogenic induction medium for 21 days. Cell types within the same 
age group not labeled with the same letter are significantly different from each other 




3.3.5 Alkaline phosphatase (ALP) activity 
There was a significant difference in ALP activity between osteogenic induced and non-
induced control BM-MSCs in newborn (p<0.0001), yearling (p<0.0001), and adult horses 
(p=0.01). No difference was seen between osteogenic induced and non-induced cells in 
the middle-aged or geriatric horses, or in any of the AT-MSC age groups (Figure 3.9). No 
statistical effect of donor age was seen in any of the pair-wise comparisons within cell 
types for BM-MSCs or AT-MSCs, and large inter-animal variation was seen within most 
age groups as indicated by the standard deviation in Figure 3.9. When comparing the 3 
osteogenic induced cell types independent of age groups, the ALP activity was seen in 
the following order: BM-MSC > AT-MSC > DF (p<0.0001). When comparing across 
cell types within age groups, BM-MSCs had a higher ALP activity compared to AT-
MSCs in yearlings only (p=0.0155).       
 
Figure 3.9: Bar plot showing alkaline phosphatase (ALP) activity of equine bone marrow 
(BM)- and adipose tissue (AT) derived mesenchymal stem cells and dermal fibroblasts 
(DF) (biological negative control) in 5 different age groups after 7 days of culture in 
either osteogenic induction medium or expansion medium (non-induced control) (n=4, 
N=60). Error bars indicate standard deviation. *N: Newborn, Y: Yearling, A: Adult, M: 
Middle-aged, G: Geriatric.   
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3.3.6 Alizarin Red S (ARS) concentration  
There was a significantly higher ARS concentration in osteogenic induced cultures 
compared to non-induced controls for all BM- and AT-MSC age groups, except for 
middle-aged BM-MSC, and the geriatric horses of both BM- and AT-MSCs (Figure 
3.11). Representative images of osteogenic induced and non-induced BM-MSCs from a 
newborn foal in relation to ARS staining are shown in Figure 3.10. The ARS 
concentration of osteogenic induced DFs (biological negative control) were significantly 
lower compared to both BM- and AT-MSCs (p<0.0001) (Figure 3.11).  
As shown in Figure 3.11, there was a significant decrease in calcium deposition 
with increasing donor age for both BM- and AT-MSCs. Interestingly, a significant 
difference was seen already in pair-wise comparisons between newborn and yearlings for 
osteogenic induced BM-MSCs (p=0.0003). On the other hand, a significant difference in 
calcium deposition was only seen in pair-wise comparisons including geriatric horses for 
osteogenic induced AT-MSCs (p<0.0001). Nevertheless, the highest mean ARS value 
across all cell types were seen in BM-MSCs from newborn foals (mean ARS = 2.18 mM, 
SD=0.716). No sigificant difference was however detected between BM- and AT-MSCs 
in the newborn, adult, or geriatric age group. For yearling (p=0.0064) and middle-aged 
(p=0.0012) horses, AT-MSCs had a significantly higher calcium deposition compared to 




Figure 3.10: Representative images of BM-MSCs from a newborn foal after 21 days of 
culture in osteogenic induction medium (+) or in expansion medium (-), where 
mineralized aggregates can be visualized in the (+) osteogenic induced wells (Image A). 
Image B shows the same cells after 40 mM Alizarin Red S staining (calcium deposits 
stain red). Image C shows the same cells after calcium extraction using 10% acetic acid.    
 
 
Figure 3.11: Bar plot showing Alizarin Red S concentration (mM) as a measurement of 
calcium deposits of equine bone marrow (BM)- and adipose tissue (AT) derived 
mesenchymal stem cells and dermal fibroblasts (DF) (biological negative control) in 5 
different age groups after 21 days of culture in either osteogenic induction medium or 
expansion medium (non-induced control) (n=4 horses per cell type per age group per 
medium). Age groups with in the same osteogenic induced cell type not labeled with the 
same letter are significantly different from each other (p<0.05). Error bars indicate 
standard deviation. *N: Newborn, Y: Yearling, A: Adult, M: Middle-aged, G: Geriatric.  
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GENE EXPRESSION DATA: 
3.3.7 Gene expression 
After having cultured the pellets in chondrogenic induction medium for 21 days, there 
was a decrease in some proliferative markers like MYC (Figure 3.13) and PCNA, and a 
decrease in some growth factors like HDGF and FGF18 compared to non-induced 
monolayer cultures harvested at ~80% confluence (CHM). Following chondrogenic 
induction there was furthermore a general increase in expression of chondrogenic 
markers with most prominent rise in pellets from BM-MSCs (Figure 3.12). For the early 
markers of chondrogenesis, SOX5 and SOX9, there was a significantly higher gene 
expression of SOX5 in pellets compared to non-induced controls from BM-MSCs in all 
age groups (p<0.0001) and from AT-MSCs from horses below 8 years of age (p≤0.0031). 
For SOX9, there was a significantly higher expression in BM-MSC pellets compared to 
non-induced controls in newborns and yearlings (p≤0.0089), whereas no difference was 
seen for AT-MSCs or DFs.  
The signaling and transcription factors, CTGF and TGFB3, showed no difference 
between pellets and non-induced controls from AT-MSCs or DFs. For BM-MSCs, 
TGFB3 expression was significantly higher in pellets compared to non-induced controls 
in all age groups (p≤0.0017), whereas CTFG only showed difference in pellets versus 
non-induced controls in horses below 8 years of age (p≤0.0034).  
With regards to later markers of chondrogenesis, the same trend was seen. For 
MIA, there was a greater expression in chondrogenic induced BM-MSC pellets compared 
to non-induced controls in all age groups (p<0.0001), whereas no difference was seen in 
AT-MSCs or DFs. For the essential cartilage extracellular matrix components, COMP 
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and ACAN, a significant difference between pellets and non-induced controls was seen 
for both BM- and AT-MSCs in all age groups (p<0.0001). The specific marker of 
articular cartilage, COL2A1, was greater expressed in pellets compared to non-induced 
controls in BM-MSCs (p<0.0001) and AT-MSCs (p≤0.0009) in all age groups. No 
difference was seen in expression of the fibrocartilage marker, COL1A1, between pellets 
and non-induced cells in any of the cell types. Nevertheless, the expression of COL1A1 
was 1.6 fold higher (SE=0.567) in AT-MSCs pellets compared to BM-MSCs pellets, 
although not significant (p=0.0924).   
When comparing the cell types independent of age group, BM-MSCs had a 
significantly greater expression of ACAN, COL2A1, MIA, and SOX9 than AT-MSCs or 
DFs (p<0.0001). No difference was seen between AT-MSCs and DFs for the same 
biomarkers.   
When comparing within BM-MSCs, COMP and ACAN was significantly greater 
expressed in pellets from newborn compared to geriatric horses (p=0.0138 and p=0.0013, 
respectively). Likewise, MIA was up-regulated in newborn BM-MSC pellets compared to 
all other age groups (p<0.0001) except yearlings, who also had a higher expression 
compared to all older age groups (p≤0.0006) (Figure 3.14).     
With regards to extracellular collagens, a clear trend towards less COL2A1 
expression was seen with increasing donor age in pellets from BM-MSCs. The trend was 
however not significant presumably due to inter-sample variation. Nevertheless, BM-
MSC pellets from newborn foals had a significantly higher expression of COL11A1 
compared to middle-aged (p=0.0331) and geriatric horses (p=0.0003). On the other hand, 
pellets from geriatric horses had a significantly higher expression of COL4A1 compared 
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to newborn (p<0.0001) and adult horses (p=0.0186). With regards to COL1A1, middle-
aged horses had significantly lower expression compared to BM-MSC pellets from 
newborn (p=0.0107) and yearlings (p=0.0058). However, no difference was found in 
pair-wise comparisons involving geriatric horses.  
Out of the 88 biomarkers included in the panel, 11 (13%) were affected by donor 
age in AT-MSCs, 45 (51%) in BM-MSCs, and 13 (15%) in DFs when looking at 
chondrogenic induced pellets (Figure 3.12 and Table 3.2). As shown in the Venn-diagram 
(Figure 3.15), 9 of the targets were affected by donor age in both BM- and AT-MSC 
pellets. Of these, 6 targets (PCNA, LOC100146270, BRCA1, BARD1, CASP8, DMP1) 
were up-regulated with increasing donor age in both BM- and AT-MSCs, whereas 
SMPD3 was down-regulated with increasing donor age in BM-and AT-MSCs. CLU and 
PDGFD, were up-regulated in pellets from AT-MSCs and down-regulated in pellets from 







Figure 3.12: A heatmap showing the Ln(RQ) levels of gene expression by color change 
between average levels in bone marrow (BM) and adipose tissue (AT) derived 
mesenchymal stem cells and dermal fibroblasts (DF) from horses in 5 different age 
groups (n= 4 horses per age group per cell type per medium) grown under different 
conditions. Gray boxes indicate no detection of gene expression. *N: Newborn, Y: 
Yearling, A: Adult, M: Middle-aged, G: Geriatric, P: Pellets cultured in chondrogenic 
induction medium for 21 days, CHM: grown in T75 flasks with expansion medium and 
harvested at ~80% confluence, O0B; grown in expansion medium in 6-wells and 
harvested at ~90% confluence, O21A: cultured in 6-wells in osteogenic induction 




Figure 3.13: Graphical overview of mean Ln(RQ) gene expression levels of the 
proliferative marker MYC from bone-marrow derived mesenchymal stem cells in 5 
different age groups under different culture conditions. * CHM: grown in T75 flasks with 
expansion medium and harvested at ~80% confluence, O21A: cultured in 6-wells in 
osteogenic induction medium for 21 days, O21B: cultured in 6-wells in expansion 
medium for 21 days, O0B; grown in expansion medium in 6-wells and harvested at ~90% 
confluence, P: Pellets cultured in chondrogenic induction medium for 21 days. 
    
 
Figure 3.14: Bar plots with standard deviation illustrating mean relative gene expression 
of SOX9 (A), COMP (B), COL2A1 (C), ACAN (D), and MIA (E) in chondrogenic induced 
pellets and non-induced monolayer controls from bone marrow (BM)- and adipose tissue 
(AT)- derived mesenchymal stem cells (MSCs) and dermal fibroblasts (DF) from 4 horses 
in 5 different age groups (n=4, N=60). Age groups within chondrogenic induced BM-
MSCs not marked with the same letter are significantly different from each other 
(p<0.05). No significant donor age effect was seen for SOX9 or COL2A1. Note different 
y-axes. *N: Newborn, Y: Yearling, A: Adult, M: Middle-aged, G: Geriatric.  
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Table 3.2: Donor age affected genes within pellets made from adipose tissue (AT)- and 
bone marrow (BM) derived mesenchymal stem cells (MSC) and dermal fibroblasts (DF) 
from 4 horses in 5 different age groups (n=4, N=60) after 21 days of culture in 









































































































All listed genes were significantly affected by donor age within the given cell type 
determined by one-way ANOVA when p<0.05. Red marked genes indicate an up-
regulation in gene expression with increasing donor age. Blue marked genes indicate a 
down-regulation in gene expression with increasing donor age. * Categorized based on 
main function related to chondrogenesis, but could be categorized in more than one 





Figure 3.15: Venn-diagram showing the distribution of differentially expressed genes as 
a function of donor age between chondrogenic induced pellets made from adipose tissue 
(AT)- and bone marrow (BM) derived mesenchymal stem cells (MSC) and dermal 
fibroblast (DF) from 4 horses in 5 different age groups (n=4, N=60).   
 
After having grown the monolayer cells in osteogenic induction medium for 21 days, 
there was a general decrease in some of the growth factors. FGF5 and FGF18 were lower 
expressed in osteogenic induced cells compared to non-induced cells at day 0 and day 21. 
At the same time, an increase in multiple osteogenic factors occurred in the stem cells 
after being cultured in osteogenic induction medium for 21 days, with the largest fold 
changes occurring in BM-MSCs (Figure 3.17). The early marker of osteogenesis, 
RUNX2, was significantly up-regulated after osteogenic induction in AT-MSCs in all age 
groups (p≤0.0014) and in BM-MSCs from newborn foals (p<0.0001). Arcoss all age 
groups, RUNX2 expression followed the pattern of; BM-MSCs > AT-MSCs > DFs 
(p<0.0001). Another early marker of osteogenesis, ALPL, also showed significantly 
enhanced expression after osteogenic induction in BM-MSCs (p<0.0001) and AT-MSCs 
(p≤0.0195) in all age groups when compared to non-induced cells at day 21. When 
comparing cell types, osteogenic induced BM-MSCs had significantly higher ALPL gene 
expression compared to AT-MSCs in all age groups (p≤0.0329). BMP4 was significantly 
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up-regulated in osteogenic induced cells compared to non-induced day 21 cells for AT- 
and BM-MSCs in newborns (p=0.0045, and p<0.0001, respectively), and in BM-MSCs in 
yearlings (p=0.0004).  
An up-regulation in some of the later markers of osteogenesis was also observed 
after osteogenic induction. For SP7, an enhanced expression in osteogenic induced versus 
non-induced cells was only observed in newborn (p=0.0018) and yearling BM-MSCs 
(p=0.0092). Across all age groups BM-MSCs had a higher expression of SP7 compared 
to AT-MSCs and DFs. A significant difference in LOC100146589 was also observed 
between osteogenic induced and non-induced cells at day 21 for AT-MSCs from horses 
below 8 years of age (p≤0.0241) and in BM-MSCs from newborn foals (p<0.0001). In 
newborn foals, LOC100146589 was greater expressed in osteogenic induced BM-MSCs 
than AT-MSCs (p=0.0441) and DFs (p<0.0001). No difference was observed in 
LOC100146589 expression between BM- and AT-MSCs in any of the other age groups. 
When comparing all 3 osteogenic induced cell types independent of donor age, no 
difference was seen in LOC100146589 expression (p≥0.2414). COL1A1 expression was 
higher in non-induced compared to osteogenic induced cells at day 21 for all 3 tissue 
types in all age-groups.     
When comparing within cell types, no effect of donor age was seen on ALPL 
expression in osteogenic induced BM- or AT-MSCs. The same was true for RUNX2 
expression in AT-MSCs, but a significant decrease in RUNX2 expression was seen with 
increasing donor age in BM-MSCs, specifically between newborn and adults (p=0.0088), 
and newborn and middle-aged (p=0.0491). With regards to later markers of osteogenesis, 
SP7 and COL1A1, no effect of donor age was seen in osteogenic induced AT- or BM-
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MSCs. On the other hand, BM-MSCs from newborn foals had a significantly higher 
LOC100146589 expression compared to adult (p=0.0006), middle-aged (p<0.0001), and 
geriatric horses (p=0.0242) (Figure 3.17).           
Out of the 88 biomarkers included in the panel, 15 (17%) were affected by donor 
age in AT-MSCs, 30 (34%) in BM-MSCs, and 32 (36%) in DFs when assessing 
osteogenic induced cells (Figure 3.12 and Table 3.3). As shown in the Venn-diagram 
(Figure 3.16), 7 of the targets were affected by donor age in both BM- and AT-MSC. Of 
these, 5 targets (BGN, COL11A1, CTNNB1, HGF, SMOC) were up-regulated with 
increasing donor age in both BM- and AT-MSCs. CASP3 and CLU, were up-regulated in 













Table 3.3: Donor age affected genes within monolayer cultures of adipose tissue (AT)- 
and bone marrow (BM) derived mesenchymal stem cells (MSC) and dermal fibroblasts 
(DF) from horses in 5 different age groups (n=4, N=60) after 21 days of culture in 

























































































































*All listed genes were significantly affected by donor age within the given cell type 
determined by one-way ANOVA when p<0.05. Red marked genes indicate an up-
regulation in gene expression with increasing donor age. Blue marked genes indicate a 
down-regulation in gene expression with increasing donor age. * Categorized based on 
main function related to osteogenesis, but could be categorized in more than one 




Figure 3.16: Venn-diagram showing the distribution of differentially expressed genes as 
a function of donor age between osteogenic induced adipose tissue (AT)- and bone 
marrow (BM) derived mesenchymal stem cells (MSC) and dermal fibroblast (DF) from 




Figure 3.17: Bar plots with standard deviation illustrating mean relative gene expression 
levels of RUNX2 (A), ALPL (B), BMP4 (C), SP7 (D), and LOC100146589 (E) in 
osteogenic induced cells after 21 days of induction and non-induced controls at day 0 
and day 21. The cells consist of bone marrow (BM)- and adipose tissue (AT) derived 
mesenchymal stem cells (MSCs) and dermal fibroblasts (DF) from 4 horses in 5 different 
age groups (n=4, N=60). Age groups within the same osteogenic induced cell type not 
marked with the same letter are significantly different from each other (p<0.05). Note 




In this study, we examined the effect of donor age on the in vitro chondrogenic and 
osteogenic differentiation performance of equine BM- and AT-MSCs from horses in 5 
different age groups, together with potential underlying gene expression changes in 
biomarkers related to differentiation and aging. Chondrogenic and osteogenic 
differentiation performance in culture is an important aspect of assessing stem cells 
potential to regenerate orthopedic injuries, as differentiation and growth factor excreting 
capacity has been positively linked [97], together with an increased use of scaffolds to 
enhance engraftment of stem cells within the injury site depending more on their direct 
differentiation capacity.  
The results support the hypothesis that increasing donor age is a major variable 
impacting equine BM- and AT-MSCs chondrogenic and osteogenic differentiation 
performance with decreasing capacities following non-linear kinetics, which is similar to 
previous reports in other species [27,85,97,122–125,127]. Other research groups have 
however reported no age related changes in MSC differentiation potential [100,131,137], 
which may be caused by the lack of very young individuals in the study populations and 
differences in culture conditions. Stenderup et al. reported that age related changes in 
bone formation were more associated with lower MSC proliferative capacity and hence 
lower cell numbers than a lower function of the MSCs [131]. To control for this factor, 
all our assays were performed at passage 4 and all cells were plated at the same density in 
all steps.  
The data furthermore showed that BM-MSCs have higher potential for generating 
cartilage under standard chondrogenic induction conditions than AT-MSCs, which is 
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supported by previous equine studies [35,41,69]. Nevertheless, our data showed a 
significant decrease in proteoglycan content with increasing donor age in pellets from 
BM-MSCs already in pair-wise comparisons between newborn and yearlings. This 
finding on protein level was supported by a decrease in ACAN gene expression with 
increasing donor age, as aggrecan is an essential proteoglycan in articular cartilage [4]. 
The higher extracellular proteoglycan content in BM-MSCs from young horses was 
surprisingly not reflected in pellet size where no statistical difference was detected as a 
function of donor age. This may be partly due to an increased number of senescent cells 
in BM-MSC pellets from old horses as GLB1 expression was up-regulated in aged 
horses, and senescent BM-MSCs are reported to have a larger cell morphology [105,131].  
On a morphological level, BM-MSC pellets from newborn foals were most 
uniform in redness and contained similarities to native articular cartilage with areas of 
lacunae occupied by single cells, proteoglycan rich matrix between the cells, and minimal 
necrotic cells. In the older age groups, more necrotic cells appeared centrally, which was 
also seen in pellets from AT-MSCs and DFs in all age groups. A zonal architecture of 
chondrogenic induced pellets have been reported previously [35,71]. The lack of or 
minimal necrotic center in newborn BM-MSC pellets is particularly interesting as it 
suggests a cellular adaptation to lower oxygen levels. Such a characteristic would be an 
important feature, as articular chondrocytes live under hypoxic conditions with low 
oxygen levels between 1% and 10% depending on the length to the articular surface [19]. 
Changes in the level of necrotic core as a function of donor age and cell type may also be 
caused by different diffusion efficiency of oxygen and nutrients in matrices of different 
pellet types, which is likely as pellets from aged BM-MSC, AT-MSCs and DFs appeared 
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more dense with less extracellular matrix. Pellet size may also be a contributing factor, 
but no significant difference in pellet size was seen as a function of donor age in BM-
MSCs, and the pellet size of newborn BM- and AT-MSCs was not significantly different 
from each other. Additionally, it is possible that equine BM-MSCs from newborns are 
less heterogeneous compared to the heterogeneous population described in adult horses 
[35,92,133], but this remains to be investigated. The lower chondrogenic potential seen 
already in yearlings may be highly problematic for autologous treatments of cartilage 
injuries if cells are not harvested and potentially cryopreserved at an early age.   
It was furthermore interesting that the chondrogenic differentiation performance 
of AT-MSCs very closely resembled that of DFs (biological negative control) in all age 
groups. Additionally, AT-MSC pellets had a higher expression of COL1A1 and lower 
expression of COL2A1 compared to BM-MSCs. Expression of COL1A1 is documented 
in chondrogenic induced MSC pellets [35,38], but is considered undesirable as COL1A1 
is a marker of biomechanically inferior fibrocartilage compared to hyaline cartilage with 
high COL2A1 content [4]. In contrast, other studies have reported a chondrogenic 
differentiation potential of AT-MSCs, although lower than seen for BM-MSCs 
[41,69,163]. The different results may be related to different culture conditions, as some 
of the studies used hydrogels, together with variances in chondrogenic induction formulas 
and assays. Together, this highlights the limitations of AT-MSCs as a therapeutic choice 
for cartilage regeneration.   
A previous study by Asumda et al. [97] reported that BM-MSCs from 15 months 
old rats were not at all able to perform chondrogenic or osteogenic differentiation. This 
was partly supported by our data were only minimal chondrogenic and osteogenic 
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differentiation was seen in BM-MSCs from geriatric horses, with no statistical 
differences in ALP activity or calcium deposition between non-induced and induced 
cells. ALP is an early marker of osteogenesis and is highly expressed in mineralized 
tissue where it enzymatically degrades inhibitory pyrophosphates that bind calcium to 
enhance mineralization. As such, ALP is considered a hallmark of osteogenic 
differentiated cells in culture with highest expression 6 to 7 days after initiation of 
osteogenic induction [87,89,90]. The data showed the highest ALPL gene expression in 
BM-MSCs and no effect of donor age. This finding was supported by a protein activity 
assay, where APL activity was highest in osteogenic induced BM-MSCs followed by 
AT-MSCs and DFs with no effect of donor age in BM-MSCs. Even though no effect of 
donor age was shown on alkaline phosphatase activity, a trend towards decreased levels 
in aged horses was seen, suggesting that this part of the study might be under-powered. 
Interestingly, the ALP activity was significantly higher in osteogenic induced cells versus 
non-induced cells in BM-MSCs from horses below 8 years of age. In contrast, AT-MSCs 
and DFs demonstrated no difference in ALP activity between osteogenic induced and 
non-induced cells in any age group, highlighting the low ALP potential of osteogenic 
induced equine AT-MSCs.  
On the other hand, Chen et al. [134] and Shi et al. [137] previously reported that 
human and mouse AT-MSCs osteogenic differentiation potential was less affected by 
donor age than BM-MSCs. This finding was partly supported by our data, where a 
decrease in ARS concentration of osteogenic induced BM-MSCs occurred already 
between newborn and yearlings, whereas calcium deposition only decreased in AT-MSCs 
from geriatric horses. Differences in initial calcium deposition may be a contributing 
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factor, as the highest ARS concentration was reported in newborn BM-MSCs although 
not significantly different from newborn AT-MSCs. As mineralization depends on 
multiple factors [89], a decrease in ARS concentration with increasing donor age is 
possible even though no statistical donor age effect was seen for ALP.   
The data furthermore showed that BM-MSCs from young horses have higher 
potential for generating bone under standard osteogenic induction conditions than AT-
MSCs, which is supported by previous human and equine studies [31,44,45,164,165]. 
Park et al. furthermore showed that BM-MSCs were more effective towards osteogenic 
differentiation under dynamic hydraulic compression than AT-MSCs [44], which may be 
an important feature as osteocytes have to withstand and respond to mechanical stimuli in 
vivo [166]. On the other hand, Kang et al. reported that osteogenic induced canine AT-
MSCs had a higher ALP activity and mineralization compared to BM-MSCs after 14 
days of culture, but that in vivo healing of bone radial defects was slightly better when 
using BM-MSCs [167]. Furthermore, Chung et al. demonstrated similar osteogenic 
differentiation potential between canine BM- and AT-MSCs, and found that hypoxia 
inhibited the proliferation of both cell types and osteogenic differentiation of AT-MSCs 
[168], which should be considered when using MSCs in hypoxic environments such as 
fractures and infections [166]. Differences in potential may be due to different species, 
donor age groups, and induction methods.    
As expected, some of the proliferation markers were down-regulated after 
inducing the cells to undergo chondrogenesis as 3D pellets and osteogenesis as 
monolayers. Of greater interest are, however, the 6 genes all related to proliferation 
(except for DMP1) that were up-regulated with increasing donor age in both 
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chondrogenic induced BM- and AT-MSCs, as they may be markers of genes consistently 
affected by donor age in equine MSCs under chondrogenic induction. The tumor 
suppressors p16, BRCA1, and BARD1 and apoptosis factor CASP8 were all up-regulated 
in chondrogenic induced stem cells from aged donors. This may be related to cellular 
senescence or to the pelleting procedure as less oxygen is provided to the centrally 
located cells, which thereby would make them more prone to undergo cell death as seen 
on the H&E slides if not adapted to hypoxia.   
Of the targets affected by donor age in both AT- and BM-MSCs, none of the 
targets affected under chondrogenic culture were intersecting with targets affected under 
osteogenic culture. This suggests that the biomarkers affected by donor age in MSCs may 
be influenced by culture conditions, which is likely as different transcription factors and 
hence pathways are provided to the cells together with pelleting versus monolayer 
culture. In support of this finding, a recent proteomics study by Peffers et al. also 
reported no intersection of age-affected proteins in chondrogenic and osteogenic 
constructs made from human BM-MSCs [85]. The highest proportion of biomarkers 
affected by donor age was seen in BM-MSCs. This was, however, not surprising, as BM-
MSCs also had the highest chondrogenic and osteogenic potential to begin with in 
newborns.    
On an osteogenic level, the biggest fold changes were seen in early markers of 
osteogenesis (e.g. RUNX2 and ALP) after 21 days of osteogenic induction. RUNX2 is an 
early marker of osteogenesis and an essential transcription factor for activation of 
osteoblast associated genes like osteocalcin and alkaline phosphatase [169]. Down-
regulation in RUNX2 seen already in BM-MSCs from adult horses may very well be a 
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major player in the osteogenic differentiation decrease seen with increasing donor age in 
BM-MSCs as its expression correlated relatively well with downstream targets. Some of 
the later markers of osteogenesis like SP7 (osterix) and LOC100146589 (osteocalcin) 
were only significantly up-regulated after osteogenic induction in young horses. 
Osteocalcin was furthermore found at relatively high levels in day 0 DFs. Osteocalcin is 
specifically excreted by osteoblasts and is essential for mineralization. Low expression of 
osteocalcin can be partly explained by it mainly being produced by mature osteoblasts 
during bone mineralization [89]. Hence, it is possible that higher expression would be 
seen with longer culture in osteogenic medium as shown previously [87,170]. Since 2007 
it has been realized that osteocalcin also plays an important role in the relationship 
between energy metabolism and bones, and hence are released from osteoblasts into the 
circulation where it targets other organs [89,171]. This may be the reason for its presence 
in DFs.  
It has previously been reported that DFs incapable of osteogenic differentiation 
can produce non-apatitic spontaneous calcium deposits when cultured with more than 2 
mM β-glycerophosphate [172]. This was however not demonstrated in our study, where 
DFs showed minimal calcium deposition after being cultured in osteogenic induction 
medium containing 10 mM β-glycerophosphate for 21 days. Likewise, DFs showed no 
chondrogenic differentiation after being cultured in chondrogenic induction medium for 
21 days. The credibility of the differentiation results obtained from the MSCs are 
therefore strengthened, as the induction mediums were not able to produce measurable 




All cells were collected immediately after euthanasia. This is however not 
believed to affect the translational value of the results into autologous transplantations, as 
no difference have been reported in MSCs from newly euthanized and anesthetized 
horses [133]. Collection of BM-MSCs varied for newborn and the other age groups as the 
newborn sternum was too cartilaginous and Jamshidi
®
 bone marrow aspiration 
unfeasible. By splitting the sternum and growing the trabecular bone marrow as tissue 
explants, the same principles as described for foals previously were utilized [42]. The 
newborn age group furthermore consisted only of cells from ponies, but there is a lack of 
studies evaluating potential horse breed effects on the differentiation potential. However, 
the 2 ponies in the middle-aged age group performed similar to the other horses in that 
age group, and the newborn cells followed the same proliferation pattern as seen in 
yearlings. A recent study did however show different surface markers on equine BM-
MSCs between Thoroughbreds and Standardbreds [173]. The cells were collected from a 
mixture of female and male horses, with both genders represented in each age group. 
However, there was a higher presentation of cells from female horses, but in vitro 
differentiation has been shown not to be affected by gender [130].      
In conclusion, the chondrogenic and osteogenic differentiation performance of 
equine BM- and AT-MSCs decline with increasing donor age. BM-MSCs from newborn 
foals have the highest chondrogenic and osteogenic potential in vitro for regenerating 
cartilage and bone injuries when compared to older age groups and AT-MSCs. A 
decrease in chondrogenic proteoglycan content and osteogenic calcium deposition was 
seen already in pair-wise comparisons between newborn and yearling BM-MSCs. AT-
MSCs showed minimal ability to perform chondrogenic differentiation, but was less 
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affected by donor age than BM-MSCs when making calcium deposits, where no 
difference was seen in ARS concentration in horses below 18 years of age.  Gene 
expression alterations showed changes in regulators of proliferation and differentiation 
markers with increasing donor age. Together, this highlights the importance of donor age 
considerations and MSC tissue type selection for autologous treatments in horses.   
This study is the first equine study comparing donor age effects on the 
chondrogenic and osteogenic differentiation performance of MSCs. Incorporation of 5 
well-distinguished clinically relevant age groups furthermore sets it apart from most 
previous studies in other species where few wider age groups have been compared. The 
results are thus believed to be highly interpretable for clinical practice and when advising 
horse owners. By assessing changes in gene expression, we have furthermore identified 
targets to potentially improve the differentiation capacity of MSCs from horses with low 
differentiation potential as a function of age through molecular manipulations. Further 
transcriptome and mechanistic studies will be valuable in elucidating the exact effect of 
the identified biomarkers, their pathways, and how they are involved in regulating equine 
MSC chondrogenesis and osteogenesis as a function of donor age. Moreover, it would be 
interesting to test age-related changes in equine BM-MSCs sensitivity to hypoxia.  
Our results showed a decrease in BM-MSC chondrogenesis and osteogenesis in 
vitro already in yearlings, which is likely problematic for autologous treatments to treat 
cartilage and bone injuries unless the cells are harvested at a young age and 
cryopreserved for potential later use. Nevertheless, the differentiation performance in 
culture needs to be held together with their in vivo potential to heal cartilage and bone 
injuries, which remains to be investigated as a function of donor age in horses.  
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CHAPTER 4. REFLECTIONS AND LOOKING AHEAD TO FUTURE STUDIES  
4.1 Reflections 
Research efforts in this dissertation were designed to investigate the effect of donor age 
on equine mesenchymal stem cells (MSCs) in vitro potential to treat orthopedic injuries. 
The specific objectives were to 1) examine the effect of donor age on the in vitro cellular 
proliferation of equine bone marrow (BM)- and adipose tissue (AT) derived MSCs, and 
to 2) determine the effect of donor age on the chondrogenic and osteogenic 
differentiation performance of equine BM- and AT- MSCs in culture.  
Within the emerging field of regenerative medicine, cellular therapy of orthopedic 
injuries with MSCs is gaining increasing interest in equine practice, as they have shown 
potential to facilitate the repair of orthopedic injuries together with treating the symptoms 
[17,18,21,22]. As described in the previous chapters, autologous treatment is currently 
preferred and multiple studies in other species have shown a decline in our ability to 
expand the cells with increasing donor age, together with a sharp age-related reduction in 
their chondrogenic and osteogenic potential [27,94,97,122–124]. As both of these 
parameters are essential for the therapeutic efficiency of MSC therapy, it is essential to 
understand potential donor age effects on MSCs in horses, as the horse is an important 
patient population in its own right, and no direct age-conversion scale exists between 
horses and humans or rodents.  
As presented in chapter 2, the cellular proliferation of equine BM- and AT-MSCs 
declined with increasing donor age, but interestingly only in pair-wise comparisons 
involving geriatric horses. The data hence showed that it is possible to expand MSCs in 
vitro at high rates from horses below 18 years of age, which is promising to obtain 
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sufficient numbers for autologous treatments, together with the fact that multiple 
treatments often are recommended [51]. The data furthermore showed that the cellular 
proliferation of BM- and AT-MSCs was equally affected by donor age, and that there 
was no significant difference in their proliferation performance in any of the age groups. 
This finding is believed to be positive for autologous treatments as BM-MSCs have 
shown a general higher potential to treat cartilage and bone injuries [35,41,44]. 
Nevertheless, it is important to remember that the frequency of MSCs is higher from 
adipose tissue than from bone marrow aspirates as shown previously [31,42], whereby 
higher cell numbers can be obtained faster for AT-MSCs. This was however not 
investigated as a function of donor age in the present dissertation. The data furthermore 
indicated that equine MSCs from geriatric donors may be more susceptible to cellular 
senescence, as steady state mRNA changes showed a primary up-regulation in tumor 
suppressors including p53, p21, and p16 with increasing donor age, which has also been 
proposed in previous studies leading to decreased proliferation [27,131].   
In contrast to the promising age-related expansion findings in chapter 2, the data 
from chapter 3 showed a sharp decline in chondrogenic and osteogenic potential of BM-
MSCs already in pair-wise comparisons between newborn and yearlings. Nevertheless, 
the chondrogenic potential of newborn BM-MSCs seems very promising for cartilage 
regeneration, as the chondrogenic markers and proteoglycan matrix were highly up-
regulated and the cells showed additional capability to make some lacunae formation and 
to potentially adjust to hypoxia, which is found in articular cartilage and also documented 
in fetal cartilage progenitor cells after chondrogenic induction [35]. Even though the 
chondrogenic performance declined with increasing age, it should be noticed that the 
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proteoglycan content was significantly higher in chondrogenic pellets from BM-MSCs 
compared to the negative control (DFs) in all age groups, indicating that some (minimal) 
chondro-regenerative effect may be maintained. On the other hand, our data showed 
minimal chondrogenic performance of AT-MSCs in vitro in all age groups, which is 
critical as these cells currently are being used in clinical practice to treat cartilage 
injuries. Our data strongly indicate that BM-MSCs are superior compared to AT-MSCs 
for regenerating cartilage injuries with regards to their direct differentiation potential, and 
that BM-MSCs potentially should be harvested at an early age and stored for later use. 
These results are important to convey to equine veterinarians to improve the clinical 
outcome of stem cell therapies in horses, and highlights why it is important for clinical 
applications to be based on solid research.    
Likewise, BM-MSCs in general showed superior osteogenic performance 
compared to AT-MSCs, but interestingly appeared to be earlier affected by donor age 
than AT-MSCs. The data thereby indicate that stem cell choice to treat bone injuries in 
older horses does not matter as much as in young horses. Furthermore, both stem cell 
types showed higher osteogenic potential than dermal fibroblasts.  
Together this shows that even though equine MSCs can be expanded at high rates 
until late in life, they lose large parts of their chondrogenic and osteogenic differentiation 
performance earlier in life, which is discouraging for autologous treatments in older 
horses if the cells are harvested at the time of injury. This information is critical to 
convey to clinicians as autologous MSC treatment currently is being applied with various 
success in adult and older horses with cells harvested at the time of injury. The age of the 
donor and cell choice are hence believed to be critical for the clinical outcome, and can if 
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wrongly applied explain certain minimal benefits some clinicians complain about, 
although more in vivo studies are required.   
Other suggested approaches to be advanced in old horses are instead to harvest 
and cryopreserve BM-MSCs from when the horse is young, find compatible allogenic 
MSCs or MSC derived extracellular vesicles from young horses, or to rejuvenate MSCs 
through molecular manipulations. More research obviously needs to be performed in 
these areas of which some are suggested in the future studies section below.  
Limitations associated with trypsinization, tryphan blue, and cell counting 
techniques could potentially have affected the accuracy of cell numbers used to make 
pellets even though 500,000 cells were strongly attempted per pellet. Furthermore, 2D 
images does not account for the non-circular 3D shape seen in most pellets. Together, this 
could explain some of the inter-animal variances in pellet size observed within each age 
group. For future studies, 3D imaging and automated cell counting could be used to try to 
standardize the procedure even more, but in our experience automated cell counting also 
has limitations especially when working with cells of different sizes.   
Under ideal conditions, the studies would have been performed on paired samples 
in the same laboratory. This was, however, not feasible due to the degree program, 
logistical reasons, time and economic constraints, and because some of the cells already 
were stored in the laboratories. Instead inter-laboratory control cells were applied 
together with incorporation of laboratory and animal number as factors in the statistical 
analyses to control for these potential effects.  
Power analyses were performed on pilot data from the EdU proliferation assay and 
from the Alizarin Red S assay. Ideally, power analysis would have been performed on all 
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assays, but this was not feasible due to the study set up. A sample size of 4 horses per cell 
type per age group was determined based on the performed power analyses, but it appears 
that especially the results of the alkaline phosphatase activity assay could have benefitted 
from a larger sample size as it might be under-powered. That said, the study population 
used in this study is quite exceptional and spans over more age-groups and tissue types 
than seen in the majority of existing studies from newborn to geriatric.     
 
4.2 Future studies 
As with any other research, answering one question leads to more questions to be 
investigated. There are multiple ways to expand on the knowledge generated in this 
dissertation and some priority future study directions will be suggested below.  
In the present work, 96 selected gene loci of interest were analyzed for their gene 
expression as a function of donor age. Full transcriptome analysis will be valuable to 
identify additional loci affected by donor age and to allow for better pathway and 
mechanical clustering of the effected genes and their function.  
By assessing changes in gene expression as a function of donor age, targets have 
been identified to potentially improve the cellular proliferation and chondrogenic and 
osteogenic differentiation capacity of MSCs from older horses through molecular 
manipulations. In chapter 2, we showed an up-regulation in tumor suppressors in MSCs 
from geriatric horses, and it would be very interesting to see if the proliferative capacity 
could be regained by e.g. knocking-down p16, p53, and/or p21 using small interfering 
RNA (siRNA). As siRNA application in vitro is a transient transfection, minimal risk of 
tumor formation should occur after siRNA is ―washed‖ out [174]. Nevertheless, 
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additional in vitro and in vivo studies would need to be conducted to assess potential 
oncogenic effects of down-regulating tumor suppressors in MSCs in vitro.   
In support of the decreased proliferation capacity described in chapter 2, it would 
be valuable to investigate where the cells are located in the cell cycle as a function of 
donor age. The shown up-regulation in p16, p53, and p21 expression, suggests that a 
larger proportion of the cells may be arrested in G1, but this remains to be investigated in 
equine MSCs. Fluorescence-activated cell sorting (FACS) could be used to assess cell 
cycle location, and would furthermore be able to calculate the amount of apoptotic cells 
as apoptotic cell‘s DNA appear degraded on FACS histograms [110]. Knowing the exact 
cell cycle location of the cells as a function of donor age, would provide more 
information that could be used for later mechanistic approaches to see if the cell cycle 
location changes with e.g. siRNA manipulations as described above. 
In chapter 2, it was proposed that equine MSCs from geriatric horses may be 
more susceptible to cellular senescence as described in other species [27,131]. To test this 
hypothesis in horses, additional passaging studies would need to be performed using 
MSCs from horses in multiple age groups and to include telomere length and β-
galactosidase activity as markers of senescence.  
An additional mechanistic approach would be to investigate if any of the gene loci 
affected by donor age have concurrent changes in DNA methylation patterns, especially 
in the promotor region. DNA methylation patterns in some genes have been shown to  
change with aging [102,103]. DNA methylation changes in the promotor region could 
represent a molecular mechanism for changes in gene expression as a function of donor 
age [102]. Additionally, Horvath demonstrated an association between DNA methylation 
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age and cellular proliferation in human BM-MSCs, and suggested that DNA methylation 
changes may be related to a decline in stem cell function with increasing age [102,175]. 
Interestingly, epigenetic remodeling has furthermore been shown to rejuvenate cells 
without affecting the cell fate [176,177]. As such, it would be of great relevance to 
investigate if this would be a potential area to increase expression of some of the 
chondrogenic and osteogenic markers down-regulated with increasing donor age, such as 
ACAN and RUNX2.      
In chapter 3, it was enlightening to see how aged BM-MSCs and AT-MSCs 
showed minimal chondrogenic potential compared to young BM-MSCs under the same 
experimental conditions. Using the chondrogenic pellets already generated, it would thus 
be interesting to explore the localization of collagen type II and collagen type I as 
markers of hyaline- and fibrocartilage in the different cell types and age groups using 
immunohistochemistry. As the distribution of collagen type II and type I are of great 
clinical relevance, efforts in the MacLeod laboratory (M.H. Gluck Equine Research 
Center, University of Kentucky, USA) have previously been made to optimize 
immunohistochemistry on equine MSC pellets with varying success. Through the 
continuous development of new antibodies and commercially available kits, this may be 
more successful in the future. Further studies investigating the stem cells response to 
oxygen tension would also enhance our understanding of their cell biology, which may be 
especially relevant for newborn BM-MSCs that presumably showed relatively more 




All our donor-age related research efforts in horses have so far been conducted in culture, 
and we thus do not know how MSCs behave in vivo as a function of donor age. Based on 
the high chondrogenic and osteogenic in vitro potential of BM-MSCs from newborns, it 
would be interesting to see if these cells exhibited higher levels of integration and direct 
differentiation capacity when injected by themselves or in a scaffold into osteoarthritic 
joints. A study by Dressler et al. showed no significant difference in patellar tendon 
repair when treating 4 year old rabbits with autologous BM-MSCs harvested from the 
same animals at 1 and 4 years of age. There was, however, a trend towards higher tendon 
repair when using the young cells harvested at 1 year of age [178]. On the other hand, 
Rauscher et al. showed significantly better healing of atherosclerosis in mice when 
applying cells from young donors compared to old donors [179]. Similarly, a recent study 
by Khong et al. reported accelerated wound healing when applying allogenic MSCs from 
young donors [66]. A longitudinal study design similar to the rabbit study by Dressler et 
al. [178] would provide knowledge on potential donor age-related effects in horses and 
avoid allogenic confounding factors. It would likewise be important to compare the 
immunomodulatory properties as a function of donor age, together with the paracrine 
excretion, such as growth factors and cytokines. A study by Siegel et al. reported that 
biological age did not affect human BM-MSCs ability to suppress proliferation of 
activated allogenic T-cells in vitro [130], but this remains to be investigated in horses.   
So far, our in vitro studies have examined the intrinsic effect of donor age on 
MSCs, but studies in other species have also shown an important extrinsic effect and that 
the age of the recipient may affect the outcome [27,105]. Extrinsic age-related effects on 
MSCs potential could be examined in a cross-sectional study where horses in different 
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age groups were treated with allogenic young cells to assess the response, or in a 
longitudinal study where the same animals were treated with autologous cells at various 
ages to avoid allogenic confounding factors.  
Due to the described challenges with autologous and allogenic MSC treatments, 
extracellular vesicles released from MSCs have been proposed as a new treatment for 
orthopedic injuries. Extracellular vesicles are nanoscale particles that carry a cargo of 
signaling molecules from the parent cell and are believed to be responsible for the 
paracrine effect of MSCs [180]. It would therefore be a very natural step to investigate 
how donor age affects the cargo of MSC derived extracellular vesicles both in vitro and 
in vivo related to joint injuries.    
 
In summary, the results of this dissertation showed that the cellular proliferation 
and chondrogenic/osteogenic differentiation performance of equine BM- and AT-MSCs 
declined with increasing donor age following non-linear kinetics. Interestingly, 
significant differences in the cellular proliferation were only seen in pairwise 
comparisons involving geriatric horses, and high proliferation rates were observed in 
MSCs from horses below 18 years of age. On the other hand, a decline in BM-MSCs 
chondrogenic and osteogenic differentiation performance occurred already in pairwise 
comparisons between newborn and yearlings, whereas a decline in AT-MSCs osteogenic 
calcium deposition only occurred in geriatric horses. BM-MSCs from newborns showed 
high chondrogenic and osteogenic differentiation performance. In contrast, AT-MSCs 
showed minimal chondrogenic potential in all age groups. This dissertation highlights the 
importance of donor age considerations and MSC tissue type selection for autologous 
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treatment of orthopedic injuries. Understanding the effect of donor age on equine MSCs 
has the potential to optimize autologous stem cell therapies of cartilage and bone injuries 






APPENDIX 1. Sample information for RT-qPCR 
Sample-ID Final concentration of 
cDNA (ng/uL) 
260/280 260/230 RIN 
value 
PELLETS 
BM-EQF1701-P 13,90 1,91 2,17 8,60 
BM-EQF1703-P 13,90 1,97 2,15 9,00 
BM-EQF1704-P 13,90 2,01 2,24 7,70 
BM-EQF1705-P 13,90 1,99 1,95 9,00 
BM-EQA1504-P 13,90 1,97 2,13 9,10 
BM-EQA1505-P 13,90 1,70 1,98 8,60 
BM-EQA1506-P 13,90 1,89 2,02 8,90 
BM-EQA1507-P 13,90 2,03 2,11 8,00 
BM-0115-P 13,90 1,94 1,82 8,00 
BM-1607-P 13,90 1,94 2,09 9,20 
BM-1608-P 13,90 1,98 2,21 7,50 
BM-V1807-P 13,90 1,94 1,89 8,00 
BM-1606-P 13,90 1,89 2,02 9,20 
BM-1116-P 13,90 1,88 2,15 9,30 
BM-S1702-P 13,90 1,85 1,98 8,00 
BM-S1703-P 13,90 2,06 1,92 9,00 
BM-G1801-P 13,90 1,75 2,20 8,20 
BM-G1802-P 13,90 1,80 2,03 8,50 
BM-0314-P 13,90 1,83 1,97 9,00 
BM-G1609-P 13,90 1,86 2,03 8,20 
AT-EQF1701-P 13,90 2,06 2,07 8,60 
AT-EQF1703-P 13,90 1,87 2,21 8,00 
AT-EQF1704-P 13,90 1,94 2,03 8,10 
AT-EQF1705-P 13,90 1,76 1,87 8,10 
AT-EQA1504-P 13,90 1,97 2,13 8,40 
AT-EQA1505-P 13,90 1,98 2,13 9,40 
AT-EQA1508-P 13,90 2,10 1,98 8,70 
AT-EQA1509-P 13,90 1,98 2,06 9,30 
AT-1607-P 13,90 1,94 2,06 8,00 
AT-1608-P 13,90 1,93 2,19 8,30 
AT-V1807-P 13,90 1,85 2,21 8,30 
AT-0115-P 13,90 1,96 2,14 9,40 
AT-1606-P 13,90 1,93 2,16 9,00 
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AT-0315-P 13,90 1,99 2,11 9,30 
AT-0415-P 13,90 2,00 2,09 9,10 
AT-0916-P 13,90 1,96 2,12 9,00 
AT-0314-P 13,90 1,89 2,10 8,30 
AT-G1609-P 13,90 1,92 2,13 8,90 
AT-G1801-P 13,90 1,97 1,83 8,50 
AT-G1802-P 13,90 1,86 2,07 8,70 
DF-EQF1703-P 13,90 2,05 2,24 7,50 
DF-EQF1704-P 13,90 1,83 2,22 9,80 
DF-EQF1701-P 13,90 1,90 2,10 9,50 
DF-EQF1705-P 13,90 2,00 2,05 8,90 
DF-EQA1504-P 13,90 1,98 2,08 9,90 
DF-EQA1505-P 13,90 1,84 2,06 7,90 
DF-EQA1507-P 13,90 1,85 2,00 8,50 
DF-EQA1508-P 13,90 1,98 2,03 8,90 
DF-V1804-P 13,90 2,00 2,06 9,10 
DF-V1805-P 13,90 2,00 2,13 8,40 
DF-V1806-P 13,90 1,90 2,01 9,00 
DF-V1807-P 13,90 1,92 2,08 9,10 
DF-S1703-P 13,90 1,94 2,23 8,90 
DF-S1702-P 13,90 1,90 1,99 8,70 
DF-S1705-P 13,90 1,92 1,94 8,30 
DF-S1704-P 13,90 1,87 2,00 9,00 
DF-G1801-P 13,90 1,90 2,20 8,00 
DF-G1802-P 13,90 2,07 1,84 8,90 
DF-G1609-P 13,90 2,07 2,18 8,80 
DF-G1610-P 13,90 1,99 2,18 8,60 
T75 monolayer cells 
BM-EQF1701-CHM 13,90 2,03 2,06 8,60 
BM-EQF1703-CHM 13,90 2,04 1,95 9,00 
BM-EQF1704-CHM 13,90 2,10 2,12 8,90 
BM-EQF1705-CHM 13,90 2,06 2,00 9,10 
BM-EQA1504-CHM 13,90 2,03 1,96 9,10 
BM-EQA1505-CHM 13,90 2,02 2,07 9,00 
BM-EQA1506-CHM 13,90 2,09 2,19 8,90 
BM-EQA1507-CHM 13,90 2,01 2,13 10,00 
BM-0115-CHM 13,90 2,00 1,94 9,10 
BM-1607-CHM 13,90 2,01 2,04 9,40 
BM-1608-CHM 13,90 2,02 2,06 9,10 
BM-V1807-CHM 13,90 1,93 2,08 9,60 
BM-1606-CHM 13,90 2,01 2,16 9,80 
BM-1116-CHM 13,90 2,24 1,83 8,00 
BM-S1702-CHM 13,90 2,03 2,12 8,90 
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BM-S1703-CHM 13,90 2,08 2,04 8,70 
BM-G1801-CHM 13,90 1,99 2,15 8,50 
BM-G1802-CHM 13,90 2,04 1,98 9,00 
BM-0314-CHM 13,90 2,02 1,84 8,90 
BM-G1609-CHM 13,90 2,02 2,09 9,00 
AT-EQF1701-CHM 13,90 2,07 2,10 9,00 
AT-EQF1703-CHM 13,90 2,02 2,01 10,00 
AT-EQF1704-CHM 13,90 2,00 2,08 9,80 
AT-EQF1705-CHM 13,90 2,05 2,08 8,80 
AT-EQA1504-CHM 13,90 2,06 2,14 9,10 
AT-EQA1505-CHM 10,00 2,20 1,56 7,50 
AT-EQA1508-CHM 13,90 2,04 2,11 9,00 
AT-EQA1509-CHM 13,90 2,08 2,10 9,20 
AT-1607-CHM 13,90 1,99 2,06 9,80 
AT-1608-CHM 13,90 1,98 1,98 9,00 
AT-V1807-CHM 13,90 2,02 2,00 9,30 
AT-0115-CHM 13,90 2,01 2,03 9,10 
AT-1606-CHM 13,90 2,05 1,99 9,00 
AT-0315-CHM 13,90 2,04 2,00 9,00 
AT-0415-CHM 13,90 2,00 1,93 9,30 
AT-0916-CHM 13,90 2,03 2,04 9,60 
AT-0314-CHM 13,90 2,02 2,02 8,80 
AT-G1609-CHM 13,90 2,02 2,07 9,10 
AT-G1801-CHM 13,90 2,06 2,00 9,00 
AT-G1802-CHM 13,90 2,10 2,28 8,90 
DF-EQF1701-CHM 13,90 2,00 2,11 9,00 
DF-EQF1703-CHM 13,90 2,02 2,02 9,70 
DF-EQF1704-CHM 13,90 2,05 2,17 9,50 
DF-EQF1705-CHM 13,90 1,99 2,10 9,20 
DF-EQA1504-CHM 13,90 2,01 2,05 9,80 
DF-EQA1505-CHM 13,90 2,04 1,82 8,80 
DF-EQA1507-CHM 13,90 2,05 2,10 9,00 
DF-EQA1508-CHM 13,90 2,00 2,03 8,90 
DF-V1804-CHM 13,90 2,03 2,11 9,40 
DF-V1805-CHM 13,90 2,02 2,01 9,50 
DF-V1806-CHM 13,90 1,98 2,04 9,20 
DF-V1807-CHM 13,90 2,01 2,10 9,50 
DF-S1702-CHM 13,90 1,97 2,00 8,90 
DF-S1703-CHM 13,90 2,07 2,05 9,30 
DF-S1705-CHM 13,90 1,98 2,05 9,60 
DF-S1704-CHM 13,90 2,00 2,06 9,20 
DF-G1801-CHM 13,90 2,00 2,02 9,70 
DF-G1802-CHM 13,90 2,05 1,80 9,00 
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DF-G1609-CHM 13,90 2,10 2,08 10,00 
DF-G1610-CHM 13,90 2,08 1,86 9,60 
Osteogenic DAY 0 (O=osteogenic, 0=day 0, B=non-induced control) 
BM-EQF1701-O0B 13,90 1,97 1,83 9,00 
BM-EQF1703-O0B 13,90 2,02 1,80 9,00 
BM-EQF1704-O0B 13,90 2,08 2,15 9,30 
BM-EQF1705-O0B 13,90 1,99 2,08 9,20 
BM-EQA1504-O0B 13,90 2,01 1,87 9,40 
BM-EQA1505-O0B 13,90 2,10 2,13 9,10 
BM-EQA1506-O0B 13,90 2,08 2,22 9,30 
BM-EQA1507-O0B 13,90 2,09 2,13 9,50 
BM-0115-O0B 13,90 2,02 2,09 9,20 
BM-1607-O0B 13,90 1,96 2,17 9,20 
BM-1608-O0B 13,90 1,99 2,00 9,50 
BM-V1807-O0B 13,90 2,00 2,03 9,10 
BM-1606-O0B 13,90 2,05 2,04 9,00 
BM-1116-O0B 13,90 2,07 1,86 8,90 
BM-S1702-O0B 13,90 1,90 1,95 9,10 
BM-S1703-O0B 13,90 2,08 2,02 9,40 
BM-G1801-O0B 13,90 2,09 1,81 8,20 
BM-G1802-O0B 13,90 2,06 1,96 9,00 
BM-0314-O0B 13,90 2,05 1,88 8,90 
BM-G1609-O0B 13,90 2,03 2,15 9,10 
AT-EQF1701-O0B 13,90 2,08 1,97 9,00 
AT-EQF1703-O0B 13,90 2,01 1,84 9,00 
AT-EQF1704-O0B 13,90 2,04 2,05 9,50 
AT-EQF1705-O0B 13,90 1,75 1,87 7,90 
AT-EQA1504-O0B 13,90 1,98 1,80 8,90 
AT-EQA1505-O0B 13,90 2,06 1,87 8,50 
AT-EQA1508-O0B 13,90 2,08 2,09 9,30 
AT-EQA1509-O0B 13,90 2,05 2,10 9,80 
AT-1607-O0B 13,90 2,04 2,07 9,00 
AT-1608-O0B 13,90 2,00 1,99 9,00 
AT-V1807-O0B 13,90 2,02 2,11 8,90 
AT-0115-O0B 13,90 2,00 1,87 8,80 
AT-1606-O0B 13,90 2,05 2,08 8,90 
AT-0315-O0B 13,90 2,01 1,86 9,00 
AT-0415-O0B 13,90 2,03 2,04 9,60 
AT-0916-O0B 13,90 2,03 2,08 9,00 
AT-0314-O0B 13,90 1,97 2,08 8,70 
AT-G1609-O0B 13,90 2,00 1,99 9,30 
AT-G1801-O0B 13,90 1,87 1,89 8,50 
AT-G1802-O0B 13,90 2,11 1,85 8,00 
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DF-EQF1703-O0B 13,90 1,94 1,80 8,90 
DF-EQF1704-O0B 13,90 1,98 1,80 9,00 
DF-EQF1705-O0B 13,90 2,05 1,88 8,90 
DF-EQA1504-O0B 13,90 2,02 1,80 9,00 
DF-EQA1505-O0B 13,90 2,00 1,87 9,10 
DF-EQA1507-O0B 13,90 2,03 2,08 9,00 
DF-EQA1508-O0B 13,90 1,99 2,05 8,90 
DF-V1804-O0B 13,90 2,01 2,12 9,20 
DF-V1805-O0B 13,90 2,05 2,01 9,00 
DF-V1806-O0B 13,90 1,98 2,00 9,10 
DF-V1807-O0B 13,90 2,00 2,01 9,50 
DF-S1703-O0B 13,90 1,70 1,92 7,90 
DF-S1704-O0B 13,90 1,97 2,08 8,70 
DF-S1705-O0B 13,90 2,01 1,87 8,90 
DF-G1609-O0B 13,90 1,98 2,03 8,90 
DF-G1610-O0B 13,90 1,99 2,00 9,00 
DF-G1801-O0B 13,90 2,01 1,87 9,20 
DF-G1802-O0B 13,90 1,97 1,89 9,40 
Osteogenic day 21 (O=osteogenic, 21=day 21, A=induced, B=non-induced control) 
BM-EQF1701-O21A 13,90 2,00 1,98 8,80 
BM-EQF1701-O21B 13,90 2,01 2,02 8,90 
BM-EQF1703-O21A 13,90 1,93 1,85 9,00 
BM-EQF1703-O21B 13,90 1,84 1,84 8,20 
BM-EQF1704-O21A 13,90 1,88 1,88 8,70 
BM-EQF1704-O21B 13,90 2,03 2,10 9,40 
BM-EQF1705-O21A 13,90 1,96 1,89 9,00 
BM-EQF1705-O21B 13,90 2,03 1,81 9,00 
BM-EQA1504-O21A 13,90 1,99 1,81 9,10 
BM-EQA1504-O21B 13,90 2,02 1,80 9,40 
BM-EQA1505-O21A 13,90 2,08 1,88 7,50 
BM-EQA1505-O21B 13,90 2,01 2,14 9,50 
BM-EQA1506-O21A 13,90 1,77 1,94 8,80 
BM-EQA1506-O21B 13,90 1,96 2,08 9,50 
BM-EQA1507-O21A 13,90 2,01 1,80 9,50 
BM-EQA1507-O21B 13,90 2,01 2,12 9,70 
BM-0115-O21A 13,90 1,80 1,80 8,80 
BM-0115-O21B 13,90 2,01 2,06 9,00 
BM-1607-O21A 13,90 1,99 1,88 9,30 
BM-1607-O21B 13,90 2,00 2,11 9,50 
BM-1608-O21A 13,90 1,98 2,08 9,10 
BM-1608-O21B 13,90 2,08 1,83 8,80 
BM-V1807-O21A 13,90 1,70 1,80 8,30 
BM-V1807-O21B 13,90 2,03 2,09 9,20 
137 
 
BM-1606-O21A 13,90 1,94 1,84 8,90 
BM-1606-O21B 13,90 1,99 1,87 9,30 
BM-1116-O21A 10,00 1,59 1,46 7,40 
BM-1116-O21B 13,90 2,06 1,86 9,20 
BM-S1702-O21A 13,90 2,09 2,06 9,20 
BM-S1702-O21B 13,90 2,05 2,04 9,00 
BM-S1703-O21A 13,90 2,07 1,83 7,70 
BM-S1703-O21B 13,90 2,07 1,95 9,40 
BM-G1801-O21A 13,90 2,10 2,03 9,10 
BM-G1801-O21B 13,90 1,97 1,89 8,90 
BM-G1802-O21A 13,90 1,91 1,94 9,00 
BM-G1802-O21B 13,90 2,04 1,90 9,00 
BM-0314-O21A 10,00 2,30 1,55 7,60 
BM-0314-O21B 13,90 2,01 1,88 8,70 
BM-G1609-O21A 13,90 1,97 1,83 7,90 
BM-G1609-O21B 13,90 2,07 1,98 9,00 
AT-EQF1701-O21A 13,90 2,04 2,17 9,10 
AT-EQF1701-O21B 13,90 2,03 2,15 9,80 
AT-EQF1703-O21A 13,90 1,98 2,04 9,50 
AT-EQF1703-O21B 13,90 1,85 1,80 8,90 
AT-EQF1704-O21A 13,90 1,95 1,95 9,00 
AT-EQF1704-O21B 13,90 1,93 1,80 8,60 
AT-EQF1705-O21A 13,90 1,94 1,89 9,50 
AT-EQF1705-O21B 13,90 2,03 1,88 8,00 
AT-EQA1504-O21A 13,90 1,97 1,84 8,50 
AT-EQA1504-O21B 13,90 1,98 1,80 8,60 
AT-EQA1505-O21A 13,90 2,04 1,88 9,00 
AT-EQA1505-O21B 13,90 1,97 1,82 8,90 
AT-EQA1508-O21A 13,90 1,98 2,06 9,60 
AT-EQA1508-O21B 13,90 2,07 2,13 9,20 
AT-EQA1509-O21A 13,90 2,05 2,19 9,20 
AT-EQA1509-O21B 13,90 2,05 2,09 9,00 
AT-1607-O21A 13,90 1,96 2,15 9,10 
AT-1607-O21B 13,90 2,02 2,11 9,50 
AT-1608-O21A 13,90 2,03 2,13 9,40 
AT-1608-O21B 13,90 2,02 2,10 9,10 
AT-V1807-O21A 13,90 1,98 2,18 8,70 
AT-V1807-O21B 13,90 1,98 2,13 9,40 
AT-0115-O21A 13,90 1,99 2,09 9,10 
AT-0115-O21B 13,90 2,05 1,98 9,00 
AT-1606-O21A 13,90 2,03 2,13 8,70 
AT-1606-O21B 13,90 1,99 2,07 9,00 
AT-0315-O21A 13,90 1,89 1,99 8,60 
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AT-0315-O21B 13,90 2,01 1,92 9,00 
AT-0415-O21A 13,90 2,08 2,05 8,80 
AT-0415-O21B 13,90 2,01 1,89 9,00 
AT-0916-O21A 13,90 1,98 1,86 9,10 
AT-0314-O21A 13,90 2,00 2,08 8,60 
AT-0314-O21B 13,90 1,95 1,80 9,00 
AT-G1609-O21A 13,90 1,96 1,95 9,20 
AT-G1609-O21B 13,90 1,97 1,81 8,70 
AT-G1801-O21A 13,90 2,19 1,85 8,10 
AT-G1801-O21B 13,90 2,10 1,93 8,60 
AT-G1802-O21A 13,90 1,96 1,97 8,90 
AT-G1802-O21B 13,90 2,02 1,82 8,30 
DF-EQF1701-O21A 13,90 2,02 2,11 9,50 
DF-EQF1701-O21B 13,90 2,03 2,13 9,40 
DF-EQF1703-O21A 13,90 2,06 2,11 9,00 
DF-EQF1703-O21B 13,90 2,01 1,82 9,10 
DF-EQF1704-O21A 13,90 1,99 2,05 8,30 
DF-EQF1704-O21B 13,90 2,00 2,10 8,50 
DF-EQA1504-O21A 13,90 2,04 2,12 8,60 
DF-EQA1504-O21B 13,90 2,08 1,88 8,40 
DF-EQA1505-O21A 13,90 2,01 1,86 9,00 
DF-EQA1505-O21B 13,90 2,10 1,83 9,20 
DF-EQA1507-O21A 13,90 1,96 1,99 9,20 
DF-EQA1507-O21B 13,90 1,97 1,88 8,70 
DF-V1804-O21A 13,90 1,95 2,08 8,40 
DF-V1804-O21B 13,90 2,01 1,99 7,90 
DF-V1805-O21A 13,90 1,95 2,00 8,40 
DF-V1805-O21B 13,90 2,04 2,01 8,60 
DF-V1807-O21A 13,90 1,94 2,04 8,90 
DF-V1807-O21B 13,90 2,01 2,11 9,00 
DF-S1702-O21A 13,90 1,99 2,10 8,60 
DF-S1702-O21B 13,90 2,01 1,92 8,40 
DF-S1703-O21A 13,90 1,96 1,88 8,50 
DF-S1703-O21B 13,90 1,99 1,84 8,70 
DF-S1705-O21A 13,90 2,08 1,83 8,00 
DF-S1705-O21B 13,90 2,07 1,88 9,20 
DF-G1609-O21A 13,90 2,01 1,86 8,70 
DF-G1610-O21B 13,90 2,10 1,89 8,90 
DF-G1801-O21A 13,90 2,02 1,87 8,50 
DF-G1801-O21B 13,90 2,03 1,82 8,50 
DF-G1802-O21A 13,90 2,00 1,82 8,70 
DF-G1802-O21B 13,90 2,05 1,81 9,00 
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APPENDIX 2.  Gene list and annotation for primer-probe sets used for RT-qPCR  
Gene ID Annotation 
ABI3BP Decrease proliferation. Necessary for the switch from proliferation to differentiation in 
MSCs 
ACAN Proteoglycan found in articular cartilage -  withstands compression 
ALPL Early marker of osteogenesis – high levels in bone (osteoblasts), bone mineralization 
AQP1 Involved in chondrocyte proliferation, migration and adhesion 
AREG EGF family member. Has mitogenic effect on several cell types including epithelial 
cells, fibroblasts and immune cells 
BARD1 Forms a heterodimer with BRCA1, which phosphorylate and stabilize p53. p53 is a 
transcription factor for  p21, which leads to cellular arrest 
BAX Pro-apoptotic gene – belongs to the BCL2 protein family 
BCL2 Anti-apoptotic. Expression affected by donor age in BM-MSCs [66] 
BGN Belongs to the leucine-rich repeat protein family. Binds to collagen fibrils. Plays a role in 
skeletal bone growth and remodeling 
BMP2 Induces cartilage and bone formation – activates osteoblast differentiation 
BMP3 Increases MSC proliferation while inducing osteogenesis 
BMP4 Involved in cartilage and bone formation, specifically limb development and fracture 
repair. Involved in bone mineralization 
BMP6 Induce the growth of bone and cartilage. Able to induce osteogenic markers in MSCs 
BMP7 Plays a role in bone development. Induces ectopic bone formation and promote fracture 
healing 
BRCA1 Up-regulate p21 and induce G1/S arrest 
CASP3 Cell apoptosis 
CASP8 Cell apoptosis - DNA hypermethylation is found with aging [103] 
CAVIN1 Found in osteoblasts. Helps to form caveolea. Stops cell division in older cells (induce 
senescence) 
CCND1 Cyclin 1 forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, 
whose activity is required for cell cycle G1/S transition. Expression affected by donor 
age in BM-MSCs [66] 
CDKN1A Induce G1/S arrest. Increased level in senescent cells [27] 
CHADL Glycosaminoglycan. Cartilage matrix protein that mediate adhesion of chondrocytes. 
Promotes attachment of chondrocytes, osteoblasts, and fibroblasts  
CLU  Anti-apoptotic. Inhibits BAX and p53 activation. Involved in several basic events such 
as cell death, tumor progression, and neurodegenerative disorders  
COL1A1 Major protein component of the bone extracellular matrix and in fibrocartilage 
COL2A1 Specific marker of articular cartilage 
COL4A1 Extracellular glycoprotein essential in cartilage 
COL5A3 Encodes an alpha chain for low abundance fibrillar collagens 
COL9A2 A fibril associated collagen, that associates with COL2 and COL11 in articular cartilage 
(together it makes the inter-territorial matrix of AC) [4] 
COL11A1 Key component of articular cartilage. Heterodimer, which forms fibrils in association 
with type II collagen in articular cartilage [4]. Essential for normal bone mineralization 
COL12A1 Homotrimer found in association with COL1 
COMP A non-collagenous extracellular matrix protein, found in the extracellular matrix of 
cartilage, believed to play an important role in proliferation and apoptosis. Promotes 
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proliferation by activating the Akt pathway   
CRTAC1 Secreted by articular chondrocytes 
CRYAB Significantly increased in osteogenic differentiated human bone marrow MSCs in vitro 
CSF2 The protein encoded by this gene is a cytokine that controls the production, 
differentiation, and function of hematopoietic progenitors. Affected by cellular 
senescence 
CTGF Promotes the proliferation and differentiation of articular chondrocytes 
CTNNB1 Regulate cell growth and adhesion between cells.  Expression in BM-MSCs affected by 
donor age [66] 
DCN Osteoprogenitor marker. A member of the small leucine-rich proteoglycan family 
DMP1 Produced by osteoblasts and is found both intracellularly and extracellularly. Following 
osteoblast activation, DMP-1 undergoes Ca2+ mediated phosphorylation, which induces 
its secretion into the ECM, where it participates in mineralized bone matrix formation 
EBF2 Play an important role in in a variety of developmental processes. Mouse studies suggest 
that this gene may be involved in osteoblast differentiation 
EPGN Ligand for the epidermal growth factor receptor and play a role in cell survival, 
proliferation and migration. High mitogenic activity but low affinity for its receptor  
FGF1 Mitogenic and cell survical activity 
FGF5 Broad mitogenic and cell survival activity 
FGF18 Growth factor. Important role in cell proliferation, differentiation and migration. 
Required for normal ossification and bone development, and enhances chondrogenesis 
FGFR3 Highly expressed in chondrocytes, negative regulator of bone growth 
FN1 Encodes a glycoprotein found in the extracellular matrix. Binds to integrins (membrane 
spaning receptor proteins), and other extracellular matrix molecules such as collagen, 
fibrin and heparan sulfate proteoglycans 
GDF6 This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) 
superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading 
to recruitment and activation of SMAD family transcription factors that regulate gene 
expression. The encoded pre-protein is proteolytically processed to generate each subunit 
of the disulfide-linked homodimer. This protein is required for normal formation of some 
bones and joints in the limbs, skull, and axial skeleton 
GLB1 Senescent marker. Overexpression and accumulation of endogenous lysosomal beta-
galactosidase is seen specifically in senescent cells [154]  
GLI3 Transcription factor. Controls chondrocyte proliferation and maturation 
HAPLN1 Stabilizes the aggregates of proteoglycan monomers (primarily aggrecan) with 
hyaluronic acid in the extracellular cartilage matrix 
HDGF Mitogenic and DNA-binding activity 
HGF Regulate cell growth, cell motility and morphogenesis in numerous cell and tissue types. 
Secreted by mesenchymal cells. May also play a role in tissue regeneration  
IBSP Major structural protein of bone matrix, synthesized by osteoblasts 
IGF1 Potent mitogen for a multitude of cells including neural progenitor-like cells and hair 
follicle cells. Acts as a regulator of bone growth and development. Anabolic growth 
factor for articular cartilage, expressed in growth plate chondrocytes. Can induce 
chondrogenesis in vitro. DNA methylation pattern affected by biological age [103] 
IGFBP5 IGF-binding proteins 
LOC100146270 Cell cycle regulator. Works in the p16/RB pathway. Biomarker of cellular senescence. 
Stops cell division in older cells. Increased in Senescent cells. DNA methylated [103]  
LOC100146589 Secreted solely by osteoblasts, essential for mineralization of bone, binds to calcium 
MATN1 Mainly expressed in cartilage. Cartilage matrix protein. Defects in Matrilin-1 leads to 
e.g. early onset osteoarthritis and other cartilage diseases  
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MEPE Expressed in bone, where it regulates the mineralization. Secreted by osteoblasts  
MET A member of the receptor tyrosine kinase family that transduces signals from the 
extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF 
ligand. Regulates many physiological processes including proliferation, differentiation, 
scattering, morphogenesis and survival 
MIA Marker for chondrocyte differentiation. Found in equine cartilage and chondrocytes.  
MMP3 Chondrogenic marker. Involved in break-down of extra cellular matrix in normal tissue 
remodeling and in diseases like arthtitis. MMP3 gene encodes an enzyme that degrades 
fibronectin, laminin, collagen III, IV, IX, X, and cartilage proteoglycans  
MMP13 Chondrogenic marker 
MYC A master regulator of cellular growth regulation. C-Myc overexpression result in 
coordinated changes in level of expression of gene families which result in increased 
cellular proliferation 
NODAL Member of the TGF-Beta superfamily. Essential for mesoderm formation and 
subsequent organization of axial structures in early embryonic development 
OMD Implicated in biomineralization processes 
PCNA Cofactor of DNA polymerase delta. The encoded protein acts as a homotrimer and helps 
increase the processivity of leading strand synthesis during DNA replication 
PDGFD Mitogenic factor for cells of mesenchymal origin 
PHB Evolutionary conserved. Plays a role in senescence and tumor suppression. Anti-
proliferative activity is localized to the 3' UTR region. Inhibits DNA synthesis 
PHEX A transmembrane endopeptidase that belongs to the type II integral membrane zinc-
dependent endopeptidase family. Involved in bone mineralization  
PTCH2 A tumor suppressor in the hedgehog signaling pathway 
RUNX2 Early marker of osteogenesis – transcription factor, master switch for activation of 
osteoblasts 
RUNX3 Tumor suppressor – member of the runt domain-containing family of transcription 
factors associated with BMP and TGF-beta pathways 
S100A1 S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and 
involved in the regulation of a number of cellular processes such as cell cycle 
progression and differentiation; Probably acts as a Ca(2+) signal transducer. Inhibits 
microtubule assembly 
SMOC1 Plays a critical role in limb development. Found in the basement membranes. Help 
anchor cells to one another during embryonic development. Modulates growth factors 
that stimulate growth and development of tissues, especially skeletal formation. SMOC-1 
protein promotes the maturation (differentiation) of osteoblasts  
SMPD3 Participates in bone mineralization 
SNAI2 A transcription factor; acts as a transcriptional repressor that binds to E-box motifs and is 
also likely to repress E-cadherin transcription; involved in EMT; has anti-apoptotic 
activity 
SOST Regulator of bone homeostasis. Expressed by terminally differentiated osteocytes and 
hypertrophic chondrocytes. Expression is induced by BMP-2, 4 and 6. Inhibited by PTH. 
SOST binds to BMP-2, 4 and 6 and inhibits the osteogenic differentiation induced by 
BMPs. SOST reduces the proliferation of MSCs and induce MSC apoptosis  
SOX5 Chondrogenic marker. Essential for chondrocyte differentiation and hence cartilage 
formation 
SOX9 Early chondrogenic marker 
SP7 Later osteogenesis marker – bone specific transcription factor, required for osteoblast 
differentiation and bone formation 
SPARC Glycoprotein in bone, binds calcium, secreted by osteoblasts during bone formation, 
initiating bone mineralization – affinity for collagen type 1 and calcium 
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SPP1 Extracellular structural protein in bone, a linking protein, binds calcium 
TBX3 Transcriptional repressor involved in developmental processes (anterior/posterior limb 
pattern formation). Acts as a negative regulator of PML function in cellular senescence 
TERT Catalytic subunit of teleomerase, implicated in aging and cancer. Less expression with 
increasing donor age and senescence. DNA methylation affected in chronological aging 
[102]  
TGFA Binds to the epidermal growth factor receptor, which activates a signaling pathway for 
cell proliferation, differentiation, and development. Expression affected by donor age in 
BM-MSCs [66] 
TGFB1 Regulate cell activities including proliferation, differentiation, motility and apoptosis. 
Highly abundant in tissues that make up the skeleton, where it regulate the formation and 
growth of bone and cartilage. Prevent tumor growth 
TGFB2 Regulate proliferation, differentiation, adhesion, migration 
TGFB3 Controls the growth and proliferation of cells, differentiation, motility, and apoptosis. 
Keeps cells from growing and dividing too rapidly, can suppress tumor formation. 
Involved in regulation of bone growth and in vitro chondrogenic induction of MSCs. 
Increase proliferation of MSCs, while inducing chondrogenesis  
TIMP2 Inhibits matrix metalloproteinases, and hence prevent degradation of extracellular 
matrix. Suppresses proliferation of endothelial cells  
TNF Pro-apoptotic. Involved in apoptosis, proliferation, differentiation, lipid metabolism and 
coagulation. Expression in BM-MSCs affected by donor age [66]. DNA hypomethylated 
in promotor with increasing age [103]  
TNFRSF11B Also known as osteoclastgenesis inhibitory factor. Expressed in osteoblasts. Plays a role 
in regulating bone density and as a decoy receptor for RANKL - hence inhibits 
osteoclastgenesis and bone resorption 
TNFSF11 induces osteoclastgenesis by activating multiple signaling pathways in osteoclast 
precursor cells 
TP53 Tumor suppressor. Transcription factor for p21. Induce cell cycle arrest - DNA repair or 
apoptosis. Increased level in senescent cells and in aged BM-MSCs [66]  
VEGFA Growth factor which induces proliferation and migration of vascular endothelial cells. 
Member of the PDGF/VEGF growth factor family  
B2M Encodes a serum protein found in association with MHC class I on the surface of nearly 
all nucleated cells 
GUSB Encodes a hydrolase that degrades glycosaminoclycans. The enzyme forms a 
hemotetramer that is localized to the lysosome  
RPLP0 Encodes a ribosomal protein component of the 60S subunit  
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